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Embryonic Stem Cells 
Mouse embryonic stem cells (mESC) have been a key tool in understanding early diff eren  a  on 
events in development since their fi rst isola  on in 1981[1]. These cells have the remarkable ability 
to con  nuously self-renew in culture and are pluripotent: they have the ability to diff eren  ate 
into deriva  ves of the three germ layers that make up an embryo. In addi  on, mESC can be 
gene  cally modifi ed and contribute to all soma  c  ssues and the germ line in chimeric mice, 
making them an ideal tool for dele  ng specifi c genes to study their func  on in development 
and crea  ng disease models. Even though mESC research quickly became a robust technology 
and the poten  al for regenera  ve medicine became clear, it unfortunately it took another two 
decades before human embryonic stem cells (hESC) were derived [2]. One of the challenges 
in isola  ng hESCs was the fundamental diff erence in their biological characteris  cs, culturing 
techniques and the growth factors needed to maintain their pluripotent state compared to 
mESCs. For example, although both mESC and hESC were fi rst isolated on mouse embryonic 
fi broblasts (MEFs) [1] mESC needed leukemia inhibitory factor (LIF) to maintain a pluripotent 
state[3] , whilst ac  vin/nodal signaling was required to maintain hESCs [4]. While hESCs and 
mESCs do share some surface markers, such as E-cadherin and c-KIT, they have several dis  nct 
markers such as SSEA1 being expressed in mESC and not in hESC, whereas SSEA3, SSEA4, TRA-
1-81 and TRA-1-60 are expressed in hESC and not in mESC. Even though hESC diff er from mESC 
they are not completely unique as they are rather similar to human embryonal carcinoma (EC) 
cells (the undiff eren  ated cells in teratocarcinomas) with respect to alkaline phosphatase (AP) 
ac  vity, and SSEA3 and SSEA4 expression [5;6] rather than mouse EC cells which also have high 
AP ac  vity but diff er in surface marker expression. This has been hypothesized as being due to 
diff erences in the ‘ground state’ of these cells. hESC are more closely related to mouse Epiblast 
Stem Cells (mEpiSC) [7;8]. mEpiSC have similar morphology to hESC and are maintained in culture 
in a similar manner. The deriva  on of mEpiSCs from the mouse epiblast, which develops soon 
a  er the blastocyst forms, brings into ques  on the diff erent ground states of pluripotent stem 
cells. mESC appear to be in a more naïve pluripotent state than mEpiSC or hESC [9]. Furthermore, 
it now appears that hESC are not as closely related to the inner cell mass (ICM) of the embryo as 
mESC [10]. There have been several a  empts to transform hPSC into a more naïve pluripotent 
state but in the few successful reports, the cells appear to be only stable for a limited number 
of passages [11;12].
Induced pluripotent stem cells: Growth and Considera  on
In 2006, Takahashi and Yamanaka from Kyoto University in Japan made a ground-breaking 
discovery for stem cell research. By introducing only four transgenes into mouse soma  c 
cells, they were reprogrammed to a pluripotent, embryonic stem cell-like state [13]. In 2007 
this was also done with human soma  c cells [14;15]. This discovery changed the stem cell 
fi eld in a mul  tude of ways: ethically because no embryos were required, for cell therapy 
since gene  cally matched pluripotent cells could be derived for transplanta  on, for disease 
modeling since the pa  ent genome could be captured and understanding of human embryo 
and disease development. These new induced pluripotent stem cells (iPSC) have helped open 
the fi eld to many for whom na  onal regula  on laws have limited the use of tradi  onal human 
embryonic stem cells[16] because of  ethical and moral concerns [17;18], over the requirement 
for destruc  on of an embryo. Furthermore, in regenera  ve medicine, these cells can be 
derived from the pa  ent awai  ng stem cell therapy, so in contrast to (unmatched) donor hESC 
deriva  ves,  it has been predicted that they would not undergo immunorejec  on In addi  on 
pa  ent-specifi c iPSC contain any (disease-causing) muta  ons aff ec  ng the pa  ent allowing the 
disease in principle to be modeled. Although introduc  on of a disease muta  on into hESC would 
also create a disease model, the severity of the phenotype would never been known. 
Thus iPSCs have created a new impulse to researchers worldwide to study and create cures for 
many diseases as well as move towards the personaliza  on of stem cell medicine. While this 
hope verges on hype among the general public and among many pa  ent groups, researchers in 
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the fi eld soon realized that while this discovery was a great leap forward in stem cell research, 
the use of human iPSC (hiPSC) in the clinic is s  ll decades away for many diseases and their use 
as personalized medicine is, for the moment, economically prohibi  ve [19;20].
The fi rst hiPSCs were generated using an “integra  ng” method in which genes were introduced 
into the soma  c cell genome using, retroviral vectors. Four “reprogramming genes”, OCT4, SOX2, 
KLF4, and c-MYC (more commonly known as the Yamanaka factors), [14] or OCT4, SOX2, NANOG 
and LIN28 (more commonly known as the Thomson factors [15]) were suffi  cient to return cells 
to pluripotency. Later reports also showed fewer transgenes could be used in some cells types. 
For example, if high levels of these genes were endogenously expressed [21-23]. Addi  onally, 
other studies showed that the combina  on of Yamanaka factors plus LIN28 and NANOG was 
even more effi  cient than just the original four [24;25]. Furthermore other myc family members 
has been demonstrated to be as eff ec  ve with less chance of malignancies [26]. Nevertheless 
integra  ng methods, using retroviral or len  viral vectors, permanently introduce new 
informa  on into the DNA; the eff ects of permanently modifying the genome are unclear. Since 
the integra  on site(s) are o  en unknown there is a chance that normal gene expression pa  erns 
are altered, perhaps aff ec  ng maintenance and/or diff eren  a  on of the iPSC. Furthermore the 
possibility of re-expression of the exogenous reprogramming genes would always be a concern. 
In addi  on cells with ectopic gene expression may represent a major safety concern for clinical 
use.  The use of excisable viral vectors and transposons which remove the reprogramming genes, 
has reduced these concerns but most excision methods s  ll leave a gene  c footprint such as a 
loxP site in the cells. The use of non-integra  ng methods (adenoviruses[27], miRNA[28], and 
Sendai virus[29;30] was another step closer to making iPSCs more closely resembling hESC , 
since they lacked the permanent integra  on of  the exogenous factors and would therefore be 
safer in clinical use. Unfortunately, with the excep  on of the new Sendai virus method [29] and 
newer episomal methods [31] these methods are in general less effi  cient and rela  vely labor 
intensive (miRNA), which could lead to addi  onal muta  ons in the newly derived iPSC lines or 
the preferen  al reprogramming of already mutated soma  c cells. (A more detailed explana  on 
of iPSC genera  on can be found in Chapter 2).
Not only should the method of reprogramming be a considera  on but also the choice of soma  c 
cell. While mouse iPSC (miPSC) have been generated from most cell types [32], the genera  on 
of hiPSC has been more challenging. Not only are some human soma  c cell types more diffi  cult 
to reprogram [33] but they are not all as easily accessible as others, especially (for ethical 
reasons) from children. While dermal fi broblasts were fi rst used in reprogramming, collec  on 
of a skin biopsy is considered mildly invasive and so may be diffi  cult to obtain from all pa  ents 
of interest or from children. Confounding this issue is the possibility of epigene  c memory, the 
no  on that iPSC ‘remember’ from which soma  c cell they are generated from and thus directed 
diff eren  a  on may be eff ected. Epigene  c memory was fi rst evident in miPSC but appeared to 
only be present during the early passages, just a  er reprogramming [32;34]. However, there 
Figure 1: Schema  c of an electrocardiogram (ECG) and its 
rela  onship to a cellular ac  on poten  al.  An ECG consists of a P 
wave (the electrical impulse of the atrium), the ORS interval (the 
depolariza  on of the heart’s ventricles), and the T wave (ventricle 
repolariza  on). The ac  va  on, depolariza  on and repolariza  on 
of the heart are controlled by the fl uxing are sodium, calcium and 
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are some reports which claim the epigene  c memory of hiPSC is retained even a  er long-term 
culturing [35] but these need to be confi rmed by more laboratories. 
Since the hiPSC can be derived from a pa  ent’s own cells, it has been assumed from the 
outset that immune rejec  on would be of no concern. However,  a 2011 report from Zhao 
et al apparently demonstrated immunogenicity of miPSC [36] re-introduced into the same 
inbred mouse strain from which they were derived compared to mESC from the same strain. 
While this study only examined undiff eren  ated miPSC and mESC and not their diff eren  ated 
deriva  ves, which would be more clinically relevant than the introduc  on of non-diff eren  ated 
pluripotent stem cells into a pa  ent, it does raise the ques  on if these ‘autologous cells’ are 
really immunologically matched a  er going through reprogramming. However a newer report 
using several iPSC and ESC lines have found no diff erence in regards to teratoma forma  on or in 
gra  s of diff eren  ated cells [37].  
Are hiPSC and hESC equivalent?
While hiPSC are very similar to hESC in terms of morphology, pluripotent gene expression and 
their ability to form teratomas [38], a number of diff erences between them have been reported 
par  cularly in their epigene  c state and transcriptome profi les [38;39].  Some early studies 
comparing iPSC and ESC found diff erences in the DNA methyla  on pa  erns [40-42] as well as 
persistent expression of donor cell genes [34;43;44]. Some of the diff erences found included 
X-inac  va  on. During development, female embryos inac  vate one of their X genes and while 
this process is s  ll not clearly understood, it has been found that some hESC have two ac  ve X 
genes. This re-ac  va  on of the X gene is some  mes but not always seen in hiPSC [39;45;46]. 
In addi  on the expression of the imprinted gene Dlk-Dio3 is o  en found to be diff eren  ally 
expressed in various iPSC lines [39]. Furthermore gene expression arrays have also found a 
separate set of genes, which are only expressed in hiPSC and not in hESC or the original soma  c 
cells [34;39;41].  S  ll, later studies using increased numbers of independent ESC and iPSC lines 
(>50 as opposed to ±10) failed to fi nd diff erences between hESC and hiPSC [47-49]. Nonetheless, 
Figure 2: Schema  c representa  on of a normal and hypertrophic heart. Hypertrophic heart are characterized by an 
increase wall thickening which can be seen in the interventricular septum and le   ventricular wall.
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there have been reports of reduced diff eren  a  on poten  al of hiPSCs compared to hESCs [50;51] 
but this may be due to the increased heterogeneity (e.g. insert loca  on, diff eren  a  on ability, 
single nucleo  de variants [52], etc.) of hiPSC clones [38], or incomplete reprogramming[41] and 
not a fundamental diff erence.    
hiPSC and disease modeling 
While the clinical applica  ons of hiPSC as cell therapy may be decades away for many condi  ons, 
their use for modeling human diseases is a more immediate possibility [53-55]. Using hESCs, 
which were diffi  cult to modify gene  cally and could only be cloned a  er improvements in single 
cell culture condi  ons and recombina  on techniques, it has, un  l recently, been diffi  cult to 
create targeted and disease lines [56;57]. However, if generated from a pa  ent with a hereditary 
disease, hiPSC contain the disease muta  on and they are gene  cally iden  cal to the individual 
from whom they are derived. In addi  on any cellular phenotypes could be matched with the 
pa  ent’s clinical phenotype. hiPSCs can diff eren  ate to mul  ple cell types much like hESCs using 
very similar protocols [58;59], thus their poten  al use for gene  c disease modeling is evident. 
While many types of soma  c cells, like fi broblasts or skeletal muscle cells, are already used in 
disease modeling, they are limited by their rela  vely short life spans in culture and/or sites in 
the body that make isola  on diffi  cult (e.g. the brain or heart). With the excep  on of cancer 
cells or immortalized cell lines, cells in culture are limited in prolifera  on by Hayfl ick’s factor 
[60], the maximum number doublings before becoming senescent due to the shor  ng of the 
telomeres. hiPSC, like hESC, have telomerase ac  vity  [14;61;62], the ability to self-renew and 
thus provide a limitless supply of star  ng material to create the soma  c cell type of choice. 
Unfortunately most of the soma  c deriva  ves of pluripotent stem cells are in an immature state. 
This presents challenges on the extent to which they can recapitulate a disease phenotype, 
which o  en manifests postnatally, and o  en only in aged adults. Nevertheless there have been 
reports describing disease phenotypes in hiPSC deriva  ves as well as some examples of (par  al) 
rescue of the phenotype (cardiac diseases reviewed in [53] ; see Table 1 for a summary of cardiac 
pa  ent specifi c hiPSC). 
The use of hiPSC is proving useful in studying some types of cardiac disease. The isola  on of 
cardiomyocytes from a human pa  ent is diffi  cult and once isolated these cells can only be 
maintained in culture for several days if not hours [63]. Whilst there are many animals models 
for cardiac disease the diff erences between species can make them less than ideal [53]. For 
example the speed of the mouse heart makes studying human arrhythmias diffi  cult as well as 
the diff erences in ion channel and their contribu  on to the ac  on poten  al puts channelopathy 
studies in ques  on. In addi  on, as previously stated above, the manipula  on of hESC is 
complicated and so there are limited hESC cardiac disease models [56;57]. However, using cues 
from development, a number of cardiac diff eren  a  on methods have been established, fi rst for 
hESCs and later hiPSC (see chapter 2 for a more details) facilita  ng their poten  al use in cardiac 
disease modeling. Even though the cells are in an immature state they express many of the ion 
channels and form sarcomeric structures. Nevertheless these cells also have their limita  ons 
such as a lack of organiza  on (in regards to sarcomeres) and heterogeneity of cell types and 
impurity.   
The Heart and Cardiac Disease
The human heart is a complex organ composed of excitable (e.g. cardiomyocytes, pacemaker 
cells, Purkinje fi bers and smooth muscle cells) and non-excitable cells (e.g. fi broblasts, endothelial 
cells, and adipocytes). Cardiomyocytes are striated muscle cells, which can be characterized by 
a specifi c set of transcrip  on factors (e.g. Nkx 2.5, GATA4 and Mef2a) and sarcomeric proteins 
(e.g. myosin heavy chain, troponin and α-ac  nin). Cardiac func  on is modulated by the fl ux of 
sodium, potassium and calcium ion channels. Altera  ons in these currents in the individual heart 
chambers can be visualized as an ac  on poten  als which taken together produce the PQRST 
intervals on an electrocardiogram (ECG) (Figure 1).  
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Cardiac disease is the one of the major causes of mortality in the Western world [56;64] and while 
many cardiac associated deaths are related to environmental factors (e.g. diet and exercise) or 
other diseases (e.g. cancer), there are a large number of channelopathies and cardiomyopathies 
which are linked to a gene  c muta  on. Channelopathies are cardiac diseases associated with 
muta  ons in the ion channel subunits [65]. For example, long QT syndrome (LQT), characterized 
by an increased QT interval is associated with various muta  ons found in the potassium and 
sodium channels [66]. On the other hand, cardiomyopathies are cardiac diseases, which more 
directly aff ect the heart muscle with muta  ons found in various genes, such as sarcomeric genes 
or transcrip  on factors, depending on the myopathy [67;68].
One of the many cardiomyopathies is hypertrophic cardiomyopathy (HCM). HCM is a gene  c 
cardiac disease characterized by increased heart size and wall thickening in the absence of other 
cardiac or systemic diseases (e.g. aor  c valve stenosis or hypertension, fi gure 2) [68]. It aff ects 
1:500 individuals and is the leading cause of sudden cardiac death in young adults[69]. Clinically, 
it is most o  en diagnosed by 2D echocardiography, presen  ng with a le   ventricle wall thickness 
of greater than 15mm[70]. From the cellular perspec  ve hypertrophy is characterized by an 
increase in cell size, increase in protein/DNA ra  o and the re-expression of fetal genes, such as 
atrial natriure  c factor (ANF), brain natriure  c pep  de (BNP) and fetal isoforms of contrac  le 
proteins[71]. In addi  on increased suscep  bility to apoptosis, ineffi  cient energy u  liza  on and 
abnormal calcium signaling have been observed [71;72].
Muta  ons in eleven sarcomeric genes are associated with the familiar HCM (fi gure 3). Muta  ons 
are most prevalent in β- myosin heavy chain (MYH7, 40%), troponin T (TNNT2, <15%) and myosin 
binding protein C3 (MYBPC3, >30%) [73]. MYBPC3 is a cardiac specifi c sarcomeric protein involved 
in the modula  on of force contrac  on through intracellular calcium regulated phosphoryla  on 
[69;74;75]. In addi  on MYBPC3 is important to sarcomere forma  on though not essen  al as 
evident from viable MYBPC3 knockout mice [76;77]. It is transversely arranged in the sarcomere 
Figure 3: Schema  c of a cardiac sarcomere. Cardiac sarcomeres consist of alterna  ng segments of thick and thin 
fi laments. The sarcomere contains numerous proteins including ac  n, troponin,   n, myosin heavy chain (MHC), 
Myosin Binding Protein C (MYBPC), and tropomyosin.
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A-bands and binds to myosin heavy chain in the thick fi laments and   n in the elas  c fi laments. 
It consists of eight Ig-like domains and three FN3 domains. The N-terminus contains myosin (s2) 
and ac  n binding sites as well as phosphoryla  on sites, while a   n-binding region and myosin 
(LMN) site as well as A-band incorpora  on are found in the protein’s C-terminus [76;78]. 
In the Dutch popula  on, three founder muta  ons in the MYBPC3 have been iden  fi ed. These 
muta  ons account for more than 25% of HCM cases in the Netherlands. The most common of 
these muta  on is 2373insG [70], a muta  on on exon 25. This muta  on is associated with a late 
onset of symptoms (a  er 30 years of age) and pa  ents present with various clinical phenotypes 
[70]. The muta  on is predicted to produce a truncated MYBPC3 protein. However studies of 
pa  ent biopsies have never been able to detect the predicted protein thus the disease phenotype 
is thought to result from decreased protein levels (haploinsuffi  ciency) [70;78]. Unfortunately 
there is a s  ll a great deal of missing informa  on regarding how this muta  on causes an HCM 
phenotype in pa  ents.
Table 1: Cardiac Disease-Specifi c hiPSC previously described in literature
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Aim and outline of this Thesis
There is no single approach for using hiPSC as models for cardiac disease and development. 
There are a number of aspects, which must be carefully considering before genera  ng and using 
hiPSC technology. Some are related to the hiPSC themselves, such as cell source, method of 
transgene introduc  on and the quality of the deriva  ves produced during diff eren  a  on. Others 
are related to the assays developed to assess cardiac phenotype at the cellular level and are 
perhaps the more challenging since they may be disease specifi c and ideally carried out on intact 
cardiac  ssue or even the whole heart rather than on individual or groups of cells. Chapter 2 
is a more in depth look into the history and development of hESC/hiPSC technology and its 
poten  al as a model for cardiac diseases. Chapter 3 inves  gates diff erent soma  c cell types for 
use in genera  ng hiPSC lines, their pros and cons in regards to transduc  on and reprogramming 
effi  ciency using a polycistronic len  viral vector as well as the ease of collec  on and isola  on 
of samples from pa  ents. Chapter 4 discusses the selec  on of hiPSC clones based on insert 
number and loca  on along with cardiac diff eren  a  on poten  al. During the genera  on of hiPSC 
hundreds of clones are produced. Currently the clones used for further studies are randomly 
selected without any informa  on regarding the insert number or loca  on or if this clone can 
effi  ciently diff eren  ate to the lineage of interest. One of the main reasons for this is a lack of 
rapid, high or mid-through put methods to determine this In chapter 4 an ultra-rapid method 
for iden  fi ca  on of insert number and loca  on as well as cardiac diff eren  a  on is described. 
Chapter 5 describes a cardiac diff eren  a  on method par  cularly designed to produce a large 
number of cardiomyocytes in a uniform manner. One of the interest areas of PSC is their use in 
drug tes  ng and disease modeling.  However if the lines diff er in the effi  ciency and quality of 
diff eren  a  ons, their usefulness is somewhat decreased. Thus a standard method for producing 
cardiomyocytes and selec  ng cardiomyocytes from mixed popula  ons of PSC deriva  ves is 
ideal. Chapter 6 inves  gates the use of hiPSC as a model for HCM in pa  ents with a muta  on 
in MYBPC3. One of the major advantages of iPSC technology is to model a gene  c disease and 
gain new insights into disease development. As a fi rst step we have generated and confi rm a 
phenotype in HCM-iPSC derived cardiomyocytes, which with further inves  ga  on will teach us 
something new about this disease and/or possible treatments. Chapter 7 studies the eff ects of 
serum on cardiomyocytes a  er diff eren  a  on from hPSC. In many studies cardiac diff eren  a  on 
of PSC is carried out in serum-containing medium. At the same  me, there are several studies 
that have examined how serum aff ects rat cardiomyocytes; there is currently limited informa  on 
on the eff ects of serum on PSC derived cardiomyocytes. Serum contains many unknown 
components which vary from batch to batch and thus can unknowingly alter the characteris  cs 
or responses of cardiomyocytes. Chapter 8 inves  gates the use of adeno-associated viral vectors 
(AAVs) as a method for purifying hPSC derived cardiomyocytes. As men  oned above one of the 
problems with PSC derived cardiomyocytes is that they are only a subpopula  on among the 
mixture of cell types produced during diff eren  a  on. Currently there are limited methods to 
select out cardiomyocytes from non-gene  cally modifi ed lines. A universal tool for selec  ng 
cardiomyocytes derived from any PSC line is needed. AAVs are small non-integra  ng viral 
vectors, which make them well suited for transient expression of a selec  on casse  e. Finally, 
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More than 10 year a  er their fi rst isola  on, human embryonic stem cells are fi nally 
“coming of age” in research and biotechnology applica  ons as protocols for their 
undiff eren  ated expansion in culture and diff eren  a  on protocols become robust and 
scalable and validated commercial reagents become available. Produc  on of human 
cardiomyocytes on a daily basis is now feasible for many laboratories with  ssue culture 
exper  se. An addi  onal recent surge of interest resul  ng from the fi rst produc  on 
of human induced pluripotent stem cells (iPSC) from soma  c cells of pa  ents now 
makes these technologies of even greater importance since it is likely that (gene  c) 
cardiac disease phenotypes can be captured in the cardiac deriva  ves of these cells. 
Whilst cell therapy based on replacing cardiomyocytes, lost or dysfunc  onal as a result 
of cardiac disease, are likely as far away as ever, biotechnology and pharmaceu  cal 
applica  ons in safety pharmacology and drug discovery will likely impact this clinical 
area in the very near future. Here, we review the state-of-the-art in this exci  ng area 
of transla  onal research. 
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Embryonic Stem Cells and Cardiomyocyte Development
Embryonic stem cells are derived from early embryos before they implant in the uterus. They 
are pluripotent that is they have the unique ability to diff eren  ate into deriva  ves of the three 
germ layers of the body while retaining the capacity to self-renew indefi nitely. This makes them 
important scien  fi c tools in biomedical and cellular research since they can, in principle, form 
~220 diff erent cell types present in the adult body and do this repeatedly over many years. 
A  er the isola  on of the fi rst mouse embryonic stem cells (mESC) in 1981 [1], the poten  al of 
these cells in regenera  ve medicine became evident. Researchers began a  empts to isolate 
human embryonic stem cells (hESC) from surplus embryos used in assisted reproduc  on 
procedures (in vitro fer  liza  on). However, due to diff erences in growth requirements, the 
limited availability of surplus human embryos and the nature of hESC  themselves, it took 
another 17 years before the fi rst hESC lines were isolated [2]. 
Aside from poten  al clinical applica  ons in cell therapy for the heart, interest in deriving 
cardiomyocytes from hESC has been driven by curiosity on the diff erences in the physiology, 
metabolism and expression of protein markers in the mouse and human heart and the ques  on 
of whether these diff erences would be refl ected in cardiac deriva  ves of stem cells in culture 
in the absence of a true heart structure. The most obvious diff erence between the mouse (or 
any small rodent) and human heart is the rate of bea  ng. The mouse heart beats at 500 beats 
per minute (b/m) while the human heart beats at 70 b/m. Another diff erence is the expression 
of myosin heavy chain (MHC) isoforms. βMHC is the isoform predominantly expressed in fetal 
mouse hearts whilst αMHC is predominant in the adult; the reverse is seen in humans [3]. Despite 
these diff erences, mice are o  en used as models in cardiac research because it is rela  vely easy 
to introduce specifi c muta  ons or targeted dele  ons in mice through mESCs. Some of these 
muta  ons result in cardiac developmental defects or adult disease, providing models that allow 
molecular and cellular dissec  on of the underlying mechanisms causing the abnormality. For 
studies on isolated cardiomyocytes though, stem cells can provide human alterna  ves as well 
as disease models, par  cularly now that methods for targe  ng specifi c genes in hESC have been 
developed [4-11] and cardiomyocytes can be derived from disease-bearing human induced 
pluripotent stem cells (iPSC). iPSC are a new kind of pluripotent stem cell that can be generated 
by reprogramming soma  c cells directly rather than using embryos [12,13]. This is par  cularly 
a  rac  ve since it is diffi  cult to obtain adult or even fetal primary human cardiomyocytes [14] and 
they cannot be kept in culture for more than a few hours or days. 
In this review we describe the current state of hESC and human iPSC research with respect to 
their diff eren  a  on into cardiomyocytes and contribu  on to understanding normal and aberrant 
cardiomyocyte biology. In addi  on, we briefl y consider the hurdles of using these cells for cell 
replacement therapy for the heart but refer the reader to specialized reviews on this subject for 
more detailed discussion [15,16].  
Embryonic Stem Cells
Embryonic stem cells are derived from the inner cell mass of blastocyst stage embryos, in humans 
on day 5 post fer  liza  on [2,17] in mice on day 3.5 [1] Most of our prior knowledge on the 
characteris  cs of these cells are derived from studies in the 1960s on embryonal carcinoma cells, 
the tumorigenic counterpart derived as spontaneous or induced tes  s tumors in mice [18] and 
as spontaneous germ cell tumors in humans [19]. Whilst expression of the principle pluripotency 
transcrip  on factors, like OCT4, SOX2 and NANOG, is conserved between mouse and human 
ESC, these cells diff er in their expression of surface markers and culture requirements [18]. This 
has recently been a  ributed to mESCs being in a more naïve state than hESC:  mouse epiblast 
stem cells (EpiSC), isolated from mouse embryos later in development, appeared more like 
hESC than mESC [20]. For example, mESC require leukemia inhibitory factor (LIF) in the culture 
medium to remain undiff eren  ated and its removal will cause spontaneous diff eren  a  on. 
hESC and mEpiSC do not require LIF but bFGF and ac  vin signaling to remain undiff eren  ated in 
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Figure 1: Pluripotent stem cells and cardiomyocytes. There are now mul  ple sources of pluripotent cells in humans. 
The most well known are embryonic stem cells isolated from the inner cell mass of human blastocyst stage embryos 
on day 5 a  er fer  liza  on. Amongst the newest are induced pluripotent stem cells (iPSC) generated by introducing key 
pluripotency–associated transcrip  on factors into soma  c cells. In mice there are addi  onally (EpiSC) isolated from 
later stages of (pos  mplanta  on) embryo development which are similar to hESC in terms of condi  ons suppor  ng 
maintenance, growth factor responses and gene expression, although not iden  cal. These three pluripotent cell 
types are dependant on ac  vin/TGF-β signaling for self-renew but have the ability diff eren  ate into all three germ 
layers when these growth factors are removed. Upon directed diff eren  a  on towards cardiomyocytes, pluripotent 
cells will fi rst pass through a progenitor stage which can be iden  fi ed by the expression of specifi c transcrip  on 
factors, for example Nkx2.5. The diff eren  a  on can con  nue further and produce various types of cardiomyocytes. 
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culture [21,22]. Typically though, hESC and mESC are maintained undiff eren  ated by co-culture 
on fi broblast “feeder” cells where they retain the ability to self-renew indefi nitely. Removing the 
cells from feeders and/or growing them in suspension as aggregates (called embryoid bodies or 
EBs) causes diff eren  a  on to deriva  ves of the three germ layers, endoderm (pancreas, liver), 
ectoderm (neurons) and mesoderm (cardiomyocytes, vascular endothelial cells, muscle, blood). 
Much research eff ort has gone into simplifying these complex growth and diff eren  a  on 
protocols. In 2001 Xu et al. showed that hESC could be maintained in an undiff eren  ated state in 
the absence of feeder cells on Matrigel™ (an extracellular matrix derived from mouse sarcoma) 
or on natural laminin for at least 130 popula  on doublings [23], although feeder-cell condi  oned 
medium was required. Human recombinant extracellular matrixes, such as laminin-511 [24] or 
vitronec  n [25] in combina  on with  appropriate culture media, have more recently also been 
shown to maintain hESC in an undiff eren  ated state and Villa-Diaz et al have derived a synthe  c 
polymer which reportedly sustains long term expansion [26]. 
Elimina  on of feeder cell requirements is not the only improvement that has been made to hESC 
culture condi  ons. The fi rst fully defi ned culture medium was described in 2006 [27] and later 
marketed as mTeSR™1. This was shown to be eff ec  ve in combina  on with a matrix containing 
either a mixture of human collagen IV, fi bronec  n, laminin and vitronec  n [27] or Matrigel™. 
Further development has led to a xenofree version called TeSR™2 in which bovine serum 
albumin has been replaced by human serum albumin, making it in principle clinically compliant. 
Various groups have now described defi ned culture condi  ons using diff erent basal media and 
supplements [27-31], although for most prac  cal purposes, the commercial media are highly 
reliable for most cell lines used in most laboratories. Furthermore, the addi  on of a selec  ve 
inhibitor of p160-Rho-associated coiled-coil kinase (ROCK) to the culture medium has been found 
to increase the survival of hESC cells during cryopreserva  on [32-34], a  er dissocia  on  [35], 
passaging under serum free condi  ons [36,37] and during various diff eren  a  on procedures 
[38]. This has been most helpful when cloning from a single cell, o  en required during gene 
targe  ng or the genera  on of transgenic hESC lines.  
In addi  on, improvement of hESC culture condi  ons con  nues with respect to op  mizing methods 
for scale-up and maintenance of karyotypic stability either through enzyma  c passaging [39] or 
suspension cultures [40,41]. Olmer et al. for example recently published a method for growing 
hESC and hiPSC in suspension cultures. While their procedure is not designed for con  nuous 
maintenance, they were successful scaling up cultures by several orders of magnitude [40], as 
would be required for future clinical applica  on as well as biotechnology.
Embryonic Stem Cells and Induced Pluripotent Stem Cells
2006 was a landmark in the history of stem cell biology. The introduc  on of just four transcrip  on 
factors into mouse soma  c cells turned out to “reprogram” cells into a pluripotent, embryonic 
stem cell-like state [42] (fi g 1). A year later, the procedure was repeated with human cells 
[43,44]. Apart from circumven  ng the ethical issues surrounding hESC deriva  on from human 
embryos, the procedure presented opportuni  es for deriving pluripotent stem cell lines from 
specifi c living individuals without the use of soma  c cell nuclear transfer (SCNT or “therapeu  c 
cloning”)[45]. iPSC appear overall to be very similar to ESC in terms of morphology, global gene 
and protein expression and diff eren  a  on poten  al, but epigene  c varia  ons between iPSC and 
ESC have been described [46-48].
The fi rst iPSC lines were generated from fi broblasts using gamma-retroviral vectors to introduce 
OCT4, SOX2, KLF4, and c-MYC [42,43] or OCT4, SOX2, NANOG, and LIN28 [44]. Over a period of 
several weeks, these transcrip  on factors induce expression of endogenous pluripotency genes 
like OCT4 and SOX2, and then become silenced once the endogenous genes take over control of 
pluripotency. Since the fi rst descrip  on of reprogramming by ectopic gene expression in this way, 
reprogramming of many other soma  c cell types, using diff erent methods of transcrip  on factor 
introduc  on have been published in quick succession. There are now reports describing miPSC 
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from almost every cell type in the mouse body, although crea  ng hiPSC from the equivalent 
human cell sources is s  ll more diffi  cult. Nevertheless, in addi  on to adult and fetal dermal 
fi broblast, iPSC have been created from mul  ple human  ssues including lung fi broblasts, 
fi broblast-like synoviocytes [43], kera  nocytes [49], cord blood [50,51], peripheral blood [52,53], 
mesenchymal stromal cells [54] and more recently oral mucosa fi broblasts [55] and T-cells 
[56,57]. The use of retroviral vectors to create iPSC has a number of limita  ons and thus much 
eff ort has gone into fi nding alterna  ves. Among these are len  viral vectors which, in contrast to 
retroviruses, can infect nondividing as well as dividing cells and also have a larger insert capacity 
than retroviral vectors. In principle this allows all of the reprogramming factors to be included in 
a single vector rather than requiring each to be incorporated into a separate vector.  Secondly, 
other viral vectors which do not integrate into the genome, such as adenoviral vectors, have 
also been used although they reprogram cells with extremely low effi  ciency [58,59]. Thirdly, 
viral-free methods are under development. These include the use of transposons [60], protein 
[61] and mRNA [62] introduc  on methods. The fi rst two methods also have low effi  ciency but 
the removal or absence of the transgenes has a number of advantages and more eff orts into 
transgene-free or removable transgene methods are ongoing. The mRNA approach however, 
has effi  ciencies similar to viral integra  on so will likely become a preferred method in the future. 
A fourth area of research inves  gates the use of small molecules to improve or replace the use 
of transgenes in reprogramming. For example, the addi  on of valproic acid (VPA) has been found 
to improve the overall effi  ciency of reprogramming [63]. 
iPSC have not only expanded the ethical acceptability of pluripotent stem cell research but 
have also allowed the deriva  on of cell lines from individual pa  ents, facilita  ng the crea  on 
of gene  c disease models in culture [64-66]. Moreover, in the context of clinical applica  on 
in cell therapy, once alterna  ves to viral integra  on methods for genera  ng iPSC are fully 
developed, it is possible that  ssue matching to the recipient may no longer be an issue although 
there will s  ll be the same kinds of hESC associated risks, such as teratoma forma  on from 
any residual undiff eren  ated cells in the transplanted cell popula  ons. Risks aside, the costs 
of cell produc  on for transplanta  on would nevertheless need to be greatly reduced for any 
individualized treatment.  
Human Embryonic Stem Cells and Cardiac Diff eren  a  on
While spontaneous diff eren  a  on of ESCs is easily achieved simply by omi   ng diff eren  a  on 
repressing factors or growing cells as EBs, directed diff eren  a  on, par  cularly of hESC, is 
more challenging. Using lessons from the embryogenesis, three main approaches have been 
developed to direct hESC towards the cardiac lineage in vitro. The fi rst approach is based on 
EB forma  on but includes mul  ple inducers, usually growth factors, and repressors known to 
infl uence heart development in the embryo (fi g. 2). This spontaneous form of diff eren  a  on 
can occur in regular growth medium containing fetal calf serum and is fi rst evidenced by 
contrac  le areas of rhythmically bea  ng cardiomyocytes [67]. The addi  on of growth factors 
and/or small molecules can further enhance EBs to a more directed diff eren  a  on down the 
cardiac lineage [68-72]. A method in which EBs were placed in “hanging drops” on a Petri 
dish lid had limited success with hESC compared with mESC [73]. However, the effi  ciency of 
cardiomyocyte diff eren  a  on in hESC, not normally more than 5% of all cells,  was greatly 
increased using defi ned growth factor condi  on and “spin EBs” (EBs created from precise cell 
numbers - ~3000/100μl diff eren  a  on medium -  and centrifuga  on in V-shaped wells of a 96-
well plate) [74,75]. Crucial addi  ons described in the literature include: transforming growth 
β-family members (bone morphogene  c proteins or BMPs and ac  vin), members of the Wnt 
family and fi broblast growth factor (FGF) family, all major regulators in cardiac development [76]. 
Additonally, vascular endothelial cells growth factor (VEGF), p38 inhibitor, stem cell factor (SCF), 
the wnt inhibitor Dkk1 (added late) and ascorbic acid [77-79] have been shown to be important 
and more recently, sulfonyl-hydrazone [80], a GSK-3 inhibitor (BIO) [81] and dorsomorphin [82] 
have been added to the list as possible candidates to improve cardiac diff eren  a  on.  
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Table 1 Summary of muta  ons associated with two cardiac diseases
IKs, slowly ac  va  ng delayed rec  fi er K+ current; IKr, rapidly ac  va  ng delayed rec  fi er K+ current; IVa, 
voltage-gated Na+ current; IK1, inward rec  fying K+ current; ICaL, L-type Ca+ current.











– TNNT2 Troponin T – <5
– TNNI3 Troponin I – <5














– TNNC1 Troponin C – <1
– TTN Ti  n – <1
LQTS LQT1 KCNQ1 KvLQT1 IKs 30–50
LQT2 KCNH2 HERG IKr 25–40
LQT3 SCN5A Nav1.5 INa 5–10
LQT4 ANK2 Ankyrin-B Mul  ple 1–2
LQT5 KCNE1 MinK IKr 2–3
LQT6 KCNE2 MiRP1 IKs <1
LQT7 KCNJ2 Kir2.1 IK1 <1
LQT8 CACNA1C Cav1.2 ICaL <1
LQT9 CAV3 Caveolin-3 INa <1





LQT12 ANTA1 α-Syntrophin INa <1
A second approach is based of stromal cell co-culture. This exploits the instruc  ve infl uence of 
endoderm for cardiac diff eren  a  on during embryogenesis and uses co-culture with endoderm-
like cell lines or their condi  oned medium. The use of a mouse visceral endoderm-like (END-2) 
cells without serum and insulin has been used to produce cardiomyocytes with a human fetal 
ventricular cell-like phenotype from various hESC lines provided they are “mechanically” rather 
than enzyma  cally passaged as undiff eren  ated cells [83-85]. 
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A third method u  lizes a high-density monolayer model supplemented with BPM4 and ac  vin 
A in a defi ned serum-free medium. Lafl amme et al. reported this method to be much more 
effi  cient than EB-based methods [86], although to date the number of publica  ons describing its 
use is limited and its reproducibility across diff erent hESC lines is s  ll unclear.
Ongoing improvements are being made to these methods, o  en involving the introduc  on of 
diff erent growth factors or small molecules at various phases in the diff eren  a  on process. In 
addi  on, many groups are looking into methods to produce more homogenous cardiac cell 
popula  ons (i.e. specifi c atrial, ventricular, conduc  on system type cell popula  ons rather than 
mixtures) whilst others are addressing the issue of cell maturity. Cardiac cells derived from 
stem cells generally show immature phenotypes. Recently, Otsuji et al. published a method for 
inducing matura  on involving  repla  ng of cardiomyocytes derived using the END2 co-culture 
method onto fresh END2 cells followed by a short 3D culturing step [87]. These cardiomyocytes 
could be maintained for one year during which  me they were found to become more mature in 
terms of their electrophysiological proper  es, and to contain an increased number of pacemaker 
cells [87]. Alterna  vely, allowing the cells to undergo cyclic stretch or forcing alignment using 
 ssue engineering approaches [88] may enhance maturity. 
Purifi ca  on of hESC derived Cardiomyocytes
The use of embryonic stem cell deriva  ves in research as well as possible clinical therapies is 
plagued with many problems including insuffi  cient purity. The inadvertent introduc  on of 
any undiff eren  ated ESCs into host  ssue will result in teratomas, benign tumors containing 
deriva  ves of all three germ layers. In addi  on, many diff eren  a  on techniques produce 
heterogeneous cell popula  ons with cardiomyocyte numbers varying from 1- ~50% of the cell 
total. In addi  on, in the END2 co-culture system, approximately 85% of the cardiomyocytes 
produce are ventricular [84], whilst other EB-based methods produce a mixture of cardiac atrial 
and ventricular cell types. Probably the most effi  cient cardiomyocyte diff eren  a  on protocols at 
the present  me are based on adap  on of undiff eren  ated hESC to feeder-dependent enzyma  c 
passage in KOSR (knock out serum replacement) followed by spin EBs containing ~3000 cells and 
the addi  on of BMP4 and ac  vin A at concentra  ons in the range of 20ng/ml [75]. Repla  ng 
of these EBs a  er 7 days in regular culture medium can yield up to 50% cardiomyocytes. In 
a  empts to enhance the diff eren  a  on of hESC to par  cular cardiac subtypes, Zhu et al found 
that inhibi  on of the NRG-1β/ErbB signaling pathway increased the propor  on of nodal-like 
cells, whereas its ac  va  on produced the reverse eff ect[89]. 
While many researchers are working on improving the effi  ciencies of diff eren  a  on and 
producing more homogenous popula  ons of cells, others are inves  ga  ng how best to purify 
the mixture of cells and select the required cell type. There are a number of diff erent approaches 
Figure 2: Cardiac transcrip  on factors and exogenous control of pluripotent stem cell diff eren  a  on The 
diff eren  a  on of pluripotent stem cell to cardiomyocytes is sequen  al with steps being dis  nguished by the 
expression of various (combina  ons of) transcrip  on factors. There are a number of diff erent diff eren  a  on 
methods but a specifi c set of exogenous factors are s  ll needed to force pluripotent stem cells down the cardiac 
lineage. While all the steps in the process are not clear, the  me of introduc  on of these factors is very important. In 
general, ini  al introduc  on of BMP4, ac  vin A and bFGF will start the directed diff eren  a  on and later introduc  on 
of a Wnt signal inhibitor (Dkk1) and VEGF will help to push the cells further to form cardiomyocytes. 
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being tested to select cardiomyocytes from mixed cell popula  ons. In some cases, fl uorescent 
reporters have been a  ached to cardiomyocyte-associated promoters and used to produce 
transgenic reporter lines [90-92]. The yield of cardiomyocytes a  er selec  on can be >90% but 
requires gene  c manipula  on which has not been successful in all hESC lines [90] and might 
not feasible for rou  ne use in hiPSC. Another approach uses Percoll gradient centrifuga  on to 
isolate the cardiomyocytes physically, based on their larger size compared with most other cells 
[93]. A third method selects cardiomyocyte progenitors using the cell surface protein Flk1 (also 
called KDR or VEGF receptor) [77]. However, these cells are also progenitors for endothelial and 
smooth muscle cells so that mixed popula  ons of cells might s  ll result. Furthermore, Flk1 is 
expressed on undiff eren  ated cells of some lines. A fourth approach was recently reported by 
Ha  ori and colleagues [94]. The researchers used a nontoxic dye tetramethylrhodamine methyl 
ester perchlorate (TMRM) which reversibly labeled the mitochondria. Labeling a mixed culture 
of cells produced three frac  ons, a high fl uorescent frac  on with >99% cardiomyocytes, an 
intermediate frac  on with other viable cells and a low frac  on which contained dead or blood 
cells. The ease and reversibility of this method may prove extremely useful in the future although 
at present it only works on cardiomyocytes maintained for long periods in culture (>50days).
Poten  al Uses of hESC derived Cardiomyocytes 
There are a number of uses envisaged for hESC derived cardiomyocytes both as research tools 
and for clinical applica  ons. These include drug screening and pharmacosafety analysis, disease 
modeling and gene targe  ng, as well as regenera  ve medicine.
In vitro drug screening
Many steps are required before a drug is approved for clinical applica  on and one of these is 
evidence for low toxic risk on the heart. Drugs may be recalled if signifi cant side eff ects occur 
and the heart is one of the most sensi  ve organs for this. Even a  er numerous tests in animals 
these side eff ects may remain undetected [95]. This may not be surprising since the diff erence 
between animal and human physiology is signifi cant, as men  oned earlier, and the way ion 
transport is handled diff ers between species. There is an increasing need for human models of 
healthy as well as diseased hearts. We have recently shown that hESC derived cardiomyocytes 
respond to specifi c drugs in much the way that the human heart responds, as assessed using 
readouts from microelectrode arrays [95]. Furthermore the ability of hiPSC to form various 
cardiac lineages may make them good candidates for some of the drug screening presently 
carried out using animals.
Gene targe  ng in hESC to create reporter lines and disease models
While there are now mul  ple descrip  ons of gene  c modifi ca  on of hESC in the literature, 
they have been considerably more challenging to modify than mESC. Substan  al progress over 
the last several years has led to mul  ple cell lines becoming available that have undergone 
targeted muta  on. Gene  c modifi ca  ons can now be introduced through non-homologous, 
homologous, site-specifi c or transposi  onal recombina  on. Non-homologous recombina  on 
is a straigh  orward and easy method of introducing exogenous DNA but has extremely low 
effi  ciency. In classical homologous recombina  on, exogenous DNA is introduced in the genome 
through the natural poten  al of cells to incorporate iden  cal or similar DNA sequences. The 
effi  ciency of this process varies between species and cells types. The effi  ciency of homologous 
recombina  on has also been found to be extremely low. Among the hurdles that have 
confounded this technology are the diffi  culty in cloning hESC from single cells [96], and  the low 
effi  ciency of DNA introduc  on using condi  ons which work well with mESC for example through 
electropora  on [97]. The use of zinc fi nger nucleases in homologous recombina  on has been 
reported to increase effi  ciency signifcantly. Zinc fi nger nucleases introduce double strand breaks 
at specifi c sites in the genome using novel DNA binding proteins. Zinc fi nger nucleases have been 
used in targe  ng a number of human genes including VEGF-A, HoxB13 and CFTR [98]. They have 




Site-specifi c recombina  on allows for more controlled introduc  on of exogenous DNA 
sequences. Two types of site-specifi c recombina  on are Cre-loxP and phiC31. In the Cre-loxP 
system a pair of recogni  on sequences promotes a reciprocal recombina  on reac  on, while 
phiC31 is an irreversible recombina  on using bacteriophages which a  ach to a  P sequences in 
the genome. Although Cre-loxP has been successfully used with hESC [99], to date there are no 
reports of gene  c modifi ca  on of hESC using phiC31 [100]. Another technique uses transposons 
to modify hESC, employing three diff erent systems, Sleeping Beauty [101], PiggyBac [102] and 
Mu [103]. All of these systems allow the integra  on of non-targeted DNA along chromosomes. 
They have diff erent effi  ciencies, cargo sizes, and excisability but all off er an alterna  ve to viral 
vector integra  on of DNA into the genome (reviewed in [104]).
The modifi ca  on of hESC by introduc  on of ectopic reporters or targe  ng developmentally 
important loci is becoming a very useful tool in understanding the diff eren  a  on of 
cardiomyocytes. It is of signifi cant interest in the study of heart disease, since it represents an 
opportunity to introduce diff erent muta  ons against a single gene  c background if using just 
one hESC line. In this respect gene  c modifi ca  on of hESC lines can compliment studies with 
human iPSC cells since deriving lines from diff erent individual pa  ents automa  cally implies a 
diff erent gene  c background.  
Which cardiac diseases will be useful to model using human pluripotent stem cells?
The most important task of the heart is to pump blood throughout the body. For this highly 
orchestrated temporal and spa  al ac  vi  es consis  ng of electrical ac  va  on and subsequent 
mechanical contrac  on of cardiomyocytes are essen  al. Disturbances in these processes may 
lead to serious or even life-threatening condi  ons. Over the past two decades, our knowledge 
of the gene  c basis of cardiac diseases has increased enormously. In that same period, many 
diff erent animal models have been generated for studying cardiac diseases, and although 
these have shed light on our understanding of the onset and progression of cardiac diseases, 
the emergence of new drugs and improved therapies have lagged behind. Several major 
breakthroughs in the stem cell fi eld in recent years, as described above, have made the academic 
and industrial biotechnology communi  es realize that development of human in vitro models 
for studying disease and drug discovery are within reach. In par  cular, development of more 
effi  cient and robust protocols for the produc  on of specialized cell types, like cardiomyocytes, 
from hESC has strengthened this awareness.
In order to develop predic  ve human in vitro cardiac disease models, a ra  onal choice would 
be to avoid complex, mul  -gene cardiac diseases involving mul  ple cell types or secondary 
aberra  ons in morphology and/or func  on. Instead, ini  al preference should be in cardiac 
diseases associated with muta  ons in single genes which most likely have an impact at the 
single cell level (e.g. autologously on cardiomyocytes). In this regard, many muta  ons in genes 
encoding cardiac ion channels and sarcomeric proteins, associated, for instance, with disturbed 
ion channel func  on (cardiac channelopathies) or impaired contrac  lity (cardiomyopathies), 
have been iden  fi ed. For both channelopathies as well as cardiomyopathies, the majority of 
muta  ons associated with the disease are present in a rela  vely small set of genes (Table 1). 
Along with further characteriza  on, of the hESC and hiPSC models, their value in understanding 
disease mechanisms needs demonstra  ng and their use as models for drug discovery remains 
to be shown. Nevertheless, proof of principle that this approach may be successful is beginning 
to emerge (see below). 
The imbalance in ion currents across the sarcolemma in pa  ents diagnosed with cardiac 
channelopathies is the cause of a change in the ac  on poten  al morphology. It manifests as 
an abnormal electrocardiogram (ECG) with abnormal peaks and intervals indica  ng cardiac 
arrhythmias (fi g.3).  Heritable cardiac channelopathies include long-QT syndrome (LQTS), 
Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, cardiac conduc  on 
disease and sinus node dysfunc  on [105]. LQTS, has a prevalence of 1 in 5000 individuals and is 
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the most common cardiac channelopathy. LQTS, can be subdivided into mul  ple types (LQT1 to 
LQT12) depending on which gene is mutated, but all prolong the dura  on of the ac  on poten  al 
and the QT-interval on an ECG. 
Cardiomyopathy is a heart disease that may result in inadequate pumping of the heart leading to 
conges  ve heart failure. Cardiomyopathy can be further classifi ed into diff erent forms, including 
hypertrophic (HCM), dilated (DCM) and restric  ve (RCM) cardiomyopathy and arrhythmogenic 
right ventricular dysplasia (ARVD). Of these HCM is the most frequent with a reported prevalence 
of as high as 1 in 500 individuals [106]. It is also the most common cause of sudden cardiac 
death among young athletes and in people under 30 years of age. HCM is characterized by an 
increase in le   ventricular wall thickness in the absence of increased a  erload, combined with 
disarray of cardiomyocytes and cardiac inters   al fi brosis. It was the fi rst cardiac disease for 
which a gene  c basis was iden  fi ed. To date, more than 450 muta  ons, distributed over 13 
sarcomere and myofi lament-related genes, have been classifi ed (Table 1). Moreover, 50% of the 
total number of muta  ons appear in only two genes, MYH7 (β myosin heavy chain) and MYBPC3 
(myosin binding protein C). 
The challenge for the coming years is to generate in vitro models using human stem cell -derived 
cardiomyocytes harboring disease-associated muta  ons, which faithfully recapitulate the 
cardiac disease phenotype as it manifests in pa  ents. This, in combina  on with development 
of robust predic  ve assay readouts (scalable for high throughput screening) will provide novel 
pla  orms for cardiac safety pharmacology, but, more importantly, also provide opportuni  es for 
novel drug discovery.     
Disease modeling in human iPSC cells
The development of iPSC technology and the possibility of making pa  ent specifi c embryonic 
stem cell-like cells, may complement the (rather slow) development of cardiac disease models 
based on hESC thus far. If hiPSC prove to be amenable to cardiac diff eren  a  on, which many 
researchers are beginning to show [107,108], disease specifi c human cardiomyocytes will 
become a very useful tool for studying and perhaps reversing cardiac disease. However, research 
into hiPSC characteriza  on and the eff ect of reprogramming and (epi)gene  c memory on these 
cells is s  ll ongoing. The uniformity and reliability of diff eren  a  on of several well studied hESC 
lines may make these the most useful near-term research tool, thus research in targe  ng and 
gene  c modifi ca  on of hESC is s  ll vital. 
Nevertheless, recent successes using hiPSC as models for human cardiac disease have been 
reported. Two groups have generated hiPSC lines from pa  ents with heart disease which show 
a disease phenotype in culture. Lemischka and colleagues produced cardiomyocytes from two 
Figure 3: Schema  c diagrams of normal and abnormal 
electrocardiograms (ECG). An electrocardiogram 
measures the electrical ac  vity of the heart across 
the chest wall. It is collec  ons of peaks and interval 
which help diagnose diseases. a) An example of 
a normal ECG. b,c,d) Examples of abnormal ECGs 
superimposed over a normal ECG. An elongated 
QT interval (b) is seen in a number of diseases 
including Long QT syndromes and catecholaminergic 
polymorphic ventricular tachycardia. The elevated 
ST (seen in ECG ‘c’) is o  en seen with a form of 
Brugada syndrome and a delta wave (d) is associated 
with Wolff –Parkinson–White syndrome which 
accompanies numerous heart defects. 
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hiPSC lines derived from two pa  ents with a heterozygous T468M subs  tu  on in PTPN11 which 
leads to LEOPARD syndrome [12]. LEOPARD syndrome aff ects various parts of the body but 
hypertrophic cardiomyopathy (HCM) is one of the most common life-threatening symptoms of 
the disease. The authors es  mated hypertrophy based on cell size, sarcomeric organiza  on and 
nuclear localiza  on of NFATC4, wh ich was comparable to the pa  ent phenotype. Furthermore 
the use of hiPSC in this research has also lead to several new insights into signaling pathways 
related to the disease, something which may have eluded researchers if not for hiPSC technology. 
A second report by More    et al inves  gated an ion channel muta  on in pa  ents with LQT1 [13]. 
These pa  ents have a muta  on in the KCNQ1 gene which results in an elongated QT interval. 
The KCNQ1 gene encodes I
Ks
, the ion channel controlling the slow component of the delayed 
rec  fi er potassium current which is par  ally responsible for the repolarizing phase of the ac  on 
poten  al. The authors were able to recapitulate this electrophysiological phenotype in culture 
using whole-cell patch-clamp electrophysiology a  er the crea  on hiPSC lines from two related 
pa  ents from a family with a R190Q missense muta  on in KCNQ1.
These fi rst two ground breaking ar  cles on cardiac hiPSC disease modeling are only the fi rst 
steps in an area of research with great poten  al. Both ar  cles bring to light one very important 
aspect of iPSC technology: the need for proper assays to determine a cellular phenotype. The 
heart is not composed of just one cell type but several and therefore recapitula  ng a phenotype 
can be diffi  cult. These two examples of hiPSC as cardiac disease models for basic characteriza  on 
of the disease itself are of interest but the opportuni  es they present for drug discovery will, in 
the long run, be of greater interest. 
Direct reprogramming of soma  c cells to cardiomyocytes
In a recent advance in direct reprogramming, Ieda et al (2010) showed the diff eren  a  on of 
mouse fi broblasts directly into cardiomyocytes using just three cardiac transcrip  on factors 
[109]. Mouse cardiac or tail  p fi broblasts were treated with a cocktail of genes which induced 
direct cardiac diff eren  a  on. A  er wading through 14 genes, the researchers found three 
‘master regulator genes’, Gata4, Mef2c and Tbx5, which were essen  al for direct reprogramming 
of fi broblast to cardiomyocytes. The effi  ciency of this direct reprogramming was higher than 
reprogramming to iPSC (20% compared to <0.1%) and it was also more rapid. Using an inducible 
system, they were also able to show the stability of their procedure. Whilst this fi nding remains 
to be confi rmed by others and has not yet been extended into human cells, it could represent 
another route to studying pa  ent derived cardiomyocytes for certain purposes. This new 
development may help eliminate some of the obstacles when using tradi  onal ESC or iPSC, 
including teratoma forma  on due to residual undiff eren  ated cells and lower the cost and 
delivery  me to pa  ents due to higher yields and faster produc  on. It has the disadvantage 
however, that the emergent cardiomyocytes cannot be expanded in culture. The method 
thus is likely best seen as a supplement to research with iPSC cells rather than an alterna  ve. 
It may however, represent an opportunity to inves  gate whether direct reprogramming to 
cardiomyocytes is feasible in the heart in vivo, for example a  er myocardial infarc  on.
Regenera  ve Medicine
The use of cell therapy to repair the heart is not a new concept. Its foremost aim is to introduce 
new cardiomyocytes into the heart to replace those that are damaged or dead for example 
a  er an infarct. However in prac  ce this is rather complex with many aspects of how this 
could work s  ll unclear. The fi rst a  empts at cell therapy for the heart were actually based on 
non-cardiomyocyte cell popula  on like bone marrow derived cells (BMC). While ini  ally BMC 
were reported to be able to transdiff eren  ate into cardiomyocytes thereby improving heart 
func  on, it was later found that this was not correct [110-112]. Nevertheless the use of BMC 
delivery to the heart con  nued, although with limited long term benefi ts in terms of cardiac 
func  on. Any short-term improvements, most likely involved enhanced local angiogenesis and 
thus blood supply in the border zone of the damaged heart  ssue, or paracrine factors of an 
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unknown iden  ty from the transplanted cells. This is also likely the reason for reduced chest pain 
symptoms and improved cardiac contrac  le and relaxa  on performance [15,16,113]. 
The inconclusive data from adult stem cell therapy trials to date and the limited success of 
sustaining non-cardiomyocyte presence in the heart, may make iPSC, cardiac progenitors or 
hESC a be  er source for cell therapy, since these cells can form cardiomyocytes (hESC-CM) or 
cardiac progenitor cells (hESC-CPC) for repair. Studies have shown that hESC-CM introduced into 
mouse or rat hearts will survive and mature [114-116]. However the cells are o  en separated 
from the animal heart by fi bro  c  ssue, and these hearts have only shown short term func  onal 
improvements [116]. While most studies have only been performed in small animals, a recent 
study in porcine showed improved cardiac func  on a  er intramyocardial injec  on of hESC-CM 
compared to the controls [117] although long term follow-up was not described.
Despite these transient improvements in cardiac func  on following hESC-CM transplanta  on in 
animals, there are a number of other obstacles which need to be overcome before transfer to 
humans may even be considered. In vivo, hESC-CM trigger an immune response. Therefore all 
studies thus far have involved immune suppression or used immunocompromised animals. The 
discovery of iPSC may help overcome this by crea  ng immune-matched cells for transplanta  on 
but a large cell bank would s  ll be necessary to match most of the popula  on since hiPSC lines 
for individual pa  ents, at present, would not be economically viable. Not only would cheaper 
reagents be necessary for scaling up cell produc  on, but the whole procedure would also have 
to be done under condi  ons of Good Manufacturing Prac  ce (GMP). These are by themselves 
costly and labor intensive. A second obstacle is the removal of all undiff eren  ated hESC (or 
hiPSC) before introduc  on into the body as described above, since undiff eren  ated pluripotent 
stem cells can give rise to teratomas when injected into a living organism, animal or human. 
Most important though in human pa  ents is the poten  al risk of arrhythmias, which can be 
caused by the introduc  on of immature cardiomyocytes with intrinsic pacemaker-like ac  vity 
into the human heart, as well as anisotropy and other scar-implanted cell interac  ons. 
Conclusions and future perspec  ves 
Even a  er more than a decade of research, the poten  al contribu  on of human embryonic stem 
cells to understanding cardiac disease and as a cell therapy is far from fully realized. Restricted 
in some countries by ethical issues, research into these cells was slow to start and o  en lacked 
fi nancial support. The discovery of iPSC technology has helped jump start the fi eld in recent 
years and has added much to our understanding of pluripotency and manipula  on of embryonic 
stem cells. Even though many ques  ons s  ll remain unanswered there is already much learned 
from hESC and this will likely accelerate implementa  on of pluripotent cells in general and in the 
cardiac arena.  Most important and immediate is likely to be the contribu  on of these cells to 
drug discovery since this is a signifi cant unmet need for new drugs as the incidence of myocardial 
infarct and heart failure increase in the aging popula  on. The number of new drugs entering the 
market for heart disease is decreasing, whilst investment by the pharmaceu  cal industry in this 
area con  nues to increase. This is perhaps the strongest evidence that present systems on which 
drug discovery is based are inadequate for future needs. In the context of safety pharmacology, 
big pharma is generally conserva  ve and will not be keen to have addi  onal safety tests imposed 
if they do not replace those in present use.  In addi  on, replacing present tests may increase 
their risk of li  ga  on should the new predictors prove wrong.  
Whilst many scien  sts began research with hESC with view to their poten  al in therapy, 
experiments over the last decade have indicated that this will be very challenging for many 
types of disease. Excep  ons likely include macular degenera  on (age-related blindness), since 
it is fairly easy to induce diff eren  a  on of hESC to re  nal pigment epithelial cells and the eye 
is hardly sensi  ve to immune a  ack, certain types of spinal cord lesion, for which the fi rst 
transplanta  on has recently taken place in the US, and diabetes, for which the transplanta  on 
technique is straigh  orward and some groups are now able to generate β-islet-like cells with 
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some reproducibility. The heart is certainly among the more challenging organs to repair because 
integra  ng cardiomyocytes with host  ssue may require more than simple injec  on. Thus drugs 
derived from research on stem cell-derived cardiomyocytes may then have the greatest clinical 
impact.    
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The genera  on of human induced pluripotent stem cells (hiPSCs) requires the 
collec  on of donor  ssue but clinical circumstances in which the interests of pa  ents 
have highest priority may compromise the quality and availability of cells that are 
eventually used for reprogramming. Here we compared (i) skin biopsies stored in 
standard physiological salt solu  on for up to 2 weeks (ii) blood outgrowth endothelial 
cells (BOECs) isolated from fresh peripheral blood and (iii) children’s milk teeth lost 
during normal replacement for their ability to form soma  c cell cultures suitable for 
reprogramming to hiPSCs. We derived all hiPSC lines using the same reprogramming 
method (a condi  onal (FLPe) polycistronic len  virus) and under similar condi  ons 
(same batch of virus, fetal calf serum and feeder cells).  Skin fi broblasts could be 
reprogrammed robustly even a  er long-term biopsy storage. Genera  on of hiPSCs 
from juvenile dental pulp cells gave similar high effi  ciencies but that of BOECs was 
lower. In terms of invasiveness of biopsy sampling, biopsy storage and reprogramming 
effi  ciencies skin fi broblasts appeared best for the genera  on of hiPSCs but where non-
invasive procedures are required (e.g. for children and minors) dental pulp cells from 
milk teeth represent a valuable alterna  ve.  
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Introduc  on
Human induced pluripotent stem cells (hiPSCs) generated from pa  ents with gene  c diseases 
hold great promise for disease modeling, safety pharmacology and drug discovery [1-3]. This is 
par  cularly relevant for cells of the internal organs, for which biopsies are not rou  nely available 
and therefore analysis of the disease phenotype is hampered. hiPSCs are similar to human 
embryonic stem cells (hESCs) [4] in that they self-renew and can diff eren  ate into all soma  c 
cell types of the human body. 
Since the fi rst deriva  on of hiPSCs in 2007 using fi broblasts cultured from skin biopsies and the 
retroviral expression of four pluripotency genes Oct3/4, Sox2, Klf4 and c-Myc [5], considerable 
research has been devoted to reprogramming other soma  c cell types, also using other methods 
of gene delivery to the host cell. These include integra  ng methods (e.g. using len  viruses 
or transposons) and a variety of non-integra  ng approaches (adenovirus, plasmid, protein, 
episomal vectors and RNA; reviewed in [6]). The obvious advantages of non-integra  ng methods 
are s  ll limited by their rela  vely low effi  ciencies, high cost and labor intensity. In addi  on, 
general transfec  on methods require rela  vely large numbers of soma  c cells. Integra  ng 
methods by contrast are reasonably effi  cient but the quality of the resultant iPSC lines may be 
compromised by random integra  on of transgenes, altering endogenous gene expression, or 
resul  ng in incomplete silencing of transgenes a  er reprogramming [7-9].  Excisable systems for 
removing transgenes represent an important improvement in this respect.
In addi  on to skin fi broblasts, reprogramming of kera  nocytes, hepatocytes, T-cells from 
peripheral blood, adipose  ssue-derived stem cells, dental pulp from adult teeth [10] and other 
cell types has been reported (reviewed in [1]. Criteria for selec  ng which soma  c cell type to 
reprogram include (i)  ssue accessibility and invasiveness of the biopsy procedure, (ii) whether 
the  ssue sample can be stored for prolonged periods during transport from clinic to laboratory, 
(iii) whether cell culture condi  ons are adequate for suppor  ng prolifera  on of the soma  c cells 
and (iv) the reprogramming effi  ciency of the par  cular soma  c cell type. 
Direct comparison of diff erent methods is hampered by variability in reagents and experimental 
protocols. Here we studied the isola  on and reprogramming effi  ciencies of three easily 
accessible soma  c cell types with view to examining how normal constraints in the clinic impact 
the experimental outcome. For reprogramming we used an excisable, polycistronic len  viral 
vector, which can be easily produced in large quan   es at low cost and only requires a small 
number of soma  c cells. An addi  onal dTomato reporter gene in the vector also enabled real-
 me monitoring of transduc  on effi  ciencies and silencing of transgenes. Skin fi broblasts and 
blood outgrowth endothelial cells (BOECs) were obtained by minimally invasive procedures (4 
mm punch biopsy and collec  on of peripheral blood, respec  vely) and milk teeth were obtained 
a  er natural loss. Isola  on of cells from all  ssues was straigh  orward. More importantly, skin 
fi broblasts could be readily isolated at any  me within two weeks a  er collec  on of the biopsy 
and reprogrammed with robust effi  ciencies even a  er storage of the biopsy for the en  re 
period simply in cold physiological buff ered saline. Similarly, cells from milk teeth could be easily 
isolated and reprogrammed at effi  ciencies comparable to skin fi broblasts. Isola  on of BOECs 
showed pa  ent-to-pa  ent variability and required a longer period in culture than skin fi broblasts 
or dental pulp cells to obtain suffi  cient cells for reprogramming. Reprogramming of BOECs was 
also less effi  cient than that of skin fi broblasts or dental pulp cells. However, hiPSC lines from all 
three  ssues displayed expression of typical markers of embryonic stem cells and diff eren  ated 
readily into deriva  ves of ectoderm, endoderm and mesoderm in vitro. Although much of the 
methodology used is rou  ne in many hiPSC laboratories, we have validated protocols here that 
(i) facilitate  ssue collec  on and transport from distant sites and (ii) provide an addi  onal non-




Isola  on of skin fi broblasts
Nine 4 mm punch biopsies were obtained from anonymously donated skin (from the Department 
of Dermatology, LUMC) and processed immediately (d0) as described below or stored in 
phosphate buff ered saline (PBS) at 4 °C for 7 and 14 days (d7, d14, respec  vely), before being 
processed (three biopsies per  me point).
For fi broblast isola  on skin pieces were incubated overnight at 4 °C in 25 U/ml of dispase (Gibco) 
dissolved in Dulbecco’s Modifi ed Eagle Media/F12 (DMEM/F12, Gibco). The next morning the 
biopsy was rinsed with PBS and the epidermis removed and discarded. Using a scalpel the dermis 
was minced into small pieces of approximately 0.5 mm by 0.5 mm, then incubated in 0.75% 
collagenase A (Roche) and 2 U/ml of dispase (Gibco) in PBS for one hour in a shaking water 
bath at 37 °C. The samples were mixed by gently vortexing every ten minutes during incuba  on. 
During this period, the pieces disintegrated. At the end of incuba  on fi broblast growth medium 
(Dulbecco’s Modifi ed Eagle Media (DMEM) supplemented with 2 mM L-glutamine, 10 mM non-
essen  al amino acids (NEAA), 75 U/ml penicillin, 75 μg/ml streptomycin, 50 μg/ml gentamicin, 
1 mM sodium pyruvate (all Invitrogen), 10 μg/ml ascorbic acid and 10 % fetal calf serum (FCS) 
(both Sigma)) was added. Cells were centrifuged for 5 min at 200 x g, resuspended in fi broblast 
growth media and plated in a T25 fl ask. Cells a  ached within one or two days. Upon reaching 
confl uence, cells were passaged according to standard procedures using trypsin/EDTA (Gibco) at 
a split ra  o of 1:3. Fibroblasts at passage 2 were used for reprogramming.
Figure 1: Characteriza  on of hiPSCs derived from skin fi broblasts, dental pulp cells or BOECs. Bright fi eld images 
of the soma  c cells before transduc  on (column I). Undiff eren  ated hiPSCs express typical markers of hESCs 
(red: NANOG, TRA-1-81; green: OCT3/4, SSEA-4) as shown by immunofl uorescent staining (columns II and III). 
Immunofl uorescent stainings of spontaneous diff eren  a  on of hiPSCs into deriva  ves of the three germ layers 
(columns IV-VI: AFP (green): endoderm; βIII-TUBULIN (red): ectoderm; CD31 (red): mesoderm; nuclei (DAPI, blue)). 
BOECs: Blood outgrowth endothelial cells; AFP: alpha feto-protein. Scale bar: 100 μm.
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Isola  on of dental pulp cells from milk teeth
Milk teeth from a 9 year old boy and a 10 year old girl were collected anonymously and 
stored dry at 4 °C overnight. Each tooth was washed with PBS, wrapped in Parafi lm and plas  c 
bags and mechanically crushed using a hammer. The pieces were incubated in a mixture of 
4 mg/ml dispase (Gibco) and 3 mg/ml collagenase A (Roche) for 1 hour in a shaking water bath at 
37 °C, with gentle vortexing every 10 minutes. At the end of incuba  on, fi broblast growth media 
was added; the cells were centrifuged at 200 x g for 10 minutes and resuspended in fi broblast 
growth media containing 2.5 mg/L amphotericin B (Sigma). Cells were plated in a 6 cm dish 
un  l reaching confl uence and subsequently split 1:3 using trypsin/EDTA according to standard 
procedures. Amphotericin B was removed a  er the fi rst passaging. For reprogramming we used 
dental pulp cells at passage 3. 
Isola  on of BOECs
BOECs were isolated from anonymously donated peripheral blood as described previously 
[11] with the excep  on that FCS (Sigma) was used instead of pooled human platelet lysate. In 
brief, 20 ml of blood was collected in a BD Vacutainer NH 170 iU and then mixed with complete 
EGM-2 media (Lonza) supplemented with 10 % FCS and addi  onal heparin (100U/ml, Biochrom 
AG). A  er 24 hours erythrocytes were removed by gentle washes with PBS and the remaining 
cells cultured in EGM-2 with 10 %FCS un  l colonies of cells with cobblestone morphology 
appeared 14-21 days later. Once colonies had reached diameters of approximately 1 cm, cells 
were passaged using trypsin/EDTA. For reprogramming we used BOECs at passage 1 to 5. Ficoll-
based isola  on of BOECs was performed as described (Wang et al., submi  ed).
Flow cytometry analysis of BOECs
BOECs were trypsinized and incubated with an an  body against CD31 (CD31-APC, eBioscience) 
or CD34 (CD34 PerCPC/Cy5.5, BD Pharmingen) for 30 min at 4 °C and subsequently analyzed with 
a LSRII FACS ( BD Pharmingen). 
Reprogramming vector and len  virus produc  on 
Len  viruses containing a self-inac  va  ng polycistronic casse  e encoding Oct3/4, Sox2, Klf4, 
and c-Myc [12] were produced using polyethyleneimine to cotransfect HEK/293 T cells with the 
expression vector pRRL.PPT.SF.hOKSM.idTomato.preFRT and the helper vectors pCMV-VSVG, 
pMDLg-RRE, pRSV-REV. The virus was harvested a  er 48 hours. The amount of virus par  cles was 
measured by ELISA detec  ng HIV p24 using a kit (Zeptometrix) according to the manufacturer’s 
protocol and the virus  ter was es  mated by mul  plying the p24 concentra  on (ng/ml) with a 
factor of 2500 [13]. 
Reprogramming skin fi broblasts
For len  viral infec  on, 2 x 104 fi broblasts were seeded into one well of a 12-well plate and 
transduced 4 to 6 hours later with the len  virus at 0.4 mul  plicity of infec  on (MOI) in the 
presence of 4 μg/ml polybrene (Sigma-Aldrich) in fi broblast media. The virus was removed a  er 
24 hours. Six days a  er transduc  on, the cells were harvested and subjected to fl ow cytometry 
analysis (LSRII FACS, BD) for quan  fi ca  on of dTomato expression.  A  er determining effi  ciencies 
10,000 fi broblasts were seeded on mouse embryonic fi broblasts (MEFs; 2 x 106 MEFs/10 cm 
dish) and cultured in hESC KOSR Medium (Dulbecco’s Modifi ed Eagle Media (DMEM)/F12 
supplemented with Glutamax, 10 mM NEAA, 25 U/ml penicillin, 25 μg/ml streptomycin, 
100 μM β-mercaptoethanol, 20 % knockout serum replacement (KOSR; Invitrogen) and 10 ng/
ml basic FGF (PreproTech)). Medium was changed every other day un  l the appearance of hESC-
like colonies.
hiPSC lines were named according to the nomenclature suggested by Luong et al. [14]. The data 
shown in Figures 1 and 2 was generated from hiPSC line C (LUMC0016iCTRL).  
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Reprogramming of dental pulp cells from milk teeth
Dental pulp cells from milk teeth were reprogrammed as described above for skin fi broblasts 
with MOIs of 0.5, 1 and 5. The hiPSC line G (LUMC0012iCTRL) was used to generate data shown 
in Figures 1 and 2.
Reprogramming of BOECs 
BOECS were reprogrammed as described for skin fi broblasts except that MEFs were added 
a  er a  achment of transduced BOECs. Four days a  er transduc  on, BOECs were harvested 
and seeded on gela  nized 10 cm dishes in EGM-2/10 % FCS medium. The following day, MEFs 
were added at a density of 1.7 x 106 cells/10 cm in MEF medium (DMEM supplemented with 2 
mM L-glutamine, 10 mM non essen  al amino acids, 25 U/ml penicillin, 25 μg/ml streptomycin, 
10 % FCS (Sigma)) A  er 24 hours cells were cultured in hESC KOSR medium un  l the appearance 
of hiPSC colonies. The hiPSC line F (LUMC0018iCTRL) was used to generate data shown in 
Figures 1 and 2.
Picking of hiPSC colonies and expansion
hESC-like colonies were picked manually, and cultured and expanded in mTeSR1 according to the 
manufacturer’s protocol (Stem Cell Technologies). 
RT-PCR
Total RNA was isolated from undiff eren  ated hiPSCs using the NucleoSpin RNAII kit (Macherey-
Nagel) according to the manufacturer’s instruc  ons. cDNA was synthesized from 2 μg of RNA 
using the iScript cDNA synthesis kit (Invitrogen). Primers and PCR condi  ons were as previously 
described [15]. PCRs were performed with SilverStar Taq polymerase (Eurogentec). 
We used the Nkx 2-5eGFP/w hESC line [16;16] as a standard for the expression of typical markers of 
undiff eren  ated pluripotent stem cells. 
Microarray and PluriTest
For whole genome microarray total RNA was isolated from 1 x 106 cells with a RNA isola  on kit 
(Qiagen) and hybridized on Illumina HT12v4 microarrays following the manufacturer’s protocol 
and as previously described [17]  The raw microarray data was analyzed with the PluriTest 
algorithm as described [17]. 
Alkaline phosphatase (AP) staining and calcula  on of reprogramming effi  ciencies
Citrate-acetone-formaldehyde fi xed colonies were exposed to an alkaline-dye mixture according 
to the manufacture’s instruc  ons (Sigma-Aldrich, 86R-1KT). The reprogramming effi  ciencies 
were calculated as the number of AP posi  ve colonies normalized to the number of cells seeded 
on MEFs a  er transduc  on.
Southern blot
DNA from hiPSC colonies was collected using phenol chloroform extrac  on. DNA was digested 
by SphI and run on a 0.7 % TAE gel. The DNA was then transferred onto a nylon membrane and 
incubated with a 32P-labeled probed against RRE. 
Spontaneous diff eren  a  on of hiPSCs into deriva  ves of the three germ layers
hiPSC colonies were passaged as described and pieces cultured in mTESR1 on Matrigel coated 
chamber slides (BD Falcon) for two days. Subsequently cells were cultured in DMEM/F12 (Gibco) 
supplemented with 20 % FCS to induce mesoderm or in DMEM/F12 supplemented with 1 % FCS 
and 50 ng/ml Ac  vin A (R&D systems) to induce both ectoderm and endoderm.
The medium was changed every other day.  A  er 3 weeks the cells were fi xed with 2 % PFA for 
30 min at room temperature.
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Table 1: Eff ect of skin biopsy storage on reprogramming effi  ciencies. 
Number of fi broblasts 
7 days a  er isola  on
Transduc  on effi  ciency (%) Reprogramming effi  ciency (% )
Day 0 (A) 1,090,000 3.2 0.02
Day 0 (B) 266,250 5.9 0.58
Day 0 (C) 236,250 11 0.84
Day 7 (A) 100,00 3.6 0.016
Day 7 (B) 109,375 4.7 0.33
Day 7 (C) 90,625 6.4 0.58
Day 14 (A) 100,000* 2.4 0.012
Day 14 (B) 37,500 2.6 0.18
Day 14 (C) 17,500 7.8 0.55
*number of cells a  er 14 days in culture
Immunofl uorescent staining
Immunofl uorescent staining was performed according to standard procedures. Briefl y PFA fi xed 
cells were permeabilized with Triton X-100, blocked with 4 % normal goat serum for 1 hour 
before overnight incuba  on with the primary an  body (NANOG (1:500, Peprotech), SSEA-4 
(1:30, Biolegend), OCT3/4 (1:100, Santa Cruz), TRA-1-81 (1:25, Biolegend), βIII-TUBULIN (1:2000, 
Covance), AFP (1:25, Quar  et), CD31 (1:100, DAKO), von Willebrand factor (VWF, 1:1000 DAKO), 
VE-cadherin (1:200 Santa Cruz)) at 4 °C. The next day, secondary an  bodies labeled with Cy3 
(1:200, Jackson Immuno Research), Alexa 568 (1:200, Invitrogen) or Alexa 488 (1:500, Invitrogen) 
were added for 1 hour at room temperature.  Nuclei were stained with DAPI before moun  ng 
slides with Mowiol (Calbiochem).
Results:
Reprogramming cells from skin biopsies a  er long-term storage
Skin fi broblasts were isolated from three 4 mm punch biopsies under local anesthesia, which 
are regarded as minimally invasive and do not require s  tching. Since immediate processing 
of biopsies is not always possible, for example if pa  ents are in clinics distant from the iPSC 
laboratory or even in diff erent countries, we tested the eff ect of prolonged biopsy storage on 
fi broblast isola  on and reprogramming effi  ciencies. In order to assess variability between skin 
samples of diff erent origins, we took biopsies from three healthy individuals (samples A-C, 
Table 1). Fibroblasts were isolated from samples from each individual either immediately (d0) or 
a  er seven (d7) or 14 day (d14) storage in PBS at 4 °C. At each  me point fi broblasts were isolated 
enzyma  cally, plated and counted a  er one week. As expected, fi broblasts grew readily from all 
d0 biopsies with samples yielding between ~ 2.5 x 105cells and 1 x 106cells (Table 1, samples A-C). 
Skin fi broblasts were isolated immediately a  er biopsy sampling (d0) or a  er 7 or 14 days of storage in PBS (d7 
and d14) from three individuals (A, B, and C; le   column). The total number of skin fi broblasts from each  me 
point was counted one week a  er isola  on (second column from le  ). Transduc  on effi  ciencies (% of cells ex-
pressing dTomato) were determined by fl ow cytometry analysis six days a  er transduc  on with 0.4 MOI (third 
column from le  ). Reprogramming effi  ciencies based on the number AP expressing colonies normalized to the 
number of cells seeded on MEFs (right column). AP: alkaline phosphatase; MOI: mul  plicity of infec  on; MEFs: 
mouse embryonic fi broblasts.
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Surprisingly, suffi  cient fi broblasts for reprogramming could also be isolated from biopsies a  er 
long-term storage, although the effi  ciency was clearly reduced. At d7 of processing we obtained 
~ 1 x 105 cells from each biopsy corresponding to 60 % (Table 1, samples B, C) and 90 % reduc  on 
compared to d0 processing (sample A). Fibroblast numbers were further reduced when the 
biopsy was processed a  er 14 days of storage (Table 1). Nevertheless, fi broblast numbers 
obtained a  er 2 weeks storage were suffi  cient for reprogramming since we only used 1-2 x 104 
cells for len  viral transduc  on. The lifespan of fi broblasts in culture is limited by the Hayfl ick’s 
factor (the maximum number of popula  on doublings that a normal cell can undergo) and cells 
typically go into senescence a  er prolonged periods of culture [18;19]. Yet a prerequisite for 
cellular reprogramming is that soma  c cells are ac  vely dividing [20;21]. Since increased cell 
death during long-term storage of biopsies is likely to reduce the star  ng number of fi broblasts 
in the samples even before isola  on, it can be inferred that a higher number of popula  on 
doublings before reprogramming could take place. We therefore checked whether fi broblasts 
isolated from biopsies a  er long-term storage displayed any visible signs of senescence. As 
shown in Figure 1, cells from d7 and d14 had typical spindle-like fi broblast morphologies similar 
to the d0 cells and did not show any obvious signs of senescence. We were thus able to obtain 
suffi  cient numbers of prolifera  ng fi broblasts from small skin biopsies even a  er prolonged 
storage.  Next we tested whether cells isolated at diff erent  me points could be transduced with 
a polycistronic len  virus carrying the four Yamanaka factors and a dTomato reporter [12]. Equal 
numbers of cells from d0, d7 or d14 were plated and transduced overnight at a MOI of 0.4. In 
an ini  al experiment we found that MOIs between 0.2 and 0.4 generate hiPSCs with one or two 
proviral integra  ons at favorable effi  ciencies (supplementary Fig. 1). Fibroblasts were harvested 
six days post-transduc  on and subjected to fl ow cytometry for quan  fi ca  on of dTomato-
expressing cells. In general the number of dTomato-posi  ve cells did not exceed 11 % (Table 1). 
For two out of three samples, transduc  on effi  ciencies in fi broblasts from d7 or d14 were lower 
compared to d0 fi broblasts with a maximal reduc  on of roughly 50 % (Table 1, samples B, C). 
The transduc  on effi  ciency of sample A fi broblasts was low (d0 and d7) and was further reduced 
only at d14 (Table 1). Next, we tested whether fi broblasts isolated a  er long-term storage (d7 
and d14) could s  ll be reprogrammed to hiPSCs and whether the effi  ciencies diff ered from that 
Figure 2: Undiff eren  ated hiPSCs express markers of pluripotent stem cells. A) RT-PCR analysis 
of the expression of pluripotent stem cell markers in soma  c cells, hiPSCs and hESCs. GAPDH 
was used as a loading control. B) PluriTest analysis of hiPSCs derived from skin fi broblasts (d14), 
BOECs and dental pulp cells. All hiPSC lines have a high Pluripotency Score and a low Novelty 
Score indica  ng that they resemble normal pluripotent stem cells. The scores of a hESC line and 
fi broblasts, both from the reference pool are shown for comparison. BOECs: Blood outgrowth 
endothelial cells; DPCs: Dental Pulp Cells; hESCs: human embryonic stem cells; hiPSCs: human 
induced pluripotent stem cells; MEF: mouse embryonic fi broblasts.
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of freshly isolated ones (d0). A  er fl ow cytometry analysis, transduced fi broblasts were seeded 
on MEFs and cultured in hESC media. When hESC-like colonies emerged, we used AP staining to 
quan  fy the number of hiPSC colonies. We found that AP staining closely overlaps with silencing 
of the transgenes (as determined by the absence of dTomato expression) indica  ng that AP 
staining can indeed serve as a preliminary marker to es  mate the effi  ciency of reprogramming 
(supplementary Fig. 2). Silencing of the transgenes is required for successful reprogramming 
[21]. In a fi rst experiment we reprogrammed fi broblasts from sample A. For freshly isolated cells 
(d0) we obtained a reprogramming effi  ciency of 0.02 % (Table 1). Reprogramming effi  ciencies 
were similar for fi broblasts isolated from biopsies, which had been stored for 7 or 14 days 
(Table 1). Since the reprogramming effi  ciency for this par  cular sample was low compared to 
previous experiments (data not shown) we generated hiPSC lines from samples B and C. For 
both, reprogramming effi  ciencies were high (~0.6-0.8 %, d0, Table 1). Reprogramming effi  ciencies 
were only slightly decreased when hiPSCs were generated from d7 or d14 fi broblasts (Table 1). 
S  ll, even at the lowest reprogramming effi  ciency (0.18 %, 14d, sample B) we obtained eighteen 
hiPSC colonies from 10,000 cells seeded on MEFs. This is far more than the average amount of 
three clones generally used to assess clonal varia  on. Colonies with hESC-like morphology were 
picked from d0, d7 and d14 samples between 28 and 42 days a  er transduc  on and could be 
readily expanded on Matrigel and mTESR (Fig. 3B). Undiff eren  ated hiPSCs derived from d0, 
d7 or d14 fi broblasts expressed markers typical of hESCs as assessed by immunofl uorescent 
staining (Fig. 1) and RT-PCR (Fig. 2A). In addi  on all lines were able to diff eren  ate eff ec  vely 
into deriva  ves of the three germ layers in vitro (Fig. 1). In order to verify the pluripotent state, 
we used PluriTest to analyze undiff eren  ated hiPSCs derived from d14 fi broblasts. The most 
stringent assay of pluripotency in human pluripotent stem cells (PSCs) is generally regarded as 
teratoma forma  on a  er injec  on of undiff eren  ated cells into immunocompromised mice. 
Teratomas of hPSCs should contain deriva  ves of all three germ layers. However, aside from 
requiring animal use and being  me consuming, the results are diffi  cult to quan  fy. By contrast 
PluriTest is a bioinforma  c assay which predicts pluripotency based on the comparison of the 
microarray data of a query sample with the expression profi les from more than 250 pluripotent 
stem cell lines as well as from non-pluripotent cells [17]. The resul  ng “Pluripotency Score” 
indicates the extent to which the query sample contains a pluripotent signature whereas the 
“Novelty Score” reports whether the tested cells resemble normal PSCs [17]. As shown in Figure 
2B, hiPSCs derived from 14d fi broblasts had a high Pluripotency Score whereas their Novelty 
Score was low, indica  ng that they were indis  nguishable from normal hESCs. In summary, we 
have developed an effi  cient protocol to generate hiPSCs from fi broblasts isolated from biopsies 
even a  er prolonged storage in very simple and readily available condi  ons. To our knowledge 
this is the fi rst report showing that skin fi broblasts can be effi  ciently reprogrammed even when 
their isola  on from biopsies is delayed for up to 14 days.  
Reprogramming of blood outgrowth endothelial cells (BOECs)
Although punch biopsies are minimally invasive, the procedure can be unpleasant and not all 
pa  ents agree to donate  ssue in this way. Taking blood is even less invasive and o  en part of 
rou  ne pa  ent examina  ons. We therefore inves  gated whether peripheral BOECs could be 
reprogrammed into hiPSCs and how the effi  ciency compared with skin fi broblasts. To isolate 
BOECs, we used a method similar to that described by Reinisch et al. [11]. Briefl y 10-20 ml of 
blood was mixed at a ra  o of 1:4 with EGM-2 endothelial growth media containing FCS and then 
cultured in endothelial growth media un  l colonies of cells with cobblestone-like morphologies 
emerged about three weeks later. Cells expressed von Willebrand factor (VWF) and CD31 and 
were able to form typical tubular networks on Matrigel (not shown). Flow cytometry analysis 
revealed that the majority of the cells expressed CD31 (~80 %) whereas a smaller propor  on was 
double posi  ve for CD31 and CD34 (14 %, data not shown). In a fi rst experiment, we transduced 
BOECs at MOIs of 1, 10 or 25 and obtained a single hiPSC colony four weeks post transduc  on at 
10 MOI, corresponding to a reprogramming effi  ciency of 0.001 % (Table 2, sample D). The colony 
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was picked and expanded on Matrigel in mTESR1 media. hiPSCs expressed typical markers of 
pluripotency, as above, and were able to diff eren  ate into the three germ layers in vitro (not 
shown).  The low reprogramming effi  ciency could have been caused by virus overload, thus we 
aimed at op  mizing the amount of virus in the subsequent experiment: BOECs from a diff erent 
individual were transduced with 1, 2 or 4 MOI. At 1 MOI 40 % of the cells expressed dTomato 
and the percentage further increased up to 70 % at 4 MOI (table 2). hiPSC colonies appeared 
late (4-7 weeks post transduc  on, Fig. 3B) and were again scarce. Due to the low numbers, 
we only quan  fi ed hiPSC colonies based on morphology and silencing of transgenes (absence 
of dTomato). Reprogramming effi  ciencies were generally low, with ~0.002 % at 1 MOI and a 
maximum of 0.008 % at 2 MOI (Table 2, sample E). hiPSC colonies were picked and expanded on 
Matrigel in mTESR1 media. Cells expressed the typical set of pluripotency markers and were able 
to diff eren  ate into deriva  ves of all three germ layers in vitro (supplementary Fig. 3). 
 
   Table 2 :Transduc  on and reprogramming effi  ciencies for dental pulp cells and BOECs.
Transduc  on effi  ciency (%) Reprogramming effi  ciency (%)
MOI MOI
1 10 25 1 10 25
BOECs (D) N/A N/A N/A 0 0.0011 0
1 2 4 1 2 4
BOECs (E) 42 61 70 0.0019 0.0083 0.0058
BOECs (F) 2.5 4.9 16.2 0.012 0.064 0
0.5 1 5 0.5 1 5
Tooth (G) 2.5 4.9 16.2 0.012 0.064 0
Tooth (H) 3.2 4.8 16.7 0.11 0.30 0.36
Using the method for isola  on of BOECs described above, we were unable to obtain BOECs 
from about half of the blood samples. In addi  on the number of BOEC-colonies clearly varied 
between pa  ents and approximately 1x105 cells could be obtained in the best case. We therefore 
tried to isolate BOECs from 80 ml of blood with a standard Ficoll-based method. We were then 
able to obtain BOECs in four out of fi ve blood samples. Lower amounts of blood drama  cally 
decreased the success rate for the isola  on of BOECs (data not shown). For reprogramming, 
Ficoll-isolated BOECs were transduced with the len  virus at 1, 2 or 4 MOI (table 2, sample F). 
Although transduc  on effi  ciencies were low, we obtained two colonies at both 2 and 4 MOI 
corresponding to a reprogramming effi  ciency of 0.018 and 0.022 %, respec  vely. Again colonies 
were pluripotent as assessed by immunofl uorescent staining (Fig. 1) and RT-PCR (Fig. 2A) and 
readily diff eren  ated into deriva  ves of the three germ layers (Fig. 1). In addi  on, BOEC-derived 
hiPSCs were pluripotent as assessed by PluriTest (Fig. 2B).  
hiPSCs can thus be generated from BOECs isolated using diff erent methods, although 
reprogramming effi  ciencies in general tend to be lower compared to skin fi broblasts under the 
same condi  ons.  
BOECs or dental cells were transduced with increasing MOIs as indicated and transduc  on effi  ciencies 
determined by fl ow cytomtery analysis of dTomato expressing cells (second column from le  ). Reprogram-
ming effi  ciencies are based on the number of hESC-like colonies (BOECs) or AP expressing cells (dental pulp 
cells) normalized to the number of cells seeded on MEFs (right column). AP: alkaline phosphatase; 
MOI: multiplicity of infection; MEFs: mouse embryonic fibroblasts.
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Reprogramming cells from milk teeth
In the Netherlands and possibly elsewhere, medical ethics commi  ees will generally not permit 
punch biopsies from children and minors unless part of a surgical procedure. In addi  on a 
volume of 40 ml is regarded as the maximum acceptable for pediatric blood collec  on. Previously 
reprogramming of cells obtained from dental pulp from adult individuals has been reported 
[10] Here we inves  gated whether milk teeth obtained from children a  er natural loss could 
also be used for this purpose. Fibroblast-like cells were isolated from teeth stored dry overnight 
at 4 °C and these expanded readily in culture reaching numbers between 4.5x105 and 7.5x105 
cells a  er 16 or 19 days, respec  vely, with the capacity for further expansion as necessary for 
storage or  ssue banking. Next we added increasing amounts of a len  virus carrying the four 
Yamanaka factors and a dTomato reporter (0.5, 1 or 5 MOI). The transduc  on effi  ciency analyzed 
by fl ow cytometry at day 6 post transduc  on was directly correlated with the amount of virus 
although not linearly. Cells from both samples showed similar transduc  on effi  ciencies with 
a maximum of ~ 16 % at 5 MOI (Table 2). Transduced cells were plated on feeders and the 
number of hiPSC colonies was quan  fi ed with AP staining. Despite similar transduc  on rates, 
we observed a pa  ent-specifi c varia  on in reprogramming effi  ciencies (Table 2): Whereas 
one sample was reprogrammed at an effi  ciency similar to that of skin fi broblasts (sample (H), 
Table 2) the reprogramming effi  ciency of the second sample was about 5  mes lower (sample 
G). hiPSC colonies from sample H (from all MOIs) were picked 32-42 days a  er transduc  on 
indica  ng that reprogramming kine  cs of juvenile dental pulp cells and skin fi broblasts are 
approximately similar (Fig. 3B). Colonies expressed the typical set of pluripotency markers as 
assessed by immunofl uorescent staining (Fig. 1) and RT-PCR (Fig. 2A) and diff eren  ated readily 
into deriva  ves of the three germ layers in vitro (Fig. 1). Again PluriTest iden  fi ed these hiPSCs 
as closely resembling normal hESCs (Fig. 2B). Thus hiPSCs can be generated from teeth obtained 
in a completely non-invasive manner from children at effi  ciencies similar to reprogramming of 
skin fi broblasts. 
Figure 3: Len  viral vector and kine  cs of soma  c cell isola  on and reprogramming.  A) Schema  c of the 
polycistronic len  viral vector used to generate iPSCs. B) Isola  on and reprogramming  melines for skin 
fi broblast, dental pulp cells, and BOECs, respec  vely. hiPSCs: human induced pluripotent stem cells; BOECs: 




In this study, we isolated cells from three easily accessible soma  c  ssue sources and compared 
reprogramming effi  ciencies using a polycistronic len  virus. Skin fi broblasts and cells from milk 
teeth could be readily isolated and reprogrammed at similar effi  ciencies even if the skin samples 
had been stored for up to 14 days in a simple salt solu  on. By contrast the isola  on effi  ciency of 
BOECs was variable from individual to individual in our hands and reprogramming effi  ciencies in 
general tended to be lower compared to the other two cell types. 
Numerous reprogramming methods with diff erent soma  c cell types have been published 
[22-24]. Nevertheless comparisons of effi  ciencies between laboratories remain diffi  cult, even 
if the same reprogramming methods are used. The main reasons for this are diff erences in 
experimental procedures and the use of undefi ned cell culture components, which display high 
batch-to-batch variability. Although we did not reprogram skin fi broblasts, BOECs and dental 
pulp cells simultaneously, all of the hiPSC lines from the three  ssue sources were generated with 
the same reprogramming method and under similar condi  ons that is with the same batches of 
FCS, len  virus and MEFs. Our results show that skin fi broblasts and dental pulp cells can be 
isolated rapidly and are reprogrammable with similar kine  cs and at similar effi  ciencies. As we 
had observed earlier for skin fi broblasts, low amounts of virus were suffi  cient to generate hiPSC 
with a maximum of two proviral integra  ons. For most of the clones however one transgene 
copy was suffi  cient for reprogramming. Since we used an excisable len  virus, this off ers the 
possibility of genera  ng transgene-free hiPSCs by addi  on of the FLPe enzyme. This has been 
done rou  nely in independent experiments genera  ng disease hiPSC lines (Dambrot et al. and 
Mikkers et al., unpublished).
Between the fi broblasts isolated from diff erent individuals we observed some variability in 
reprogramming effi  ciencies although numbers of independent experiments were limited. For 
fi broblasts from individual A the effi  ciency of hiPSC genera  on was more than tenfold lower 
compared to samples B and C. Nonetheless transduc  on effi  ciencies were within the same 
range. This variability may therefore have been individual specifi c. 
Compared to skin fi broblasts, dental pulp cells were derived in a completely non-invasive manner 
and thus represent an excellent source of soma  c  ssue for children. The reprogramming of 
dental pulp cells from adult teeth has been reported previously [10]  but the results here show 
that this is also effi  cient from juvenile teeth at the end of their lifespan even a  er dry storage at 
4 °C. This is important since the  me point of natural loss of teeth is o  en not precisely predictable 
and experimental planning may be more diffi  cult for this type of  ssue. We demonstrated that 
immediate processing is not required. In addi  on dental pulp cells can also be isolated from 
teeth, for which extrac  on for pathological reasons is scheduled. One disadvantage of this type 
of  ssue however, is a higher risk of bacterial and fungal contamina  on since teeth are directly 
exposed to pathogens. Treatment with addi  onal an  bio  cs and fungicides immediately a  er 
isola  on can help overcome this problem.
Compared to the skin fi broblasts and dental pulp cells, isola  on of BOECs from small amounts 
of blood was only successful in some of the samples and outgrowth of the cells was more 
 me-consuming. The reason for this is possibly the low abundance of BOECs in peripheral 
blood. Indeed BOECs represent only a small frac  on of mononuclear cells and their numbers 
vary considerably between donors [25]. This may be due to pathological condi  ons which 
infl uence the abundance of the cells in the blood [26]. It is likely that higher blood volumes 
would increase the effi  ciency for isola  on of BOECs. Unfortunately this would require high 
amounts of EGM-2 media, which is expensive. As an alterna  ve method we therefore tried to 
isolate BOECs from 80 ml of blood with a standard Ficoll-based method. Indeed this increased 
the success rate for isola  on of BOECs. Nevertheless not every adult individual may agree to 
donate such a rela  vely large volume of blood. For pediatric samples a volume of 40 ml is 
regarded as the maximum. Thus for children, blood as used here is not a likely  ssue source 
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for reprogramming. Another disadvantage of blood samples maybe their limited storage. 
For the isola  on of BOECs, processing of the blood is ini  ated within two hours a  er blood 
collec  on [11]. In addi  on, culture of BOECs requires specifi c growth medium, which is rela  vely 
expensive. Importantly, compared to fi broblasts and dental pulp cells, reprogramming of BOECs 
was slower and tended to be less effi  cient. Our experiments therefore indicated that BOECs may 
be less suitable for reprogramming than skin fi broblasts and dental pulp cells, at least with this 
len  viral vector and experimental condi  ons used here. On the other hand, these cells could 
be ideal for reprogramming in other circumstances, for example, if diff eren  a  on of hiPSCs 
into the endothelial lineage is required. Eff ects of epigene  c memory, which predispose iPSCs 
to favor diff eren  a  on towards their cell of origin, have been reported for various cell types 
[27]. In addi  on, BOEC-iPSCs lack irreversible rearrangements in genes involved in T cell and B 
lymphocyte func  on, contrary to iPSCs generated from these blood cell types [28]. Finally BOECs 
are not exposed to UV irradia  on of sunlight as in the case for skin fi broblasts. These cells may 
therefore have a lower risk of acquiring addi  onal non-systemic muta  ons. 
Since this work was completed, Ge   et al. reported the genera  on of hiPSCs with retroviral 
vectors from late outgrowth endothelial progenitor cells (L-EPCs, also called BOECs) from 
peripheral blood [29]. Reprogramming effi  ciencies for L-EPCs were higher compared to skin 
fi broblasts. In our hands the polycistronic len  virus was able to reprogram skin fi broblasts and 
dental pulp cells at high effi  ciencies whereas hiPSC genera  on from BOECs tended to be low. The 
effi  ciency of reprogramming in individual cell types is likely to depend on the reprogramming 
method. Here we used a polycistronic len  virus, which off ers the possibility of transgene excision 
a  er reprogramming. In addi  on all reprogramming factors are on the same virus reducing the 
number of necessary integra  ons and elimina  ng poten  al variability between clones due to 
diff erences in factor stoichiometry.  
Beside simple, inexpensive and fast isola  on of cells and high reprogramming effi  ciencies for 
most samples, we show here that skin samples also off er the possibility of prolonged storage 
before processing. Although cell numbers were reduced, fi broblasts isolated a  er long-term 
storage in a simple salt solu  on, o  en the most readily available op  on in a standard hospital 
clinic, did not show any visible signs of senescence and were reprogrammed at similar or only 
slightly reduced effi  ciencies as fresh cells. Thus we have developed a robust protocol for obtaining 
ac  vely dividing cells from small skin pieces which are equally suitable for reprogramming as 
freshly isolated samples. In some cases, immediate processing is impossible because of long 
distances between the pa  ent center and the reprogramming facility. The ability to store skin 
samples overcomes this problem. Isola  on of cell types from other soma  c  ssues, e.g. BOECs 
or T cells from blood, o  en requires almost immediate processing, excluding these  ssues in 
such a case. 
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Supplementary Figure 1: Transduc  on of skin fi broblasts with low MOI leads to the genera  on 
of hiPSC clones with a maximum of one or two proviral integra  ons. Southern blot of 29 hiPSC 
clones from 2 diff erent fi broblast samples a  er transduc  on with MOI ranging from 0.1 to 0.5 




Supplementary Figure 2: AP staining closely overlaps with silencing of the transgenes (absence 
of dTomato) A) An example of a par  ally dTomato nega  ve colony is shown. These colonies are 
nevertheless likely to be fully reprogrammed because of their overall morphological similarity 
to hESCs. B) Quan  fi ca  on of colonies per 10 cm dish. Twenty four days a  er seeding, 10,000 
transduced fi broblasts on a 10 cm dish with MEFs, the number of colonies which (i) expressed 
dTomato (“posi  ve”), (ii) were par  ally nega  ve or (iii) were completely nega  ve for dTomato 
were counted. Subsequently AP-expressing colonies on the same plates were quan  fi ed. The sum 
of par  ally nega  ve and nega  ve colonies was similar (line X) or equal (line Y) to the number 
of AP expressing colonies. We therefore used AP staining as a preliminary marker to es  mate 
reprogramming effi  ciencies  in subsequent experiments. AP: alkaline phosphatase; dTom: dtomato.
 
Supplementary Figure 3: Characeriza  on of hiPSC derived from BOECs (line E). Bright fi eld images 
of the soma  c cells before transduc  on (column I). Undiff eren  ated hiPSCs express typical markers 
of hESCs (red: NANOG, TRA-1-81; green: OCT3/4, SSEA-4) as shown by immunofl uorescent staining 
(columns II and III). Immunofl uorescent staining of hiPSCs following “spontaneous” diff eren  a  on 
into deriva  ves of the three germ layers (columns IV-VI: AFP (green): endoderm; βIII-TUBULIN 
(red): ectoderm; CD31 (red): mesoderm; nuclei (DAPI, blue)). BOECs: Blood outgrowth endothelial cells; 
AFP: alpha feto-protein. Scale bar: 100 μm.
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Recent methodological advances have improved the ease and effi  ciency of genera  ng 
human induced pluripotent stem cells (hiPSCs), but this now typically results in a 
greater number of hiPSC clones being derived than can be wholly characterized. 
Addi  onally, individual clones display biological variability including their capacity 
to diff eren  ate, with gene  c heterogeneity thought to be a contribu  ng factor. It is 
therefore impera  ve that methods are developed which facilitate rapid selec  on of 
the hiPSC clones that are most suited to the downstream research aims. Here we 
describe a useful combina  on of procedures that enables the simultaneous screening 
of mul  ple iPSC clones to determine their genomic integrity as well as their cardiac 
diff eren  a  on poten  al within two weeks of the puta  ve reprogrammed colonies 
ini  ally appearing in culture. By coupling a splinkere  e-PCR method with Ion Torrent 
sequencing, we could ascertain the number of and map the proviral integra  on sites 
in len  viral-reprogrammed hiPSCs, enabling iden  fi ca  on of clones containing single 
copy integra  ons in genomic regions devoid of known genes or transcrip  onal control 
elements. In parallel, we developed an eff ec  ve cardiac diff eren  a  on protocol that 
generated func  onal cardiomyocytes within 10 days without requiring line-specifi c 
op  miza  on for any of 6 independent human pluripotent stem cell lines tested. Finally, 
to demonstrate the scalable poten  al of these procedures, we picked 20 nascent iPSC 
clones and performed these independent assays concurrently. Before the clones 
required passaging, we were able to iden  fy clones with a single integrated copy of the 
reprogramming vector and robust cardiac diff eren  a  on poten  al for further analysis.
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Introduc  on
Since the ini  al reports that human fi broblasts could be reprogrammed to a self-renewing, 
pluripotent state [1,2], interest in induced pluripotent stem cells (iPSC) has grown exponen  ally as 
their many applica  ons in biomedical research and regenera  ve medicine have become evident. 
However, a remaining challenge for the fi eld is to address the technical issues that contribute to 
individual cell line diff erences and thereby confound our ability to dis  nguish disease-associated 
variability from background noise. These include methods for rapidly assessing the quality and 
genomic integrity of the reprogrammed cell lines, and robust protocols for diff eren  a  on that 
are completely defi ned and readily transferable across mul  ple iPSC lines. 
Most reprogramming methods generate a large number of puta  ve iPSC clones that appear 
morphologically similar to embryonic stem cells (ESCs); however only a subset of these have 
comparable molecular and func  onal features [3]. To dis  nguish bona fi de iPSCs from those that 
are only par  ally reprogrammed, detailed characteriza  on of the clones is required, which is o  en 
lengthy and expensive. This typically limits the number of clones that are examined to fewer than 
six, with the selec  on of clones for further analysis predominantly based on subjec  ve criteria 
like morphology and culture characteris  cs [4,5]. While this is generally suffi  cient to iden  fy 
at least one genuine iPSC clone that can indefi nitely self-renew and is pluripotent, it does not 
assess the clonal variability in diff eren  a  on effi  ciency that is o  en detected when pluripotent 
stem cells (PSCs) undergo further guided diff eren  a  on to func  onal cell subtypes [6-9]. One 
poten  al source of this clonal varia  on if integra  ve reprogramming methods have been used 
might be inser  onal mutagenesis caused by the reprogramming factors [10,11]. However, the 
genomic integrity of iPSCs is frequently not assessed, despite studies demonstra  ng that the 
integra  on of viral vectors can result in the dysregula  on of adjacent genes [12,13]. This altered 
gene expression could lead to perturbed signalling pathways that may alter the pluripotency 
or diff eren  a  on poten  al of the iPSCs, similar to that observed in some virally-transduced 
hematopoie  c stem cell lines [14]. 
To address these issues, we developed a novel combina  on of methods to aid in selec  ng hiPSC 
clones for studying cardiogenesis. Furthermore, both procedures are scalable, allowing many 
poten  al iPSC clones to be screened simultaneously. To demonstrate this, the number and 
loca  on of the proviral integra  ons, as well as the cardiac diff eren  a  on poten  al of 20 puta  ve 
iPSC clones was determined within 2 weeks following their emergence during reprogramming. 
These methods require minimal amounts of star  ng material and can assist in iden  fying the 
op  mal iPSC clones for further characteriza  on. Furthermore, these procedures poten  ally could 
be applied to aid in the selec  on of transgenic human PSCs in which, for example, overexpression 
constructs, therapeu  c genes or ectopic reporters have been randomly integrated.
Materials and Methods
Ethics Statement
Human skin biopsies were obtained from pa  ents a  er individual wri  en permission using 
standard informed consent procedures, and following approval for use in this study by the 
Leiden University Medical Center’s medical ethics commi  ee. Control skin samples and milk 
teeth were obtained as waste  ssue from donors in accordance with the Dutch Federa  on of 
Biomedical Scien  fi c Socie  es “Use of human  ssue for scien  fi c research” and “Code of good 
use” direc  ves. All samples were collected and anonymized by the trea  ng physician.
Human iPSC deriva  on
Human dermal fi broblasts or dental pulp cells were reprogrammed to iPSCs using the pRRL.PPT.
SF.hOKSMidTomato-preFRT polycistronic len  viral vector as previously published [15,16]. Based 
on morphology, human (h)ESC-like colonies were manually picked 30 days a  er transduc  on. All 
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Figure 1. Genomic mapping of proviral integra  on sites in len  viral-generated hiPSCs. A) Schema  c representa  on 
of the polycistronic len  viral vector used to generate the hiPSCs following integra  on into the host genome. The 
four reprogramming factors (OKSM) are linked by 2A pep  de sequences, while a red fl uorescent protein (dTomato) 
is downstream of an IRES sequence. The posi  on and distance of the SphI site from the 3’ end of the integrated 
provirus, as well as the probe (thick black line) used for Southern blot analysis are shown. Also depicted are the 
primers (A, B) within the viral LTR used in the amplifi ca  on of the adaptor-ligated splinkere  e products (SIN, self-
inac  va  ng element; OKSM, OCT4/KLF4/SOX2/c-MYC; IRES, internal ribosome entry site). B) Southern blot analysis 
of 6 control hiPSC lines to assess the number of viral integra  ons. Genomic DNAs were digested with SphI and 
hybridized with a probe to c-myc. The * indicates the loca  on of the band corresponding to the endogenous c-MYC 
locus. C) Schema  c representa  on of the shear-splinkere  e procedure coupled to the fragment prepara  on for 
mul  plexed PCR amplifi ca  on and Ion Torrent sequencing. D) Idiogram depic  ng the genomic integra  on sites of 
the len  virus for the 6 control hiPSC lines as determined by shear-splink PCR combined with Ion Torrent sequencing. 
E) Visualiza  on of the mapped reads obtained for hiPSC line, DF4 following shear-splink PCR and Ion Torrent 
sequencing. Reads mapped to three genomic loci. The red arrows indicate the posi  on in the genome where the 
provirus integrated. F) Valida  on of the len  virus integra  on sites iden  fi ed in E by genomic PCR analysis using 
primer pairs specifi c for each integra  on locus. Inser  on of the len  virus at these three genomic loci was only 
detected in the hiPSC line, DF4. 
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PSC culture and diff eren  a  on
PSCs were cultured on Matrigel (BD Biosciences)-coated  ssue culture dishes in mTeSR1 according 
to the manufacturer’s protocol (Stem Cell Technologies). The control hESC and dermal fi broblast 
(DF)-derived hiPSC lines used in this study are listed in Table S1. To ini  ate diff eren  a  on 
to cardiomyocytes, the PSCs were dissociated into small clusters of cells and seeded onto a 
Matrigel-coated cell culture dish in mTeSR1. Three days later (diff eren  a  on day(d) 0), the 
medium was replaced with low-insulin (1 mg/L), (LI)-BPEL medium [17] and supplemented with 
BMP4, Ac  vin A, CHIR99021 and XAV939 as indicated. If the cultures were to be maintained for 
more than 16 days, the cells were overlaid with addi  onal Matrigel (1:100) on diff eren  a  on 
d3 to prevent detachment from the dishes. From diff eren  a  on d6, the LI-BPEL medium was 
refreshed twice a week. 
Southern blot
Genomic DNA was digested with SphI (Promega) overnight, resolved by gel electrophoresis and 
transferred to Hybond-N+ Nylon membrane (GE Healthcare). Hybridiza  on and detec  on of the 
probe, encompassing the coding sequences of c-Myc, was performed as previously described [18]. 
Amplifi ca  on and sequencing of vector integra  on sites
To determine the len  viral integra  on sites in either the DF hiPSC lines or the puta  ve iPSC clones, 
genomic DNA was isolated with the DNAeasy Blood and Tissue Kit (Qiagen) and splinkere  e PCR 
performed [19-21]. Oligonucleo  des and PCR amplifi ca  on condi  ons used are listed in Tables 
S2 and S3. To fragment the DNA, either 2 μg was sheared for a target peak of 200bp using a 
Covaris S2 sonicator according to the manufacturer’s protocol, or 5μg was digested with the 
restric  on enzymes CviQI, AseI and BclI (all from New England Biolabs (NEB)). The resul  ng DNA 
fragments were concentrated, blunt-ended using the NEBNext End Repair module (NEB) and 
modifi ed at the 3’ ends with the addi  on of an adenosine (NEBNext dA-Tailing Module; NEB). 
Splinkere  e adaptors were ligated to the DNA fragments using Quick T4 DNA Ligase (NEB). To 
prevent amplifi ca  on of internal len  viral sequences, samples were digested overnight with 
BglII. Primary amplifi ca  on of the adaptor-ligated splinkere  e products was performed using 
Pla  num Taq HiFi (Invitrogen) with the primer pairs, PCR_A1 and PCR_A2, followed by secondary 
amplifi ca  on with the primer pair, PCR_B1 and PCR_B2.
To de-mul  plex the splinkere  e-PCR products, the amplifi ed products were either cloned into 
the vector pCR®2.1-TOPO® (Invitrogen), transformed into bacteria and sequenced using Sanger 
sequencing, or barcoded and sequenced using ion semi-conductor sequencing [22]. For Ion 
Torrent sequencing (Life Technologies) of pooled splinkere  e-PCR products from mul  ple iPSC 
lines, “barcode” and adaptor sequences were incorporated into the primers PCR_B1 and PCR_B2. 
Adaptor and barcode sequences are listed in Table S4. 
Mapping and Processing of Sequence Reads
The Ion Torrent sequence data was processed in several steps to iden  fy the provirus integra  on 
sites in the hiPSC genome. First, the custom 3’ splinkere  e adaptor sequence was iden  fi ed 
and removed from the sequence reads by the Ion Torrent Suite so  ware (v3.4.2). The dataset 
was demul  plexed into the individual sample sets and the provirus sequences removed from 
the reads. Reads with a minimal length of 30 bases were aligned to the human genome (Hg19) 
using the TMAP sequence aligner with standard se   ngs. The Bed-tools package [23] was used to 
retrieve regions with a peak height of at least 10% reads rela  ve to the total number of aligned 
reads and a peak base width of at least 40 nucleo  des. The selected candidate integra  on sites 
were annotated to the nearest gene or transcrip  onal control element. Len  viral inser  on loci 





Diff eren  a  on d13 cells were dissociated using TrypLE Select (Invitrogen) and fi ltered through 
a 35 μm cell strainer (BD Bioscience). Intracellular fl ow cytometry with mouse an  -bovine 
cardiac troponin T (cTnT; Hybridomabank) was performed using the FIX & PERM kit (Invitrogen) 
according to manufacturer’s protocol, with the primary an  body detected with phycoerythrin-
conjugated goat an  -mouse IgG2a (Jackson ImmunoResearch). Cells were gated based on 
forward and side sca  er, and fl ow cytometric gates were set using control cells not expressing 
GFP, or diff eren  ated cells labeled with the isotype control. Samples were measured using a 
LSRII fl ow cytometer (BD Bioscience), and results analyzed using FlowJo 7.6.5 (TreeStar).
Immunofl uorescence analysis
Diff eren  a  on d20 NKX2-5eGFP/w hESCs were dissociated with TrypLE Select, seeded on 
Matrigel-coated coverslips and cultured for a minimum of 72 h before fi xing with 2% PFA. 
Coverslips were stained with an  bodies against α-Ac  nin (mouse-α-rabbit), sarcomeric 
Tropomyosin (mouse-α-chick; both from Sigma Aldrich), Troponin I (rabbit-α-human), Nkx2.5 
(rabbit-α-human; both from Santa Cruz), β-MHC (mouse-α-human; Millipore), MLC2a (rabbit-
α-mouse; provided by S.W. Kubalak), as previously published [24]. Primary an  bodies were 
detected with IgG-conjugated Cy3 (donkey-α-rabbit, Jackson Immunoresearch) or Alexa 488 
(donkey-α-mouse, Invitrogen) an  bodies. Images were captured on a Leica SP5 confocal laser 
scanning microscope (Leica Microsystems).
Electrophysiology and Ca2+ imaging
Ac  on poten  al measurements were performed on single cardiomyocytes 7-15 days a  er cell 
dissocia  on and analyzed as described previously [25]. For Ca2+ imaging, diff eren  a  on d20 
NKX2-5eGFP/w hESCs were dissociated with TrypLE Select, seeded (40,000 cells/well) into a 
Matrigel-coated 96 well imaging plate (BD Bioscience), and cultured for a further 7 days. Cells 
were loaded with 5μM Fluo-4 AM (Invitrogen) and imaged in Tyrode’s solu  on using a confocal 
microscope (Leica AF6000) as previously published [26]. Spontaneous Ca2+ transients were 
recorded at 37° C for 20 s. 
Results
High throughput mapping of len  viral integra  on sites in iPSCs
To validate and establish a procedure for high-throughput sequencing and mapping of the 
len  viral inser  on sites, we ini  ally quan  fi ed and mapped the genomic loca  ons of the 
reprogramming casse  es in six control hiPSC lines (DF1-6) by Southern blot analysis, and by 
Table 1: The number of confi rmed proviral inser  ons in the len  viral-generated 
DF-hiPSC lines as determined using diff erent mapping approaches.
Clone Number of inserts as determined by:
Southern 
blot
RE-splinkere  e; TOPO 
Subcloning
Shear-splink; Ion Torrent 
sequencing
DF1 2 2 2
DF2 2 2 2
DF3 1 0 1
DF4 1 2 3
DF5 2 1 2
DF6 1 1 1
 RE: restric  on enzyme 
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Figure 2. Effi  cient cardiogenesis of NKX2-5eGFP/w hESCs maintained as colonies in mTeSR1. A) Schema  c 
representa  on of the op  mized diff eren  a  on protocol for genera  ng cardiomyocytes from human PSCs. B) 
Overlaid bright fi eld (BF) and green fl uorescence (eGFP) images showing the typical morphology and eGFP 
expression of NKX2-5eGFP/w hESCs at various  me points during the diff eren  a  on. Scale bars, 100 μm. C) 
Representa  ve fl ow cytometry profi les showing the correla  on in the percentage of cells expressing eGFP (NKX2-5) 
and cardiac troponin T (cTnT) at diff eren  a  on d14. D) Histogram showing the mean percentage of diff eren  a  on 
d14 cells expressing eGFP (NKX2-5) or cTnT. Data represents the mean ± SEM from 5 independent experiments. E) 
Immunofl uorescence images of the cardiac markers α-ac  nin (ACTN1), troponin I (cTnI), sarcomeric tropomyosin 
(TPM1), myosin regulatory light chain 2, atrial isoform (MLC2A), beta-myosin heavy chain (βMHC), and NKX2-5 
in cardiomyocytes diff eren  ated using the protocol depicted in A. All cells were co-stained with the nuclear dye 
DAPI (blue). Scale bars represent 5 μm. F) Representa  ve electrophysiological recordings from cardiomyocytes 
derived using the protocol depicted in A. The le   panel shows a typical example of an ac  on poten  al and an 
upstroke velocity (inset) from a cardiomyocyte triggered at 1Hz. The right panel shows the calcium transient of a 
spontaneously contrac  ng cardiomyocyte. G) Average data at 1Hz for ac  on poten  al dura  on at 50% and 90% 
repolariza  on (APD50, APD90), maximal upstroke velocity (Vmax), maximal diastolic poten  al (MDP), and ac  on 
poten  al amplitude (APA) in cardiomyocytes derived from NKX2-5eGFP/w hESCs (n=7, mean ±SEM). H) Summary of 




combining splinkere  e-PCR with TOPO-shotgun cloning and amplicon sequencing. These hiPSC 
lines had been generated following transfec  on of fi broblasts with a polycistronic len  virus at 
MOIs ranging from 0.25 to 5 (Figure 1A). We had previously ascertained that MOIs above 0.4 
would frequently generate hiPSCs containing mul  ple proviral integra  ons [16], enabling us to 
assess the sensi  vity of the above procedures.
Southern blot analysis confi rmed that each of the lines contained at least 1-3 proviral integra  ons 
(Figure 1B). However, a limita  on of this technique is that it only provides informa  on on the 
number of integra  ons and not their genomic loca  on. Such data is cri  cal to fully assess the 
risk of inser  onal mutagenesis in virally-transduced cell lines. Addi  onally, if two or more 
integra  ons result in a similar sized DNA fragment when digested, this can lead to an inaccurate 
es  ma  on of the total number of integra  ons in that clone. To resolve these issues, splinkere  e 
PCR was performed on genomic DNA that was fragmented using restric  on endonucleases 
(REs), either individually or in combina  on [19,20] (Figure S1). Splinkere  e PCR is a variant of 
liga  on-mediated PCR and is commonly used in forward gene  c screens to map the genomic 
sites in which inser  onal mutagens such as viruses or transposons have integrated [19,21]. More 
recently the technique has been employed to iden  fy the integra  on sites in iPSCs reprogrammed 
using transposons, enabling the excision of the reprogramming casse  e following re-expression 
of the transposase to be monitored [18,27].However neither of these splinkere  e procedures 
iden  fi ed the minimum number of inser  on sites as determined by Southern blot analysis for all 
six clones (Table 1), most likely due to amplifi ca  on biases resul  ng from the uneven genomic 
distribu  on of RE recogni  on sites [21].
To limit these amplifi ca  on and sequencing biases, we applied a modifi ed splinkere  e method, 
termed “shear-splink”, that employed random fragmenta  on of the genomic DNA resul  ng in 
controllable size distribu  on of DNA fragments for all inser  ons [21]. By incorpora  ng ‘barcode’ 
sequences into the primers, the resul  ng splinkere  e PCR products from the diff erent clones 
could be pooled together and sequenced using ion sequencing technology (Figure 1C). All 
inser  on sites previously iden  fi ed using RE-splinkere  e procedures were also detected using 
this high-throughput method. Furthermore, the shear-splink method mapped addi  onal 
inser  ons not detected either by RE-splinkere  e or Southern blot (Figure 1D & E, Table 1, and 
Table S6). For example, with DF4, Southern blot analysis iden  fi ed one insert while shear-splink 
analysis iden  fi ed three. All inser  on events were confi rmed by locus-specifi c genomic PCR 
(Figure 1F and Figure S2). These results indicated that combining shear-splink with ion semi-
conductor sequencing can effi  ciently uncover proviral inser  on sites and is amenable to high-
throughput adapta  on.
Robust and Scalable Protocol to assess the Cardiac Diff eren  a  on Effi  ciency of human PSCs
To test the cardiac diff eren  a  on poten  al of hiPSC clones as they emerge from the 
reprogramming process, a rapid and reproducible method requiring no op  miza  on between 
the clones is needed. Building on previous fi ndings [28-30], we developed a monolayer 
diff eren  a  on protocol that could be carried out directly on mechanically passaged PSC colonies 
grown in mTeSR1 culture medium (Figure 2A). The method was ini  ally op  mized using a hESC 
line in which GFP reports the expression of the cardiac associated transcrip  on factor NKX2-5 
(NKX2-5eGFP/w hESCs) [28]. We then confi rmed the procedure also eff ec  vely induced cardiac 
diff eren  a  on in a further 5 human PSC lines (Figure S3). 
Three days a  er mechanical passaging, the medium on the colonies was replaced with BPEL 
medium supplemented with 20 ng/ml Ac  vin A, 20 ng/ml BMP4 and 1.5 μM Chir99021 for 72 h. 
Although this growth factor combina  on was suffi  cient to generate cardiomyocytes in some 
PSC lines, the yield was very low and variable between individual diff eren  a  on experiments. 
Because it has previously been demonstrated the tankyrase inhibitor XAV939 could promote 
cardiogenesis when added a  er mesoderm forma  on [30,31], we supplemented the medium 
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with 5μM XAV at day 3 for 72 h. Phase contrast photomicrographs of cultures at various  me points 
during the protocol demonstrate the typical appearance of the cells during the diff eren  a  on 
process (Figure 2B). By diff eren  a  on d6, GFP- web-like colonies were visible that subsequently 
expanded, becoming GFP+ and forming a sheet of contrac  ng cells by diff eren  a  on d10. Using 
this op  mized diff eren  a  on protocol, on average ~40% of the cells expressed NKX2-5(eGFP) 
and cTnT by diff eren  a  on d14 (Figure 2C & D). Immunofl uorescence analysis confi rmed these 
cells expressed sarcomeric markers (Figure 2E). Typical examples of ac  on poten  al, upstroke 
velocity and Ca2+ transients in the resul  ng cardiomyocytes are shown in Figure 2F. The ac  on 
poten  al proper  es of these cells, as well as the spontaneous whole cell Ca2+ pulse dura  on 
and frequency (Fig 2G & H), were comparable to those previously reported for human PSC-
derived cardiomyocytes [32-34].
Mapping proviral integra  on sites and assessing the cardiac diff eren  a  on poten  al of 20 newly 
reprogrammed hiPSC clones
To demonstrate the applicability of these methods to iden  fy the len  viral inser  on sites and 
assess the cardiac diff eren  a  on poten  al of prospec  ve iPSC clones rapidly, 20 puta  ve iPSC 
clones were selected from reprogrammed dental pulp cells based on morphology. Colony pieces 
from these clones were either plated for the cardiac diff eren  a  on assay or used to isolate 
genomic DNA (Figure 3A). The shear-splink procedure in combina  on with ion semi-conductor 
sequencing iden  fi ed that 1 of the 18 clones with mapped reads had 2 proviral inser  ons, while 
the remainder had only 1 inser  on (Figure 3B). The predominance of single copy integra  ons 
was due to a MOI of 0.25 being used for reprogramming. Based on the genomic loca  ons to 
which the len  virus was mapped, 11 of these clones were unique with the remaining 6 being 
subclones. Of these 11 clones, 2 (clones 5 & 17) had the provirus integrated outside any known 
genes or non-coding RNA sequences. A complete overview of insert loca  ons is summarized in 
Table S7.
As early as day 10 a  er ini  al pla  ng, contrac  ng clusters were observed in the diff eren  a  on 
assay with some of the clones. Analysis of cTnT expression at day 13 by fl ow cytometry indicated 
the cardiac diff eren  a  on effi  ciencies of the puta  ve iPSC clones ranged from ~0-22% (Figure 
3C & D). Based on these results, several iPSC clones (9, 11, 12, 17, and 19) were iden  fi ed as 
being the most suitable for further characteriza  on, while several other clones (1, 4, 6, 8, 13, 14 
and 20) were designated as least suitable based on their poor cardiac diff eren  a  on effi  ciency. 
Combining these fi ndings with the Ion Torrent sequencing data, the len  virus had inserted 
within intragenic regions for clones 9 and 19 (NPLOC4 and AP1G1 respec  vely), while for clone 
11 the len  virus was in exon 2 of ZDBF2. Clone 12 had two proviral integra  ons within introns 
of PRPSAP1 and PEX14. Only clone 17 contained a viral insert outside any annotated genes or 
transcrip  onal control elements, and also had rela  vely high cardiac diff eren  a  on effi  ciency.
Discussion
Current methods to iden  fy fully reprogrammed iPSCs following viral infec  on of soma  c cells 
rely on expensive and o  en lengthy protocols, highligh  ng the need for methods that will 
streamline the selec  on process. During reprogramming, hundreds of clonal iPSCs are typically 
generated, o  en with variable diff eren  a  on capaci  es possibly due to gene  c and epigene  c 
diff erences [6,9,35]. However representa  ve iPSC clones are generally selected based on 
morphology, at a  me when li  le or no informa  on is available on the number and loca  on of 
the proviral integra  ons or on the diff eren  a  on effi  ciency to par  cular lineages.
Using shear-splink PCR coupled with high-throughput ion semi-conductor sequencing [21,22], 
we were able to quickly and reliably determine proviral insert number and genomic loca  on for 
mul  ple hiPSC clones simultaneously. Indeed this combined procedure iden  fi ed integra  ons 




Signifi cant inter-clonal variability in the diff eren  a  on effi  ciency of hiPSCs, including in the 
genera  on of cardiomyocytes has been well documented [6,9,36]. Inadvertently selec  ng 
representa  ve pa  ent-specifi c iPSC clones with poor cardiac diff eren  a  on effi  ciency could 
adversely infl uence the ability to dis  nguish disease-associated phenotypes. Here we developed 
a cardiac diff eren  a  on protocol that was fast and required no op  miza  on between human 
PSC lines. We favored a monolayer diff eren  a  on-based technique due to its simplicity and 
scalability [28,37,38]. Previously published protocols o  en required prior adapta  on of the cells 
to enzyma  c passaging to enable the seeding of single or small clusters of cells, necessita  ng 
an addi  onal 1-4 weeks to establish [39,40]This makes these protocols unsuitable for rapidly 
determining the cardiac diff eren  a  on poten  al of emerging iPSC colonies, since at this stage 
the colonies are s  ll manually passaged. Aside from the  me required, maintaining >20 colonies 
while assessing the cardiac poten  al is not prac  cal and prohibi  vely expensive for high 
throughput development.
By using LI-BPEL, a serum-free diff eren  a  on medium, we limited the variability due to undefi ned 
components present in serum, as well as enhanced the eff ec  veness of the recombinant growth 
factors and small molecules [17,41]. While the combina  on of BMP4, Ac  vin A and either bFGF 
or WNT3A can induce cardiogenesis in monolayer cultures of PSCs [28,29,37], op  miza  on of 
the concentra  ons of BMP4 and ac  vin A for individual cell lines as well as the  me of addi  on 
Figure 3. Simultaneous mapping of proviral integra  on sites and assessment of cardiac diff eren  a  on poten  al 
for mul  ple hiPSC clones. A) Schema  c representa  on of the pipeline to assess newly derived hiPSCs. B) Flow 
chart summarizing the proviral insert number, genomic loca  on and locality of 20 hiPSC as determined by 
shear-splink and Ion Torrent sequencing. The red box indicates the clones most suitable for further evalua  on 
(RFs, reprogramming factors) C) Representa  ve fl ow cytometry plots showing the percentage of cardiac 
troponin T-posi  ve (cTnT+) cells a  er 13 days of diff eren  a  on for a selec  on of the 20 hiPSC clones analyzed. 
D) Histogram showing the mean percentage of cells expressing cTnT at day 16 for the 20 hiPSC clones assessed 
for cardiac diff eren  a  on poten  al.
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and removal of the growth factors has proved to be important [42]. Although small molecule 
modula  on of the regulatory elements of the Wnt/β-catenin signaling pathway has been 
shown also to result in more robust cardiac diff eren  a  on in mul  ple human PSC lines [38,43] 
than the method described here, these protocols as men  oned earlier, have all required prior 
adapta  on of the cells to enzyma  c passaging. We found combining both approaches (staged 
exposure to BMP4, ac  vin A and the GSK3β inhibitor, CHIR99021, followed by the tankyrase 
inhibitor, XAV939) resulted in robust cardiac diff eren  a  on from 6 human PSC lines without 
the need to individually op  mize  ming or concentra  ons for each line. This procedure could 
successfully induce cardiomyocyte diff eren  a  on from hiPSC colonies maintained either with 
MEFs in KOSR-containing medium or feeder-free with mTeSR1 medium, as well as from PSC lines 
passaged enzyma  cally, without any adapta  ons to the protocol. It is likely that the effi  ciency 
of cardiac development could be further op  mized for each cell line by determining the op  mal 
concentra  on and  me of applica  on of the growth factors and small molecule [42]. However 
such an approach is not feasible when screening mul  ple clones and is more suitable once an 
iPSC line is established. Similarly, reducing the level of insulin in the diff eren  a  on media further 
might lead to addi  onal improvements in cardiac diff eren  a  on effi  ciency.
To demonstrate that both procedures could be incorporated into the current workfl ow for 
iden  fying fully reprogrammed iPSCs, we analyzed 20 nascent iPSC colonies that were selected 
for further characteriza  on based on morphology. Within 16 days and prior to the clones 
requiring passaging, the cardiac poten  al along with mapping the proviral integra  on sites had 
been ascertained. It should be noted that the results from performing both of these procedures 
does not conclusively demonstrate that the poor cardiac diff eren  a  on capabili  es of a clone is 
due to the integra  on site of the provirus. Impaired diff eren  a  on could also be due to the clone 
not being fully reprogrammed, or other gene  c or epigene  c abnormali  es [9]. The purpose 
of performing such a screen is to enable the researcher to make a more informed decision on 
which iPSC clones to select for further characteriza  on based on the downstream applica  ons 
of the cell line. From the iPSC colonies that were screened, clone 11 was the most effi  cient at 
genera  ng cardiomyocytes. However with this clone, the len  virus had inserted into exon 2 
of the zinc fi nger gene, ZDBF2. Li  le is known about the func  on of ZDBF2, although there is 
evidence that it is an imprinted gene predominantly expressed in the brain and muscle [44]. 
It has also been iden  fi ed as a transcript upregulated in embryonic cardiac fi broblasts from 
microarray studies [45]. Therefore while disrup  on of ZDBF2 does not appear to be detrimental 
to cardiomyocyte diff eren  a  on, it could infl uence the phenotype if the cell line was to be used 
in developing cardiac models for example in “organ-on-a-chip” formats. Alterna  vely, clone 
17 also had rela  vely high cardiac diff eren  a  on effi  ciency along with a proviral integra  on 
site outside any known coding regions, poten  ally making this clone more suitable for such 
applica  ons.
Furthermore, both of these techniques are not limited to evalua  ng the genomic integrity and 
diff eren  a  on poten  al of reprogrammed iPSCs. With li  le modifi ca  on, these procedures could 
also be readily incorporated into a screening strategy of human PSCs that have been gene  cally 
modifi ed by either viral or transposon-based transfec  on. Here there is also a recognized need 
to generate and analyze several transgenic lines, preferably in a short  mespan, since posi  onal 
eff ects resul  ng from genomic integra  on could impact on their diff eren  a  on poten  al.
Conclusion
It is widely acknowledged that hiPSCs hold great promise for disease modeling, safety 
pharmacology and drug discovery, par  cularly with respect to the cardiovascular system [46-
48]. However, methods to iden  fy the most suitable iPSC clones for further study are o  en 
lengthy and laborious. Here, we have described a rapid and scalable pipeline consis  ng of two 
independent assays that can simultaneously be applied directly to hiPSC clones as they appear 
following reprogramming, enabling clones to be selected based on the number and genomic 
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loca  on of the integrated reprogramming casse  e, as well as the cardiac diff eren  a  on 
poten  al. Solu  ons to a number of the remaining technical issues, such as those covered here, 
could contribute to more rapid realiza  on of the poten  al of iPSCs by reducing the  me required 
between obtaining primary cell cultures for reprogramming and selec  ng the best hiPSC lines for 
the ques  on to be addressed.
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Figure S2. Valida  on of the len  virus integra  on sites iden  fi ed by Ion Torrent sequencing for the DF-hiPSC clones 
and listed in Table S6, using locus-specifi c PCR analysis. Results for clone DF4 are shown in Figure 1F.
Figure S1. Genomic mapping of proviral integra  on sites in the len  viral-generated DF-hiPSCs using restric  on 
enzyme (RE)-splinkere  e PCR. A) Schema  c representa  on of the adaptor-ligated splinkere  e products generated 
following RE diges  on of the genomic DNA. The posi  on of the BglII within the SIN sequence, as well as the 
splinkere  e adaptor (purple box with angled black line) are shown. Also depicted are the PCR primers (A1, A2, 
B1, B2) used to amplify the junc  on sequences between the endogenous genome and the proviral inser  on 
site (SIN, Self inac  va  ng element). B) Agarose gel electrophoresis depic  ng the fragments generated following 
primary and secondary PCR amplifi ca  on of the adaptor-ligated splinkere  e products for DF-iPSC clones 1-6. Note, 
following cloning of these products into a TOPO vector, transforma  on into bacteria and subsequent sequencing, 
some fragments corresponded to non-specifi c amplifi ca  on of genomic DNA sequences. Addi  onally, some bands 
corresponded to mul  ple proviral inser  ons. The column “RE-splinkere  e; TOPO subcloning” in Table 1 lists the 
number of unique proviral inserts iden  fi ed per clone using this technique. 
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Table S1: Pluripotent stem cell lines used in this study.
PSC type Iden  fi ca  on within ar  cle Full name of clone*
hESC NKX2-5eGFP/w hESCs HES3 NKX2-5eGFP/w [1]
hESC HESC-NL4 HESC-NL4 [2]









hiPSC DF9 FLB243#1 [3]
* Nomenclature of iPSC lines based on the standardized naming system proposed by Luong et 
al, Cell Stem Cell, 2011. Where applicable, the reference describing the ini  al characteriza  on of 
the cell line is included in brackets.
[1] Ellio   et al, Nat Methods, 2011; [2] Freund et al, Stem Cells, 2008; [3] Freund et al Neth Heart J, 2010
Figure S3. The monolayer diff eren  a  on protocol effi  ciently induces cardiogenesis for mul  ple 
hESC and hiPSC lines without requiring line-specifi c op  misa  on. A) The histogram shows the 
mean percentage of cells expressing cTnT at diff eren  a  on d14 for an addi  onal 4 hPSC lines 
assessed for cardiac diff eren  a  on poten  al. B) The histogram shows the mean percentage of 
cells expressing eGFP (NKX2-5) at diff eren  a  on d14 from the hESC line, Mel1 NKX2-5eGFP/w. 
Data represents the mean ± SEM from 2 independent experiments.
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Table S3: Amplifi ca  on condi  ons for primary and secondary splinkere  e-PCRs 
Primary Amplifi ca  on
Step Temperature Time # of cycles
Ini  al denatura  on 96°C 2’00” 1
Denatura  on 92°C 0’40’’
10Annealing 60°C (-1°C per cycle) 0’40’’
Elonga  on 68°C 2’00”
Denatura  on 92°C 0’40’’
10Annealing 63°C (-0.5°C per cycle) 0’40’’
Elonga  on 68°C 1’00” 
Denatura  on 92°C 0’40’’
25Annealing 50°C 0’40’’
Elonga  on 68°C 1’00” 
Elonga  on 68°C 10’00” 1
Secondary Amplifi ca  on
Step Temperature Time # of cycles
Ini  al denatura  on 96°C 2’00” 1
Denatura  on 92°C 0’40’’
6Annealing 66°C (-1°C per cycle) 0’40’’
Elonga  on 68°C 1’00” 
Denatura  on 92°C 0’40’’
14Annealing 59°C 0’40’’
Elonga  on 68°C 1’00” 
Elonga  on 68°C 10’00” 1
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Table S4: Adaptor and barcode sequences incorporated into primers PCR_B1 and PCR_B2 for 
sequencing splinkere  e products using the Ion Torrent.
Adaptor          Sequence Comment
Y 5’-CCTCTCTATGGGCAGTCGGTGAT -3’
Adaptor sequence 
a  ached to the 5’end
 of primer PCR_B1 
Z 5’- CCATCTCATCCCTGCGTGTCTCCGACTCAGXXX-3’
Adaptor and barcode 
sequence a  ached 
to the 5’end of 
primer  PCR_B2, 
where XXX  refers to 
the barcodes  listed 
below.
Barcode          Sequence Barcode Sequence
 1 5’-ACGAGTGCGT-3’ 14 5’-TCACGTACTA-3’
2 5’-ACGCTCGACA-3’ 15 5’-CGTCTAGTAC-3’
3 5’-AGACGCACTC-3’ 16 5’-TCTACGTAGC-3’
4 5’-AGCACTGTAG-3’ 17 5’-TGTACTACTC-3’
5 5’-ATCAGACACG-3’ 18 5’-ACGACTACAG-3’
6 5’-ATATCGCGAG-3’ 19 5’-CGTAGACTAG-3’
7 5’-CGTGTCTCTA-3’ 20 5’-TACGAGTATG-3’
8 5’-CTCGCGTGTC-3’ 21 5’-TACTCTCGTG-3’
9 5’-TCTCTATGCG-3’ 22 5’-TAGAGACGAG-3’
10 5’-TGATACGTCT-3’ 23 5’-TCGTCGCTCG-3’
11 5’-CATAGTAGTG-3’ 24 5’-ACATACGCGT-3’
12 5’-CGAGAGATAC-3’ 25 5’-ACGCGAGTAT-3’
13 5’-ATACGACGTA-3’
Table S5: Oligonucleo  des used to confi rm proviral genomic insert loca  ons.
Gene Forward Primer Reverse Primer





COL5A2 5’-TCTGGTTTCCCTTTCGCTTTCAGGT-3’ 5’- CATTTGGTTCATATATTTGACTTA-3’







Table S6: The proviral insert loca  ons iden  fi ed for the 6 DF-iPSC clones inves  gated in Figure 1.
Clone Genome Loca  on Nearest Gene Present in 
DF1 chr19:503428454 PTOV1-AS1 Exon
chr2:190023157 COL5A2 Intron
DF2 chr1:16232602 SPEN Intron
chr3:49349283 USP4 Exon
DF3 chr1: 153863681 GATAD2B Intron
DF4 chr1:155370199 ASH1L Intron
chr11:64046798 BAD Intron
chr5:130981785 FNIP1 Intron
DF5 chr12:114276140 RBM19 Intron
chr6:76532084 MYO6 Intron
DF6 chr12:12290145 LRP6 Intron
Table S7: Overview of the proviral insert loca  ons determined by shear-splink and Ion Torrent 
sequencing for the 20 puta  ve hiPSC clones.
Clone Genome Loca  on Nearest Gene Present in
1 N/A   
2 chr2: 207144375 ZDBF2 Exon
3 chr2: 207144375 ZDBF2 Exon
4 chr6: 44392477 CDC5L Intron
5 chr12: 28151923 upstream of PTHLH Non-coding region
6 chr1: 150653834 GOLPH3L Intron
7 chr16: 71769591 AP1G1 Intron
8 chr1: 1330539 CCNL2 Intron
9 chr17: 79562823 NPLOC4 Intron
10 chr2: 207144375 ZDBF2 Exon
11 chr2: 207144375 ZDBF2 Exon
12 chr17: 74311940 PRPSAP1 Intron
 chr1: 10660290 PEX14 Intron
13 chr2: 207144375 ZDBF2 Exon
14 chr2: 42438527 EML4 Intron
15 chr19: 1121879 SBNO2 Intron
16 N/A   
17 chr5: 116648220 upstream of CTC-504A5.1 Non-coding region
18 chr1: 1330539 CCNL2 Intron
19 chr16: 71769591 AP1G1 Intron
20 chr17: 36589101 ARHGAP23 Intron
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Human cardiomyocytes diff er signifi cantly from those of rodents, most obviously in their 
electrophysiological proper  es. For this reason, many poten  al biomedical applica  ons of 
cardiomyocytes would benefi t from using human rather than rodent cells. This is of growing 
interest as new opportuni  es arise for using induced pluripotent stem cells (iPSCs) carrying 
cardiac disease-associated muta  ons to understand the pathophysiology of heart disease and 
to develop new treatment modali  es.
There is an obvious need for robust and effi  cient cardiac diff eren  a  on protocols for human 
pluripotent stem cells, preferably under defi ned, serum free condi  ons. Although protocols 
that are eff ec  ve on mul  ple pluripotent cell lines are beginning to emerge, none has yet been 
shown to be universally applicable without individual op  miza  on, and most s  ll require a cell 
aggrega  on step to ini  ate diff eren  a  on. More than 10 years of research on human embryonic 
stem cells (hESCs) has, however, provided important clues as to which parameters are candidates 
for further improvement. Many of the recent methodological advances made using hESCs are 
proving to be transferable to human iPSCs with minor modifi ca  ons. Thus, it is now possible to 
produce cardiomyocytes from most hESC and hiPSC lines, although the effi  ciencies with which 
individual cell lines diff eren  ate can s  ll be highly variable.
Most protocols mimic in some way the signals that take place during fetal heart development. 
Among the fi rst was one that recapitulated signals from endoderm adjacent to the developing 
heart: mechanically passaged hESC colonies were co-cultured with a mouse visceral endoderm-
like cell line (END2) in serum-free culture medium. This method is eff ec  ve in most hESC and 
hiPSC lines and will yield 5–15% cardiomyocytes depending on the individual line. This technique 
provides a simple way to check for cardiomyocyte diff eren  a  on capacity of mul  ple hiPSC clones 
while they are s  ll at very early (mechanical passage) stages of development. For producing 
larger numbers of cardiomyocytes from pluripotent cells already adapted to enzyma  c passage 
on feeder cells, however, a more eff ec  ve method is based on centrifuging the cells to force 
them to make aggregates, which are called “Spin embryoid bodies”. Human pluripotent cells 
have less inclina  on to form aggregates spontaneously in suspension than mouse pluripotent 
cells and forced aggrega  on makes cells a  ach more fi rmly to one another. In the cardiomyocyte 
diff eren  a  on protocol, the aggregates do not become true embryoid bodies, since they are not 
cultured long enough to induce all three germ layers.
In this chapter we outline a basic protocol for the diff eren  a  on of hESCs into cardiomyocytes. 
The method is based on the forma  on of aggregates of a standard size using a fi xed number 
of undiff eren  ated cells in each aggregate. The aggregates are formed by centrifuga  on of 
the cells into embryoid body (EB)-like structures and are referred to as “Spin EBs”. Key to the 
procedure, and most diffi  cult, is the prior adap  on of the undiff eren  ated cells to a standardized 
single cell passaging bulk culture system in which cells are passaged enzyma  cally and grown 
on feeder layers. The method we recommend for making spin EBs a  er bulk culture adap  on 
is straigh  orward and has worked well in our hands for mul  ple hESC lines and several hiPSC 
lines. The method requires  tra  on of growth factor concentra  ons for each line to op  mize 
effi  ciencies. We also discuss alterna  ve methods and reagents that work but are not rou  nely 
used in our laboratories. In addi  on, we discuss aspects of the protocol that could be further 
op  mized. The key variables that we outline in this chapter are:
 Basal culture condi  ons
 Adap  on to bulk passage
 Genera  ng spin “embryoid bodies” (Spin EBs)
 Growth factor  tra  on curves
 Dissocia  on of EBs and repla  ng cardiomyocytes.
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While op  mizing and standardizing condi  ons, it is important to keep in mind that changing 
one reagent or parameter in the system may unexpectedly impact the outcome of the en  re 
protocol.
Procedures 
Basal Culture Condi  ons
In our laboratory, many of our stock hESC lines (e.g. HES2, HES3, HES4, NL-HES1) are grown and 
maintained as mechanically passaged “cut and paste” colonies in KnockOut Serum Replacement-
based medium on irradiated or mitomycin C-treated mouse embryonic feeder cells (MEFs). The 
colonies are cut into small pieces using glass needles and, using a pipe  e, are transferred to new 
feeder layers once weekly. See Chapters 1 and 2. For details see Mummery et al., 2007.
From Mechanical Colonies to Bulk Culture: Tips for
Successful Adap  on Prior to Genera  ng Spin EBs
Several of the hESC lines we use are rou  nely passaged enzyma  cally, twice weekly on MEFs using 
TrypLE Select. These cells can be used immediately in the spin EB protocol for cardiomyocyte 
diff eren  a  on. For cell lines that are not enzyma  cally passaged, the spin EB protocol requires 
that the undiff eren  ated colonies be adapted to single cell enzyma  c passage on feeder layers 
(referred to as bulk culture). 
It is important to select hPSC lines for adap  on that have been well-maintained with  mely 
medium refreshment and regular mechanical passaging. The colonies should look healthy with 
li  le debris and few diff eren  ated cells around the colony edges (Figure 1). 
For best results use 80–100 mechanically-passaged colonies per line to start bulk adap  on of a line.
MEFs are inac  vated by prior irradia  on at 3000 rads in suspension culture. 
Plate irradiated MEFs the day before bulk culture adap  on to allow a  achment and spreading.
Figure: 1
Example of a healthy looking 
hESC colony with a small amount 




Star  ng Bulk Cultures
1. Cut away any residual diff eren  ated parts of the colonies. These are usually the fl at 
cells around the edge and the cluster at the center.
2. Cut the colonies into extremely small square pieces in a grid (cut closely spaced 
lines fi rst in one direc  on over the whole colony then similarly spaced lines in the 
perpendicular direc  on) with standard tungsten or glass needles. Note that the 
squares should be much smaller than those generated during rou  ne mechanical 
passaging (Figure 2).
3. Li   the cut pieces from the dish using a p1000 pipe  e and place in a 15 mL tube.
4. Collect all of the pieces from a total of 80–100 colonies.
5. Centrifuge for 3 minutes at 250 g.
6. Aspirate medium and resuspend in HESC-medium using a p1000 to pipe  e colony 
pieces up and down gently several  mes.
7. Plate all of the pieces in a T25 fl ask seeded the day before with 2-3 x 104 irradiated 
MEFs (density of MEFs depends on mouse strain used to produce MEFs and should be 
op  mized empirically) per cm2 with the appropriate amount of HESC-medium.
8. Gently passage the cells in the fl ask 4 days later in a 1:1 ra  o by incuba  on in TrypLE 
Select and resuspend in hESC-medium to spread the small colonies, which tend to pile 
up, over the surface of the fl ask (Figure 3).
9. The cultures should be observed and the medium should be changed daily. The cells 
should be passaged at a low ra  o (1:2 or 1:3) on new feeder layers in HESC-medium 
when the islands of undiff eren  ated cells start to fi ll the fl ask (Figure 4).
 Note
This low split ra  o should be con  nued un  l the cells adapt (possibly up to fi ve or six passages). 
This depends somewhat on the individual cell line; some lines accept a higher split ra  o a  er only 
two passages. The cells are then cultured according to the procedure below (see Maintaining 
Bulk Cultures). 
Maintaining Bulk Cultures
Bulk cultures should be passaged approximately every 3–4 days as follows:
1. Wash once with phosphate buff ered saline (PBS).
2. Add 1–1.5 mL of TrypLE Select to the T25 fl ask.
3. Place at 37°C for 5 minutes.
4. Tap the fl ask with fi ngers to dislodge cells.
5. Resuspend cells in 5 mL of culture medium containing 10% serum and place in a 
15 mL tube.
6. Rinse the fl ask with an addi  onal 3–5 mL of the same serum-containing medium and 
add to the same tube.
7. Centrifuge for 3 minutes at 250 g.
Figure: 2
(A) Example of the size of      piec-
es for mechanical passaging 
(pieces approximately 400–500 
μm in length). (B) Example of 
grid made for bulk culture in-
i  a  on (pieces approximately 
100–150 μm in length).
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8. Gently resuspend the pellet in the appropriate amount of HESC-medium.
9. Plate down in an appropriate sized fl ask, plate, or dish pre-plated with
10. 2-3 x 104 irradiated MEFs per cm2.
 Note
If the bulk cultures were started using T25 fl asks, the fl ask size can easily be increased for 
cryopreserva  on or scaled down to 6-well plates for general maintenance. One well of a 6-well 
plate contains a suffi  cient number of cells for the next step of the procedure and reduces the 
number of MEF feeder cells required at each passage.
Genera  ng Spin EBs
One Day Before Star  ng the Spin EB Diff eren  a  on Protocol
Deplete cultures of MEF feeder cells by passaging the bulk cultures and pla  ng on to Matrigel-
coated dishes or fl asks (ra  o about 1:2/1:3 or about 8 x 105 cells per well of a 6-well plate) 
(Figure 5). The following protocol uses one well of a 6-well plate.
Day 0
1. Early morning on the day of diff eren  a  on: refresh the medium on the bulk culture 
in the well of the 6-well plate to maintain culture quality and wash away dead cells.
2. Prepare the growth factor solu  ons prior to harves  ng the cells.
3. Midday on the day of diff eren  a  on, start harves  ng the cells by washing the culture 
once with PBS.
4. Add 1 mL of TrypLE™ Select (this is for one well of a 6-well plate; adjust as necessary to 
the size of culture fl ask, dish, or well) and incubate for 5 minutes at 37°C.
5. Add 3 mL (adjus  ng again as necessary to the size of culture fl ask, dish, or well) of 
serum-containing medium to collect cells.
6. Wash the fl ask again with 3 mL of serum-containing medium to collect remaining cells.
7. Centrifuge for 3 minutes at 250 g.
8. Resuspend cells in 2 mL of BPEL medium. BPEL medium is basal medium with BSA, 
Polyvinylalcohol (PVA), and Essen  al Lipids (see Recipes).
9. Centrifuge for 3 minutes at 250 g.
10. Resuspend cells in BPEL medium (1 mL per well of 6-well plate).
11. Count cells.
Figure 3:
Example of a bulkculture a  er 4 days, 
just before the fi rst passaging.
Figure  4:
Example of bulk culture that has been adapted 
and is ready to be passaged.
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12. Plate cells at a fi nal density of 3000 cells in 50 μL of BPEL medium plus growth factors 
in each V-shaped well of a 96-well plate from a stock solu  on containing the required 
number of cells in the correct volume for all wells to be seeded.
 Note
For a complete plate only use the 60 inner wells and add 100 μL of PBS to the outer wells to 
compensate for any evapora  on of culture medium.
13. Centrifuge plate for 3 minutes at 450 g to form aggregates (Spin EBs) (Figure 6A).
14. Place in the incubator at 37°C for 3 days.
Day 3
15. Remove the BPEL medium containing growth factors and add 100 μL of growth factor-
free BPEL medium.
Day 7
16. Plate the Spin EBs in BEL medium (BPEL without PVA) on 0.1% gela  ncoated 96-well 
plates with fl at-bo  omed wells (Figure 6B).
 Note
For prac  cal reasons BPEL can also be used but PVA is not needed a  er 7 days for the con  nuous 
diff eren  a  on of the EBs. 
Day 8
17. Begin checking for bea  ng areas in the cell aggregates under a phase contrast 
microscope (203 objec  ve) (Figure 6C).
 Note
Bea  ng may begin up to 20 days later, depending on the cell line. HES3 Spin EBs usually start to 
beat around day 8 and reach a maximum at day 12 (that is, all EBs containing cardiomyocytes are 
bea  ng). Note that EBs that do not beat visibly do not usually contain cardiomyocytes if stained 
retrospec  vely with an an  body against sarcomeres. 
18. A  er 14 days, refresh wells with BEL or BPEL medium once a week.
Growth Factor Titra  on Curves
Titra  on of Ac  vin A and BMP4 is usually needed to determine the op  mal concentra  ons for 
the induc  on of bea  ng cells. Titra  on will be required for each new batch of growth factors 
(which are supplied on the basis of protein concentra  on and not specifi c ac  vity) and each new 
cell line or clone:
Figure 5:
Bulk cultures one day a  er pla  ng 
on Matrigel™ for MEF feeder cell 
deple  on.
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Final (ng/mL) Stock (ng/μL)
BMP4 Determine using  tra  on 30
VEGF 30 50
SCF 40 40
Ac  vin A Determine using  tra  on 25
One way in which a  tra  on can be done is to test new growth factor batches or cell lines in 
the middle 60 wells (6 wells by 10 wells) of a 96-well plate. Vary the concentra  on of Ac  vin A 
(0–30 ng/mL) in one direc  on and BMP4 (0–30 ng/mL) in the other direc  on. Duplicate rows 
and columns so that there are mul  ple samples of each combina  on.
Constant concentra  ons of VEGF (30 ng/mL) and SCF (40 ng/mL) are present in the Spin-EB 
medium. PVA is an essen  al component and should not be omi  ed (Figure 7).
Dissocia  on of Bea  ng Spin EBs for Experimenta  on on
Single Cardiomyocytes
1. Wash Spin EBs with PBS.
2. Add TrypLE Select for 20 min at 37°C (this depends on the size of the EBs, days of 
diff eren  a  on, etc.). Break up the EBs by gentle pipe   ng.
 Note
The  me needed for dissocia  on increases with the age of the EBs and thus the  me 
men  oned above should be monitored. 
3. Neutralize the enzyme by resuspending cells in serum-containing medium and place 
in a 15 mL tube.
 Note
Pipe  e up and down vigorously (maximum three  mes) if clumps of EBs are s  ll visible
4. Centrifuge for 3 minutes at 250 g.
 Note
For use in FACS, begin standard FACS staining protocol a  er this step. 
5. Resuspend in BEL medium containing 5 μM Rock Inhibitor.
6. Plate dissociated cells on the appropriate 0.1% gela  n-coated cell culture treated dish, 
plate, or fl ask.
 Note
5000 cells per cm2 gives a nice spread of single cells although the ideal cell density 
depends on the subsequent experiments that will be carried out. Coa  ng dishes, plates, or fl asks 
with other ECM materials (e.g. Matrigel or fi bronec  n) may improve a  achment in some cases. 
7.  Refresh medium, removing the Rock Inhibitor 24 hours later.
Figure 6:
(A) Example of Spin EB in 96 well 
V-wells at day 0 a  er centrifuging. 
(B) Example of spin EB in V-wells 
on day 7 (C) Example of Spin EB 




Use of APEL Instead of BPEL
The use of Bovine Serum Albumin (BSA) in the BPEL medium has some drawbacks, including 
batch-to-batch varia  on and the fact that it is an animal product. Replacing BSA with human 
recombinant albumin may decrease the batch-to-batch varia  on observed with BSA. Human 
recombinant albumin may also produce higher effi  ciencies of diff eren  a  on. However, human 
recombinant albumin is much more expensive than BSA. Stem Cell Technologies™ also supplies 
pretested APEL medium on a commercial basis.
PITFALLS AND ADVICE
Defi ned Media for hESC Cultures
The use of defi ned media for culture of hESCs is ideal for reducing the dependence on MEFs, 
elimina  ng the unknown components they produce and reducing variability in cultures over 
 me. There are two commercial media, mTeSR and Nutristem, which we have used to grow hESC 
cultures under defi ned, feeder-free condi  ons for up to 20 or so passages. Long-term passage 
in either media may be more likely to cause earlier karyotypic abnormali  es compared to MEF-
based mechanically passaged cultures because it is thought that the total number of cell divisions 
in a given  me period may be higher in defi ned media. In addi  on, the poten  al for subsequent 
diff eren  a  on using other protocols can vary depending on the media used, possibly due to the 
diff erences in media components. For example, higher bFGF levels in mTeSR have been found by 
some to impact the effi  ciency of diff eren  a  on to cardiomyocytes and endoderm deriva  ves.
FIGURE 7
The outcome of a typical  tra  on curve of BMP4 and Ac  vin A, using HES3 cells, showing op  mal BMP4/ Ac  vin A 
concentra  ons of 20 ng/mL for each. Higher Ac  vin A concentra  ons in HES3 lead to endoderm forma  on. Lower 
Ac  vin A and higher BMP4 concentra  ons lead to other mesoderm deriva  ves like blood. Here, the number of 
Nkx2.5 1 cells present was determined by FACS analysis of GFP (NKX2.5-GFP-Hes3 line [Elliot et al., 2011], but it 
may also be done using an Nkx2.5 an  body) in a single cell suspension (dissociated bea  ng Spin EBs, see protocol 
below). For other cell lines, similar  tra  on experiments showed concentra  ons as low as 5 ng/mL for these factors 
to be op  mal for inducing cardiomyocyte diff eren  a  on.
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Other Factors Infl uencing Diff eren  a  on Effi  ciency
While we have op  mized the Spin EB method using specifi c growth factors, there are a number 
of factors which could s  ll be added to help improve effi  ciency further. These include the 
addi  on of ascorbic acid or small molecular inhibitors of transforming growth factor β receptors. 
The presence of Wnts or Wnt inhibitors has also been reported to enhance cardiomyocyte 
diff eren  a  on if present during the earliest phases of mesoderm forma  on. Effi  cient nascent 
mesoderm forma  on is a prerequisite for subsequent pa  erning to cardiogenic mesoderm.
EQUIPMENT
 Tissue culture hood: Class II A/B3
 Tissue culture incubator, 37°C, 5% CO2, in humidifi ed air
 Inverted phase/contrast microscope with 43, 103 and 203 objec  ves
 Centrifuge, 250 to 450 g
 Water bath, 37°C
 Pipe  es, such as Eppendorf p2, p20, p200, p1000, mul  channel
 Pipe  e Aid, automa  c pipe  or for use in measuring and dispensing media
 Aspirator in the hood, with fl ask






  5 mL, 10 mL, 25 mL sterile disposable pipe  es
  6-well culture dishes
  T25 culture fl ask
 96-well Greiner bioone V-shaped bo  om low a  achment  ssue culture plates
 96-well fl at-bo  omed  ssue culture plates
 15 mL sterile conical tubes
 50 mL sterile conical tubes
 Sterile 9” Pasteur pipe  es (autoclaved)
 Pipe  e  ps for Eppendorf or similar pipe  e (use blue and yellow low a  achment 
polypropylene pipe  e  ps from Corning) 
 Hemocytometer
 0.22 μm Stericup fi ltra  on unit
 Other fi lters and syringes




Item Supplier Catalog #
Basal medium
DMEM/high glucose (Dulbecco’s Modifi ed 
Eagle’s Medium)
Life Technologies 11960-044
DMEM/F12 1:1 (GlutaMAX, no HEPES) Life Technologies 31331-028
IMDM, L-glutamine, 25 mM HEPES, no phenol 
red (Iscove’s Modifi ed Dulbecco’s Medium) Life Technologies 21056-023
F12 Nutrient Mixture (Ham), GlutaMAX Life Technologies 31765-027
Serum components
Knockout Serum Replacement (contains 
bovine products)
Life Technologies 10828-028
Fetal Bovine Serum (FBS) (batch selected) Sigma-Aldrich F7524
L-Glutamine 200 mM Life Technologies 25030-024
GlutaMAX™-I Supplement 200 mM Life Technologies 35050-038
MEM-Non-essen  al amino acids 100x Life Technologies 11140-035
2-Mercaptoethanol 50 mM (1000x) Life Technologies 31350-010
D-PBS (Dulbecco’s Phosphate- Buff ered Saline 
without Calcium and Magnesium)
Life Technologies 15230-089
Dis  lled H
2
O Invitrogen 15230-089
Basic FGF (FGF-2) Recombinant human PeproTech 100-18B
Albumin from bovine serum, powder Sigma A3311
Resin Beads Bio-Rad 142-6425
Poly(vinyl alcohol) (PVA) Sigma-Aldrich P8136
Recombinant Human VEGF 165 R&D systems 293-VE
Recombinant Human SCF PeproTech 300-07
Recombinant Human/Mouse/Rat Ac  vin A R&D systems 338-AC
Recombinant Human BMP-4, CF R&D systems 314-BP
Fasudil, Monohydrochloride Salt, >99% LC Laboratories F-4660
BD Matrigel Matrix Growth Factor Reduced (GFR) BD Biosciences 354230
Chemically Defi ned Lipid Concentrate Invitrogen 11905-031
TrypLE Select (1x) Invitrogen 12563-029
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1-Thioglycerol Sigma-Aldrich M6145
Insulin-Transferrin-Selenium-X Supplement (100x) Invitrogen 51500-056
Gela  n from porcine skin Sigma-Aldrich G1890
PFHM II: Protein free Hybridoma medium 1x Invitrogen 12040-051
L-Ascorbic acid 2-phosphate Sigma-Aldrich A8960
Pen/Strep (100x) Life Technologies 15070-063
RECIPES
 Note
Glassware should be dedicated to  ssue culture use only. If glassware is to be used instead of 
pre-sterilized plas  cware, do not expose bo  les to detergent.
Stock Solu  on Human Basic FGF (bFGF) 100 μL
Component Amount Stock Concentra  on
Human bFGF 10 μg 100 ng/μL
1. Dissolve 10 μg of human basic FGF in 10 μL of 5 mM Tris (according the product sheet).
2. Add 90 μL of PBS +0.1% BSA.
3. Aliquot in 5, 10 and 25 μL samples.
4. Store thawed aliquots at 4°C for up to 2 weeks.
5. Store frozen aliquots at -80°C (stable for up to 12 months).
Stock Solu  on 10% Deionized BSA 45 mL
Component Amount Stock Concentra  on
10% Deionized BSA 4.5 g 10% w/v in IMDM
1. Dissolve 4.5 g in 45 mL of IMDM at 37°C in a 50 ml tube.
2. Vortex to help mix.
3. A  er completely dissolved, add Bio-Rad Resin Beads in excess (.2 grams).
4. Set rolling at 4°C on a roller bank un  l beads turn yellow (beads aresaturated).
5. Remove the supernatant and place in a new Falcon tube.
6. Add new beads and set rolling on a roller bank at 4°C.
7. Repeat un  l beads remain blue.
Stock Solu  on 5% PVA 50 mL
Component Amount Stock Concentra  on
PVA 2.5 g 5% PVA in dH2O
1. Dissolve 2.5 g in 25 mL of dH2O (  ssue culture qualifi ed).
 Note
Add the powder to the dH2O and move the tube while adding the PVA powder). 
2. Mix slightly.
3. Set rolling at 4°C on a roller bank un  l completely dissolved and adddH2O up to 50 ml 
(can take up to 2 days).
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Stock Solu  on 1-Thioglycerol 10 mL
Component Amount Stock Concentra  on
1-Thioglycerol 130 μL 0.15 M
1. Add 130 μL of 1-Thioglycerol to 10 mL IMDM (making these larger volumes of 130 μL is 
more accurate than smaller volumes because the Thioglycerol is highly viscous).
Stock Solu  on BD Matrigel Matrix Growth Factor Reduced (GFR) 10 mL
Component Amount Stock Concentra  on
BD Matrigel Matrix Growth Factor 
Reduced (GFR)
10 mL Undiluted
1. Thaw 10 mL stock overnight on ice and place in icebox at 4°C. Place Eppendorf tubes 
and pipe  e  ps at -20°C.
2. Aliquot stock into 100, 200, and 500 μL samples on ice in ice-cold Eppendorf tubes and 
store at -20°C for up to 3 months.
For use in coa  ng plates:
3. Thaw 100 μL aliquot on ice.
4. Using cold pipe  es and medium add 100 μL of Matrigel to 10 mL of DMEM/F12 basal medium.
5. Using a cold pipe  e, add 2 mL of medium to each well of a 6-well plate.
6. Leave at room temperature for at least 45 minutes.
7. Plates can be used immediately or stored for 2 weeks at 4°C.
 Note
Stored plates should be le   out at room temperature for 45 minutes before use to allow them 
to warm up.
Stock Solu  on Recombinant Human VEGF 165 200 μL
Component Amount Stock Concentra  on
Recombinant Human VEGF 165 10 μg 50 ng/μL
1. Centrifuge prior to opening.
2. Dissolve in 200 μL of dH2O (according to the product sheet).
3. Aliquot in 5 and 10 μL samples.
4. Store thawed aliquots at 4°C for up to 1 week.
5. Store frozen aliquots at 280°C (stable for up to 12 months).
Stock Solu  on Recombinant Human SCF 250 μL
Component Amount Stock Concentra  on
Recombinant Human SCF 10 μg 40 ng/μL
1. Centrifuge prior to opening.
2. Dissolve in 250 μL of dH2O (according to the product sheet).
3. Aliquot in 5, 10, and 20 μL samples.
4. Store thawed aliquots at 4°C for up to 1 week.
5. Store frozen aliquots at -80°C (stable for up to 12 months).
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Stock Solu  on Recombinant Human/Mouse/Rat Ac  vin A 400 μL
Component Amount Stock Concentra  on
Recombinant Human/Mouse/Rat Ac  vin A 10 μg 25 ng/μL
1. Centrifuge prior to opening.
2. Dissolve in 400 μL of PBS +0.1% BSA (according to the productsheet).
3. Aliquot in 5, 10, and 20 μL samples.
4. Store thawed aliquots at 4°C for up to 1 week.
5. Store frozen aliquots at -80°C (stable for up to 12 months).
Stock Solu  on Recombinant Human BMP4 330 μL
Component Amount Stock Concentra  on
Recombinant Human BMP-4, CF 10 μg 30 ng/μL
1. Centrifuge prior to opening.
2. Dissolve in 330 μL of PBS10.1% BSA (according to the productsheet).
3. Aliquot in 5 and 10 μL samples.
4. Store thawed aliquots at 4°C for up to 1 week.
5. Store frozen aliquots at -80°C (stable for up to 12 months).
Stock Solu  on Fasudil, Monohydrochloride Salt, >99% 5 mL, ROCK Inhibitor
Component Amount Stock Concentra  on
Fasudil, Monohydrochloride Salt, >99% 8.15 mg 5 mM
1. Add 8.15 mg to 5 mL of dH2O.
2. Mix un  l dissolved.
3. Filter using 0.22 μm.
4. Aliquot in 5 and 10 μL samples.
5. Store at -20°C (stable up to 3 months).
Stock Solu  on “Knockout Serum Replacement”
(Invitrogen 10828-028)
This product can be kept (a  er thawing) at 4°C for 1 week.
1. A  er 1 week freeze aliquots into appropriate volumes in 50 mL tubes andstore at 
220°C.
2. Thaw at 37°C just prior to use.
Stock Solu  on L-Glutamine (200 mM) (Invitrogen 25030-081)
L-glutamine is unstable and must be stored frozen.
1. Thaw the bo  le completely and aliquot in 10 mL tubes. Store at -20°C.
2. Thaw a tube just prior to use.
3. Do not refreeze tube, store at 4°C and discard unused glutamine a  er 2 weeks.
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HESC Medium 100 mL
Component Amount Stock Concentra  on
DMEM/F12 1:1 (GlutaMAX, no HEPES) 78 mL
KnockOut Serum Replacement 20 mL 20%
100x MEM-Non-Essen  al amino acids 1 mL 10 mM
50 mM 2-Mercaptoethanol 200 μL 0.1 mM
Human bFGF (100 ng/μL) 10 μL 10 ng/mL
Pen/Strep (100x) 0.5 mL 1:200
1. Prepare all media in the  ssue culture hood using asep  c techniques.
2. Combine the basal medium and all the components except bFGF in the fi lter top. Filter 
sterilize using a 0.22 μm Stericup fi ltra  on unit.
Add 10 ng/mL bFGF a  er fi ltering.
3. Store at 4°C for up to 2 weeks.
BPEL Medium: Bovine Serum Albumin (BSA) Polyvinylalchohol Essen  al Lipids 100 mL
Component Amount Stock Concentra  on
IMDM, L-glutamine, 25 mM HEPES, no phenol red
(Iscove’s Modifi ed Dulbecco’s Medium)
42.6 mL
F12 Nutrient Mixture (Ham), GlutaMAX 42.6 mL
PFHM II: Protein free Hybridoma medium 1x 5 mL 1:20
10% Deionized BSA in IMDM 2.5 mL 0.25% w/v
5% PVA in dH2O 2.5 mL 0.125% w/v
Chemically Defi ned Lipid Concentrate 1 mL 1:100
Insulin-Transferrin-Selenium-X Supplement (100x) 100 μL 1:1000
0.15 M 1-Thioglycerol 300 μL 450 μM
5 mg/mL L-Ascorbic acid 2-phosphate 1 mL 0.05 mg/mL
200 mM GlutaMAX-I Supplement 1 mL 2 mM
Pen/Strep (100x) 0.5 mL 1:200
1. Prepare all media in the  ssue culture hood using asep  c techniques.
2. Combine all components and fi lter sterilize using 0.22 μm fi lter.
3. Store at 4°C for up to 2 weeks.
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BEL medium: Bovine Serum Albumin (BSA), Essen  al Lipids 100 mL
Component Amount Stock Concentra  on
IMDM, L-glutamine, 25 mM HEPES, no phenol red
(Iscove’s Modifi ed Dulbecco’s Medium)
42.6 mL
F12 Nutrient Mixture (Ham), GlutaMAX 42.6 mL
PFHM II: Protein free Hybridoma medium 1x 5 mL 5%
10% Deionized BSA in IMDM 5 mL 0.5% w/v
Chemically Defi ned Lipid Concentrate 1 mL 1:100
Insulin-Transferrin-Selenium-X Supplement (100x) 1 mL 1:100
0.15 M 1-Thioglycerol 300 μL 450 μM
5 mg/mL L-Ascorbic acid 2-phosphate 1 mL 0.05 mg/mL
200 mM GlutaMAX-I Supplement 1 mL 2 mM
Pen/Strep (100x) 0.5 mL 1:200
1. Prepare all media in the  ssue culture hood using asep  c techniques.
2. Combine all components and fi lter sterilize using 0.22 μm fi lter.
3. Store at 4°C up to 2 weeks.
Serum-Containing Medium 100 mL
Component Amount Stock Concentra  on
DMEM/high glucose (Dulbecco’s Modifi ed
Eagle’s Medium)
87.5 mL
FBS 10 mL 10%
100 x MEM-Non-essen  al amino acids 1 mL 10 mM
200 mM L-Glutamine 1 mL 2 mM
Pen/Strep (100 x) 0.5 mL 1:200
1. Prepare all media in the  ssue culture hood using asep  c techniques.




Lot-to-Lot Variability of Reagents
Growth factors are sold on the basis of weight/volume, not specifi c ac  vity. Eff ec  ve 
concentra  ons of growth factors required for growth and diff eren  a  on will then depend on 
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Hypertrophic cardiomyopathy (HCM) is a gene  c cardiac disease characterized by 
increased heart size and wall thickening in the absence of other cardiac or systemic 
diseases. Many cases of familial HCM are caused by muta  ons in the myosin binding 
protein C (MYBPC) gene. The paucity of appropriate in vitro or animal models and 
diffi  cul  es in obtaining cardiac biopsies from pa  ents have limited the opportuni  es 
to study underlying molecular mechanisms that may determine severity and onset of 
symptoms. Here, we derived human induced pluripotent stem cells (iPSC) from three 
HCM pa  ents by reprogramming fi broblasts from skin biopsies; two of the pa  ents were 
related, the other was not but had the same muta  on. MYBPC type 3 protein levels were 
signifi cantly reduced by Western blo   ng in HCM-iPSC cardiomyocytes compared to 
the control, consistent with reduced MYBPC3 levels previously found in heart biopsies 
from pa  ents. Dissociated and replated single HCM-iPSC derived cardiomyocytes had 
a cell surface area more than 2-fold greater than control cardiomyocytes. In addi  on, 
calcium signaling was altered in the disease cardiomyocytes compared with controls, 
consistent with previously published data. Cardiomyocytes from HCM-iPSC thus show 
essen  al features of the disease and provide a basis for further studies on the nature 
of HCM caused by muta  ons in MYBPC3. 
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Introduc  on
Hypertrophic cardiomyopathy (HCM) is a gene  c cardiac disease characterized by increased 
heart size and cardiac wall thickening [1]. It is the most common cardiomyopathy, aff ec  ng 1 
in 500 people [2]. HCM is associated with muta  ons in one of the 11 sarcomeric genes, the 
most prevalent muta  ons being found in the β-myosin heavy chain (βMHC) and myosin binding 
protein C3 (MYBPC3) genes [3]. In the Netherlands, three founder muta  ons have been found 
in the MYBPC3 gene, a cardiac sarcomeric protein that is believed to modulate contrac  le force 
through phosphoryla  on-regulated intracellular calcium although the exact mechanism and 
func  on of MYBPC3 in contrac  on is s  ll unclear [2,4,5]. The most common of these founder 
muta  ons is 2373insG. It accounts for 25% of familial HCM cases in the Netherlands [6]. The 
muta  on in exon 25 is predicted to cause protein trunca  on although truncated protein has 
not been detected in heart biopsies. The clinical phenotype is currently regarded as being due 
to haploinsuffi  ciency (Figure 1) [6,7]. This muta  on is mostly associated with late onset of 
symptoms with most individuals only displaying clinical complaints when thirty or older [6]. The 
exact mechanism of the disease remains unclear and it is not known what causes the onset of 
clinical symptoms.
There are a number of MYBPC3 mutant mouse models [8-10], although none for this Dutch 
founder muta  on. Since access to human heart biopsies from pa  ents is limited, we sought 
to establish a model based on human induced pluripotent stem cells (hiPSC) [11,12]. hiPSC, 
like human embryonic stem cells (hESC), can self-renew and diff eren  ate to deriva  ves of the 
three germ layers, including cardiomyocytes. They can also be generated from any individual 
of any gene  c background including those carrying mutant genomes.  hiPSC lines have already 
been generated from pa  ents with a variety of cardiac diseases including LQT [13-15], Brugada 
syndrome [16], Catecholaminergic Polymorphic Ventricular Tachycardia (CPTV) [17,18] and one 
form of HCM [19]. In addi  on hiPSC lines have been derived from pa  ents with mul  organ 
muta  ons that cause syndromes with heart failure or other heart defects as one of their clinical 
features [20].
In this study we generated hiPSC from three pa  ents with the same MYBPC3 muta  on (2373insG) 
but each with a diff erent clinical phenotype: they included a father and son with diff erent ages 
of disease onset and one unrelated pa  ent. A  er successful genera  on of the hiPSC lines, the 
disease phenotype was assessed in clones in which the reprogramming genes were s  ll present 
or had been removed. MYBPC3 protein levels, cardiomyocyte cell surface area and altera  ons in 
calcium signaling/handling responses were determined. MYBPC3 protein levels were reduced in 
the diseased hiPSC derived cardiomyocytes as expected, and this was accompanied an increase 
in cell surface area on a culture substrate as well as altered calcium handling. This recapitulated 
the essen  al features of the disease and contributed to valida  ng hiPSC from HCM pa  ents as 
an in vitro model for inves  ga  ng the mechanism underlying the disease pathology.
Material and Methods:
Ethics Statement
Heart biopsies and human skin biopsies were obtained from pa  ents a  er individual wri  en 
permission using standard informed consent procedures and approval of the Leiden University 
Medical Center’s medical ethics commi  ee. All samples were collected and anonymized by the 
trea  ng physician. The control skin sample was obtained as waste  ssue from an anonymized 
male donor.
Histology
Paraffi  n-embedded blocks from the le   ventricle of a 72 year-old male (cause of death 
pneumonia) and the interventricular septum of pa  ent 2 collected during Morrow surgery 
were provided by the LUMC Pathology Department. 5μm sec  ons were cut and stained using 
hematoxylin and eosin (HE) staining solu  on and for Sirius red as previously published [21].
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Isola  on of dermal fi broblasts
Dermal fi broblast were isolated as previously described [22]. Fibroblasts at passage 2 were used 
for reprogramming.
Len  viral produc  on
Len  viruses containing a self-inac  va  ng mul  cistronic casse  e encoding OCT3/4, SOX2, KLF4, 
and c-MYC were produced using polyethyleneimine to cotransfect HEK/293 T cells with the 
expression vector pRRL.PPT.SF.hOKSM.idTomato.preFRT and the helper vectors pCMV-VSVG, 
pMDLg-RRE, pRSV-REV. The virus was harvested a  er 48 h. The quan  ty of virus par  cles was 
measured by ELISA detec  ng HIV p24 using a kit (Zeptometrix) according to the manufacturer’s 
protocol. The MOI was es  mated by mul  plying the p24 concentra  on (ng/ml) by a factor of 
2500 [23].
 hiPSC genera  on and maintenance 
For len  viral infec  on, 1.25 x 105 fi broblasts were seeded into one well of a 6-well plate and 
transduced 24 h later with the len  virus at 5 MOI in the presence of 4 μg/ml polybrene (Sigma-
Aldrich) in fi broblast medium. The virus was removed a  er 24 h. Six days a  er transduc  on, 20,000 
fi broblasts were seeded on mouse embryonic fi broblasts (MEFs; 2 x 106 MEFs/10 cm dish) and 
cultured in hESC knock out serum replacement (KOSR) medium (DMEM/F12 supplemented with 
Glutamax, 10 mM NEAA, 25 U/ml penicillin, 25 μg/ml streptomycin, 100 μM β-mercaptoethanol, 
20% KOSR (Invitrogen) and 10 ng/ml basic FGF (PreproTech)). Medium was changed every other 
day un  l the appearance of hESC-like colonies. Individual colonies were mechanically picked 
and placed on Matrigel in mTeSR (Stem Cell Technologies) and subcultured according to the 
manufacturer’s protocol. hiPSC lines used in this study were denoted LUMC0004iCtrl (ctrl), 
LUMC0033iMyBPC (HCM1), LUMC0034iMyBPC (HCM2), LUMC0035iMyBPC (HCM3). 
Determining insert number 
Insert number was determined using splinkere  e PCR. DNA was collected from each clone using 
Purecore Kit B from Qiagen according to the manufacturer’s protocol (Qiagen). 5 μg of genomic 
Figure 1: Schema  c representa  ons of MYBPC3. A) Schema  c representa  on of the 37 exons on the MYBPC3 gene 
and the loca  on of the Dutch Founder muta  on 2373insG. B) The MYBPC3 protein and the predicted truncated 
protein created by the 2373insG muta  on.
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DNA was digested overnight in 10 U/μl CViQI (NEB) at 25°C or 10 U/μl DPNII (NEB) at 37°C. 300 
ng of digest was then used for overnight T4 DNA ligase reac  on in 40 μl as previously published 
[24].  Following a second diges  on to prevent amplifi ca  on of internal len  viral sequences, 5 μl 
of the ligated product was amplifi ed using touchdown PCR. A  er successful amplifi ca  on, the 
PCR product was run in a second touchdown PCR (Dambrot et al, in prepara  on). This product 
was then run on a 2.5% tris-acetate-EDTA (TAE) gel with 0.5 μg/ml of ethidium bromide to 
determine insert number.
Transgene removal
hiPSC clones with either 1 or 2 inserts were fi rst adapted to enzyma  c passage on MEFs [25]. 
hiPSC were transfected with pLV.hCMV-IE.FLPe.IRES.PurR.hHBVPRE [26] using FuGENE 6 (Roche) 
as previously described [27]. In brief, 20,000 hiPSC/cm2 were seeded on MEFs (density 30,000 
cells/cm2. Following overnight a  achment, the cells were transfected using FuGENE 6 according 
to the manufacturer’s protocol. The following day, the cells were exposed for 24 h to puromycin 
(fi nal concentra  on 1 μg/ml). Colonies reappeared 1 to 2 weeks a  er puromycin treatment 
and were screened for successful transgene removal using specifi c PCR primers (OCT3/4-KLF4: 
forward: 5’-TCGTGAGAGTGTGGTTCTGC-3’, reverse: 5’-CTCCCGCCATCTGTTGTTAG-3’;  FRT 
(triple primer set): 5’-CGAGTCGGATCTCCCTTTGGGC-3’, 5’-TGGAAGGGCTACGTAGCTAGC-3’, 
5’-GGTTCCCTAGTTAGCCAGAGAGC-3’). Transgene-free colonies were mechanically picked and 
placed on Matrigel with mTeSR for further expansion. To test for possible integra  on of the 
vector, hiPSC colonies were exposed to puromycin (fi nal concentra  on of 1 μg/ml) for 24 h of 
selec  on.
Karyotype analysis
Karyotype analysis was performed using COBRA-FISH as previously described [28]. 20 metaphase 
spreads for each sample were analyzed.
Muta  on Confi rma  on
DNA from hiPSC was collected using a phenol chloroform-based method.  MYBPC3 exon 25 
was amplifi ed by PCR (forward primer: 5’-CCTGTGGCGGTTAGTTGG-3’, reverse primer: 5’ 
CACCGGTAGCTCTTCTTCTTCTTG-3’) and used for Sanger sequencing with the forward primer. 
The muta  on was also confi rmed using muta  on-specifi c PCR primers [6] (Forward primer: 
5’-AGGACTCCTGCACAGTACAGGT- 3’, reverse primer: 5’- CACCGGTAGCTCTTCTTCTTCTTG-3’).
Spontaneous Diff eren  a  on of hiPSC into deriva  ves of the three germ layers
Pieces of hiPSC colonies were passaged onto Matrigel coated chamber slides (BD Falcon) in 
mTeSR for two days, then cultured in DMEM/F12 with 20% FCS for 3 weeks, changing medium 
every other day. Cells were then fi xed for 30 minutes in 2% paraformaldehyde (PFA).
Table 1: Clinical Data of HCM pa  ents with 2373insG muta  on in MYBPC3
Pa  ent AGE SEX
Interventricular 
Septum     
in Diastole, mm
LVEDD, mm LVESD, mm % FS LVEF%
1 44 m 13 54 32.9 39 56
2 14 m 35 41 24 41 58
3 42 m 24 55 42 24 48
Healthy 
Range
 <13 36-56 20-40 25-43 55-70
% Frac  onal shortening (FS) = (LVEDD-LVESD)/LVEDD*100%
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Monolayer Cardiac Diff eren  a  on
hiPSC were plated in mTeSR on a Matrigel-coated plate. A  er 3 days, the medium was 
removed and BEL medium (Iscove’s Modifi ed Dulbecco’s Medium (IMDM) supplemented 
with L-glutamine and 25mM HEPES (Invitrogen,), F12 Nutrient Mixture (HAM) supplemented 
with Glutamax (Invitrogen), 5% protein free hybridoma medium (Invitrogen), 0.25% deionized 
albumin from BSA (Sigma,) in IMDM, 1% Chemically Defi ned Lipid Concentrate (Invitrogen), 0.1% 
Figure 2: Histological sec  ons of heart  ssue from normal heart  ssue and heart  ssue from HCM pa  ent 2 
collected during a Morrow opera  on. A&B) Hematoxylin and eosin (HE) staining of healthy heart  ssue of the 
le   ventricle, 100x and 400x magnifi ca  ons, respec  vely, demonstra  ng uniformly shaped myocardial fi bers and 
a moderate amount of collagen deposi  on, C) HE staining of a sec  on (100x magnifi ca  on) from HCM pa  ent 2 
showing a severely thick band of collagen adjust to the myocardial fi bers. D) Sirius red staining of a subsequent 
sec  on to the HE staining of image C, confi rming the presence of collagen extending from the endocardium into the 
myocardial fi bers. E&F) HE staining of a second piece of heart  ssue from pa  ent 2 (100x and 400x magnifi ca  on, 
respec  vely) indica  ng large areas of fi brosis with infi ltra  ng infl ammatory cells including lymphocytes, plasma 
cells and macrophages (as indicated by the black arrow). G) HE staining of a third piece of heart  ssue displaying 
adipose  ssue between the collagen band and myocardial fi bers (100x magnifi ca  on). H) HE staining of fourth 
piece of hearth  ssue (400x magnifi ca  on) demonstra  ng irregularly shaped myocardial fi bers with fragmented 
cytoplasm.
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Insulin-Transferrin-Selenium-X supplement (Invitrogen), 450 μM 1-Thioglycerol (Sigma), 5mg/
ml L-ascorbic acid 2-phosphate (Sigma), 1% Glutamax (Invitrogen), 25 U/ml penicillin, 25 μg/
ml streptomycin (both Invitrogen)  plus 20ng/ml Ac  vin A (R&D systems), 20ng/ml BMP4 (R&D 
systems) and 1.5 μM CHIR99021  (Axon). The growth factors were removed 72 h later and BEL 
plus 5 μM XAV939 and Matrigel (1:100) was added for 72 h to prevent cells detaching from the 
dish. The cells were then refreshed twice weekly with BEL. 
Immunostaining
Immunofl uorescent staining was performed as previously [16]. In brief, PFA-fi xed cells were 
permeabilized with Triton X-100, blocked with 4% normal goat serum for 1 h before overnight 
incuba  on with the primary an  body (NANOG (1:500, Peprotech), SSEA-4 (1:30, Biolegend), 
OCT3/4 (1:100, Santa Cruz), TRA-1-81 (1:25, Biolegend), βIII-TUBULIN (1:2000, Covance), 
AFP (1:25, Quar  et), CD31 (1:100, DAKO) α-Ac  nin (Sigma), Troponin I (Santa Cruz), β-MHC 
(Millipore), Nkx2.5 (Santa Cruz), MYBPC3 (provided by J. van de Velde), sarcomeric Tropomyosin 
(Sigma Aldrich)) at 4 °C. The next day, secondary an  bodies labeled with Cy3 (1:200, Jackson 
Immuno Research), Alexa 568 (1:200, Invitrogen) or Alexa 488 (1:500, Invitrogen) were added for 
1 h at room temperature. For cell surface area measurements, α-Ac  nin stained cells were co-
stained with pre-conjugated Phalloidin-Alexa 488 (Invitrogen) following the secondary an  body 
(30 m room temperature). Nuclei were stained with DAPI before moun  ng slides with Mowiol 
(Calbiochem).
Protein Collec  on and Western Blot
Protein samples were collected 30 days a  er the start of diff eren  a  on. Protein samples were 
collected in Baeuerle Buff er (20mM HEPES, pH 7.9, 350 mM NaCl, 20% Glycerol, 1 mM MgCl
2
, 0.5 
mM EDTA, 0.1 mM EGTA, 1% NP-40) plus proteinase inhibitors (Proteinase inhibitor (Invitrogen, 
1:100), Orthovanadate (Sigma, 1mM), and Dithiothreitol (DTT, Roche, 0.1mM), using fl ash 
freezing in liquid nitrogen. Protein concentra  on was determined using Protein Assay buff er 
(Bio-rad) according to the manufacturer’s protocol. 100 μg of protein was run on 10% acrylamide 
gel and transferred to a Polyvinylidene fl uoride (PVDF) membrane overnight at 55 mAmps. Blots 
were blocked with 5% Milk for 1 h followed by overnight staining with primary an  body (MYBPC3, 
α-ac  nin, (as above), and ac  n (Millipore)) in 5% Milk. The next day, the appropriate horseradish 
peroxidase-linked secondary (Cell Signaling) in 5% Milk was added at room temperature for 1h. 
The bands were detected using SuperSignal West Pico Chemiluminescent Substrate (according 
to the manufacturer’s protocol, Thermo Scien  fi c) and analyzed using ImageQuant so  ware.
Cell Surface Area Measurement
Cardiomyocytes from bea  ng monolayers were dissociated into single cells 20 days a  er the 
start of diff eren  a  on using TrypLE Select (Invitrogen) for 30 minutes at 37 °C and plated onto 
Matrigel-coated coverslips. A  er 1 week, 100 μM PE was added for 72 h. The PFA-fi xed cells were 
fl uorescently stained with α-ac  nin-cy3 (Sigma and Jackson ImmunoResearch, respec  vely) 
and pre-conjugated Phalloidin-Alexa 488 (Invitrogen) as described above. Cells were visualized 
using Nikon Eclipse Ti-S microscope. Single plane of 1200x1600 pixels images at 313nm/pixel 
resolu  on were recorded using a Plan fl uor 20x/0.50 lens and analyzed using ImageJ so  ware. 
Cell surface area was determined by outlining the cell membrane of α-ac  nin posi  vely stained 
cells and using ImageJ so  ware to subsequently measure the area.
Responses to changes in external calcium
Bea  ng areas were dissected from cultures at day 20 and plated onto Matrigel-coated coverslips. 
7 to 10 days later, the bea  ng clumps were perfused with Tyrode’s solu  on (140mM NaCl, 10mM 




, pH 7.4)  with decreasing, then 
increasing amounts of external calcium (1.8mM, 1.0mM, 0.5mM, 0.3mM, 0.1mM, 0.5mM, and 
1.8mM) for 30 m intervals. A  er 30 m of perfusion, two-minute videos were captured and the 
beat rate determined from these as beats per minute. Results were normalized to beats per 
minute of the fi rst 1.8mM recording.  
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Table 2: Number of inserts iden  fy by Splinkere  e PCR 
HCM1 HCM2 HCM3
Clone Number of Inserts Clone Number of Inserts Clone Number of Inserts
1 N/A 1 N/A 1*ǂ 2
2 2 2*ǂ 2 2 1
3 N/A 3 N/A 3 3
4 N/A 4 N/A 4* 2
5 N/A 5 N/A 5 2
6 N/A 6 N/A 6 N/A
7 N/A 7 3 7 N/A
8 N/A 8 3 8 N/A
9* 1 9 N/A 9 3
10 N/A 10 N/A 10 4
11 N/A 11 N/A 11 2
12 N/A 12* 2 12 5
13*ǂ 1 13 N/A 13 1
14 2 14 N/A 14 4
15 3 15 2 15 2
* Clones selected for transgene removal.
ǂ Clones used for phenotype assessment a  er transgene removal. 
Internal Calcium Measurements
Cardiomyocytes from bea  ng monolayers were dissociated into single cells 20 days a  er the 
start of diff eren  a  on using TrypLE Select for 30 minutes at 37°C and plated onto Matrigel 
coated 96-well plates (40,000 cells/cm2). 10 days a  er pla  ng internal calcium was measured 
using Fluo-4am (Invitrogen) according to the manufacturer’s protocol and previously published 
[19]. In brief, 5 μM Fluo 4am plus 0.02% w/v Pluronic (Invitrogen) was added to each well 
and the cells were incubated for 15 minutes at 37°C, washed with Tyrode’s solu  on (same as 
above) and recorded using a Leica AF6000 microscope equipped with a Hamamatsu EM-CCD 
camera. Caff eine (10mM) was added a  er 20 s of video capture and the capture con  nued 
for an addi  onal minute. Raw calcium transients were analyzed using ImageJ so  ware and 
Z-profi le_ImJ so  ware (tailored for use here) to convert the raw data to ΔF/F measurements for 
compara  ve analysis.
Sta  s  cal Analysis
Results are expressed as mean ±SEM. Comparisons were made using one-way ANOVA or two-
way repeated measures ANOVA as indicated. Values of p ≤0.01 were considered signifi cant. 
Sta  s  cal analyses were performed using GraphPad Prism. 
Results
Clinical manifesta  on of the disease
The three pa  ents included were previously iden  fi ed by the LUMC Cardiology Department 
as carrying the 2373insG muta  on in the MYBPC3 gene. Each pa  ent displayed a diff erent 
clinical phenotype. Pa  ent 1 (HCM1) was at the  me of collec  on a 44 year old male with an 
interventricular septum (IVS) of 13mm. Pa  ent 2 (HCM2) was a 14 year old male, the son of 
pa  ent 3, with an incident of out of hospital cardiac arrest and a 44mm IVS. Pa  ent 3 (HCM3) 
was a 41 year old male (HCM2’s father) with a 29mm IVS. With the excep  on of increased IVS, 
other clinical cardiac characteris  cs (such as frac  onal shortening) were within the normal range 
(Table 1).
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Due to the large size of pa  ent 2’s IVS, he underwent a Morrow surgery, which removes pieces of 
the thickened heart wall. Some of these pieces were embedded in paraffi  n for histological studies. 
The histological sec  ons from pa  ent 2 were compared with healthy le   ventricular heart  ssue 
(Figure 2)). The HE staining of the healthy heart  ssue displayed uniformly shaped myocardial 
fi bers and a moderate amount of collagen deposi  on among the muscle fi bers (Figure 2A and 
B). Stained histological sec  ons from Pa  ent 2’s heart showed many abnormali  es, including a 
thick band of collagen that extended from the endocardium into the myocardial fi bers (Figure 
2C and D) as well as large areas of fi brosis with infi ltra  ng infl ammatory cells (lymphocytes, 
plasma cells and macrophages) (Figure 2E and F). Furthermore adipose  ssue was seen between 
the collagen band and the myocardial fi bers (Figure 2G) and many of the myocardial fi bers were 
angularly arranged, irregular in diameter and shape and in some, fragmented cytoplasm was 
visible (Figure F and H).  
Table 3: The proviral insert loca  ons iden  fi ed for the HCM clones 
Clone Insert loca  on
HCM1 #9 GATAD2B chr1: 153863681-153863723










HCM3 #4 NUMA1 Chr11: 71776625-71776694
Induced pluripotent stem cell genera  on, proviral insert iden  fi ca  on and removal
30 days a  er transduc  on of the reprogramming genes [29] 15 embryonic stem cell-like clones 
were selected from each pa  ent and the proviral insert number was determined.  The HCM-iPSC 
clones contained between 1 and 5 inserts (Table 2) with the majority of clones containing 2 or 
more inserts. Based on these results, 2 clones containing 1 or 2 inserts were selected for TOPO 
TA cloning and sequencing to determine the insert loca  on as shown in Table 3. These clones 
were then used in the subsequent experiments.
The transgenes were successfully removed from 5 out of 6 clones a  empted, using FLPe, with 
effi  ciencies ranging from 20-98% (see Table 4 for individual effi  ciencies). Specifi c PCR and 
sequencing of exon 25 of the MYBPC3 genes showed the 2373insG muta  on was s  ll present in 
the HCM-iPSC lines (fi gure 3A & B). All HCM-iPSC lines expressed pluripotency markers (NANOG, 
SSEA4, OCT3/4 and TRA1-81, fi gure 3C), and could undergo spontaneous diff eren  a  on resul  ng 
in expression of markers of the three germ layers (AFP, βIII Tubulin, CD31, fi gure 3A) comparable 
to that of a hiPSC derived from a gender and age-matched (to pa  ent 1 and 3) control line. 
Addi  onally, these lines were karyotypically normal (fi gure 3D) a  er transgene removal. 
Cardiac Diff eren  a  on and assessment of phenotype 
HCM-iPSC and ctrl-iPSC lines were induced to diff eren  ate into cardiomyocytes that showed 
spontaneous bea  ng and posi  ve immunostaining for the cardiac markers: α-ac  nin, NKX 2.5, 
Troponin T, βMHC, Tropomyosin, and MYBPC3 (Figure 4).
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The HCM phenotype of pa  ents with this MYBPC3 muta  on is thought to be due to 
haploinsuffi  ciency in MYBPC3 protein levels. To examine this in cardiomyocytes from HCM-
iPSC lines, protein samples were collected 30 days a  er the start of diff eren  a  on. MYBPC3 
protein levels in HCM-iPSC cardiomyocytes (based on normaliza  on to α-ac  nin protein levels 
to correct for possible diff erences in cardiomyocyte number and diff eren  a  on effi  ciencies) 
were compared to the healthy hiPSC-CM. MYBPC3 protein levels were 48-58% (n=4) lower in all 
HCM-iPSC-CM compared to the ctrl-iPSC-CM (Figure 5A). There was no signifi cant change in this 
outcome a  er the removal of the transgenes although pa  ent 3 then showed an 80% drop in 
protein level (n=3) (Figure 5B).
Table 4: The effi  ciency of transgene removal
Clone Effi  ciency (%)
HCM1 #9 0
HCM1 #13 40




An increase in heart size or wall thickening is a characteris  c of HCM in vivo in mouse disease 
models and in pa  ents [30-32]. However, the demonstra  on of hypertrophy in cardiomyocytes 
in vitro is more diffi  cult as most measurements are surrogates and a combina  on of evidence 
Figure 3: Characteriza  on of hiPSC. A) Sanger sequencing results of exon 25 of MYBPC3 of control and HCM-iPSC. 
B) PCR analysis of 2373insG muta  on using muta  on specifi c PCR primer pair. C) Immunofl uorescence images of 
undiff eren  ated hiPSC expressing typical pluripotency markers (red: NANOG, TRA1-81; green: OCT3/4, SSEA-4) 
and spontaneously diff eren  ated hiPSC stained for deriva  ves of the three germ layers (alpha feto-protein (AFP, 
green);  βIII-Tubulin (red); CD31 (red); nuclei (DAPI, blue). Scale bar: 50μm). D) Karyogram generated by combined 
binary ra  o labeling fl uorescence in situ hybridiza  on (COBRA-FISH) of HCM and ctrl hiPSC showing a normal 46XY 
karyotype. 
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will generally be required. Others have previously described cell surface area in culture as 
evidence for hypertrophic phenotypes, with cell size in two-dimensions as the surrogate 
measure [19,20,33,34]. Dissociated, single HCM-iPSC-CM from all three pa  ents showed a 
signifi cant 2- to 3-fold increase in cell surface area compared to the control cardiomyocytes in 
the absence of hypertrophic s  muli (fi gure 5C). Upon addi  on of 100 μM phenylephrine (PE) 
for 72 h, the ctrl-hiPSC-CM demonstrated a 2-fold increase in cell surface area compared to the 
untreated cells. There was no signifi cant change in cell surface area for the HCM-iPSC-CM (fi gure 
5C). Nevertheless, the untreated HCM-iPSC-CM remained signifi cantly larger than the PE treated 
healthy ctrl-hiPSC-CM. Upon removal of the reprogramming transgene, the cell surface areas of 
single untreated HCM-iPSC-CM was s  ll signifi cantly greater than those of the healthy individual, 
though in this case only between 1.5 and 2-fold (one-way ANOVA p≤0.05). PE had similar eff ects 
in the absence of the transgene as in its presence, demonstra  ng that its removal had no eff ect 
on the overall outcome of the experiment although the HCM-iPSC-CM were no longer larger 
than the PE treated ctrl-hiPSC-CM (fi gure 5D).  
The lack of PE-response was also evident in their chronotropic responses. Ctrl-hiPSC-CM and 
HCM-iPSC-CM from pa  ents 2 and 3 were treated with 100 μM PE or 100nM ISO and their 
automa  c responses immediately measured. While the ctrl-hiPSC-CM responded as expected 
with signifi cant increase in bea  ng frequency upon treatment with adrenergic s  muli, HCM-
iPSC-CM showed a diminished response and failed to reach sta  s  cal signifi cance (Figure 5E). 
Even strong s  muli such as serum (5 or 20%) failed to produce a response in the HCM-iPSC-CM 
although serum signifi cantly increased the bea  ng frequency of the ctrl-hiPSC-CM (Figure 5E).
    
HCM derived cardiomyocytes display an altered calcium response
MYBPC3 modulates heart contrac  on through calcium; although the mechanism is s  ll unclear 
there have been a number of studies which demonstrated an altera  on in the calcium signaling 
in primary animal and human cardiomyocytes [32,35]. In order to assess the calcium handling, 
Figure 4: Immunofl uorescence images of the cardiac markers α-ac  nin (ACTN1), troponin I (cTnI), sarcomeric 
tropomyosin (TPM1), myosin binding protein C3 (MYBPC3), beta-myosin heavy chain (β-MHC), and NKX2.5 in 
cardiomyocytes. Scale bar: 25μm.
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bea  ng clumps of hiPSC-CM were exposed to decreasing and then increasing concentra  ons of 
external calcium (stepwise 1.8, 1, 0.5, 0.3, 0.1 mM) and their bea  ng frequency determined. 
As external calcium decreased, cardiomyocytes from control and all disease lines showed an 
expected reduc  on in beat rate, but the disease lines displayed a signifi cantly altered response 
(two way ANOVA p=0.01). All of the HCM-iPSC-CM decreased their bea  ng frequency more 
rapidly compared to the ctrl-hiPSC-CM but displayed a faster recovery as the external calcium 
was returned to normal levels (fi gure 6A). 
Since changes in external calcium could aff ect other ion channel responses involved in bea  ng 
frequency, such as sodium or potassium channels, we inves  gated the HCM-iPSC-CM response 
to calcium more directly by measuring the caff eine induced calcium release using a Fluo-4am 
dye (Invitrogen). As expected, the addi  on of caff eine to the cells released the internal calcium 
stores resul  ng a detectable increase in fl uorescence. This increase was signifi cantly larger in the 
HCM-iPSC-CM (between 38-79%) than those derived from the healthy ctrl-hiPSC-CM ((between 
16-46%, Figure 6B-D), one-way ANOVA p≤0.05). Furthermore, there was no diff erence between 
lines in the absolute bea  ng frequency or the recovery  me a  er the addi  on of caff eine (Figure 6E-F). 
Figure 5: Assessment of disease phenotype of HCM-hiPSC-CM. A) Rela  ve expression of MYBPC3 (n=4) of transgene 
containing hiPSC *: p<0.05. B) Rela  ve expression of MYBPC3 (n=4) of hiPSC a  er transgene removal *: p<0.05). C) 
Cell surface area of transgene containing hiPSC ± 100 μM PE *: p<0.05. D) Cell surface area of transgene-free hiPSC ± 
100 μM PE *: p<0.05. E) Rela  ve change in bea  ng frequency of hESC-CM immediately a  er addi  on of 100 μM PE, 
100nM ISO, 5% serum, 20% serum or vehicle only control. Results normalized to ini  al bea  ng frequency. *=p<0.05 
vehicle only vs. treated n≥7 measurements. 
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Discussion
Quan  ta  ve and predic  ve assessment of cardiac hypertrophic disease phenotypes in pa  ent 
derived hiPSC is s  ll a challenge despite the increasing availability of a variety of cell lines from 
pa  ents with gene  c forms of this disease. One important issue is to ensure that the way 
the hiPSC lines have been generated, in par  cular whether the reprogramming transgenes 
are present or not, has not impacted the surrogate phenotype measurements. Whilst this is 
increasingly being overcome by using non-integra  ng methods for reprogramming, in some 
cases the lines already exist and returning to the original soma  c cells for reprogramming is not 
an op  on. Here we generated hiPSC lines from three pa  ents with a Dutch founder muta  on 
in the MYBPC3 gene that is associated with HCM and compared cardiomyocytes from these 
lines with a healthy control individual. We showed that the reprogramming transgene could be 
removed from 5 out 6 lines using a FLPe plasmid and that this did not aff ect karyotype, the ability 
to diff eren  ate effi  ciently into cardiomyocytes, or the basic hypertrophic phenotype measured 
as a func  on of protein levels and cell surface area. 
The splinkere  e PCR method was shown to be useful for determining the number of inserts 
during reprogramming, although the method contains some amplifi ca  on bias and may have 
missed some of the inserts. We iden  fi ed clones with up to 5 proviral inserts, which could 
make complete transgene removal diffi  cult. Since it was unclear at the start of our experiments 
whether the presence of the transgenes would aff ect directed diff eren  a  on or the iden  fi ca  on 
of a disease phenotype, we considered eff ec  ve transgene removal as cri  cal. Using transient 
transfec  ons with FLPe-puromycin plasmid we successfully removed the transgenes from 5 
out of 6 lines (with 1 to 3 inserts) with at least 20% effi  ciency with the excep  on of one line. 
The effi  ciency of removal appeared largely independent of insert number in the 1-3 range. For 
example, several transfec  ons with various FLPe-puromycin constructs were made but were 
unable to remove the transgenes from one clone even though only one insert was present (data 
not shown). However the transgene could be removed from another clone generated in the 
same reprogramming experiment and from the same fi broblast. This implies that the problem 
was most likely with this par  cular clone and its inser  on site (in the GATA2B gene). 
While the histological sec  ons from pa  ent 2 showed an increase in inters   al fi brosis which 
is characteris  c of HCM [36], there was a lack of myocyte disarray and no obvious hypertrophic 
cardiomyocytes. Addi  onally a number of the other characteris  cs present in pa  ent 2’s 
histological sec  ons, such as the presence of adipose  ssue between the collagen band and 
myocardial fi bers and the fragment cytoplasm, are uncharacteris  c of HCM.  Furthermore the 
thickened collagen band seen is more characteris  c of endocardial fi broelastosis and not HCM 
[37]. These non-characteris  c features could explain the unusual early onset of the disease 
symptoms in pa  ent 2 and imply that other factors contributed to onset and severity. 
In cardiomyocytes from all disease lines, we observed a decrease in the MYBPC3 protein 
levels, in line with the haploinsuffi  ciency believed to be the cause of the disease phenotype 
[6]. Addi  onally these results concur with those of van Dijk et al (2009) where heart biopsies 
collected from several pa  ents with the 2373insG MYBPC3 muta  on showed signifi cantly lower 
MYBPC3 protein levels compared with that in heart biopsies from control individuals without 
the muta  on [7]. The results therefore demonstrated the ability of hiPSC-CM to recapitulate the 
observa  ons in pa  ents.
It is s  ll unclear whether the hypertrophic phenotype in pa  ents with the 2373insG muta  on 
in MYBPC3 is due directly to the muta  on or is a secondary eff ect caused by addi  onal stress 
on the heart due to generalized disrup  on of cardiomyocyte func  on. Since our results showed 
an increase in cell surface area of HCM-iPSC-CM at a single cell level without the addi  on of 
hypertrophic s  mulus, it would seem likely that the cells do have an intrinsic hypertrophic 
phenotype that is not only a secondary eff ect of overload on the heart. Addi  onally our results 
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showed no diff erence in the disease phenotype (in Western blot or cell surface area) before or 
a  er transgene removal. This implies that for our clones transgene removal may not have been 
necessary to assess this phenotype using these criteria. 
Previous studies in primary cardiomyocytes from pa  ents with muta  ons in the MYBPC3 gene 
[5,8] as well as pa  ent with this par  cular Dutch Founder muta  on [7] reported higher calcium 
sensi  vity with respect to force of contrac  on: as external calcium increased the force of 
contrac  on increased more rapidly in cardiomyocytes from pa  ents than controls [32,38]. Our 
results show similarly higher calcium sensi  vity with respect to autonomic bea  ng frequency 
Figure 6: Assessment of calcium signaling/handling of HCM-hiPSC-CM compared to ctrl-hiPSC-CM.  A) Changes in 
bea  ng frequency in response to decreasing, then increasing external calcium. n=3-7, Two-Way ANOVA p=0.0065. 
B) The rela  ve increase in calcium transient size on caff eine-s  mula  on of transgene free hiPSC-CM. n=7 *p<0.05, 
ctrl vs. HCM. C) Average ini  al amplitude of hiPSC-CM before treatment with caff eine n≥9 *p<0.05 ctrl vs. HCM. 
D) Average amplitude immediately a  er the addi  on of caff eine n≥9 *p<0.05 ctrl vs. HCM. E) Average bea  ng 
frequency of hiPSC-CM. F) Recovery  me (in seconds) of bea  ng a  er the addi  on of caff eine.
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only when calcium was reintroduced into a calcium-deprived system. The ini  al decrease in 
external calcium star  ng from physiological calcium concentra  on (1.8mM) displays a diff erent 
eff ect, implying that the HCM cells are more profoundly aff ected by calcium than the control 
line (contrary to published results on isolated primary cardiomyocytes, as men  oned above). 
One possible reason for this apparent discrepancy is that the isola  on procedure of primary 
cardiomyocytes involves using a low calcium buff er; the published experiments began at low 
external calcium and then the concentra  ons were increased [38]. No experiments on the 
force contrac  on of primary human cardiomyocytes to date have started with external calcium 
at physiological level and then decreased it. This may be due to fragility of the primary adult 
cardiomyocytes in culture a  er dissocia  on and pla  ng compared with the more immature 
hiPSC-derived cardiomyocytes. Thus by using hiPSC-CM we may have revealed a new aspect of 
the calcium handling/signaling in these diseased cells. 
Further inves  ga  on into the altered calcium response involved the examina  on of caff eine-
induced calcium release. Upon the addi  on of caff eine to cardiomyocytes there is a release 
of the calcium stores. This has been shown previously in both hESC- and hiPSC-derived 
cardiomyocytes [39,40]. Interes  ngly when caff eine was added to HCM-hiPSC-CM, there was a 
greater rela  ve increase in amplitude compared to ctrl-hiPSC-CM. A larger increase in response 
to caff eine has been linked to greater maturity in hESC-CM [41]. Yet s  ll other studies have 
demonstrated matura  on of the immature stem cell derived cardiomyocytes can be induced 
by hypertrophic s  muli [39,42]. Thus this diff erence in response to caff eine may show a greater 
intrinsic hypertrophic response of the disease cardiomyocytes. Addi  onal caff eine-induced 
calcium experiments comparing diff erent  me points may help to explain these fi nding further.
We have presented here aspects of how hiPSC could be used for modeling HCM in humans, 
a fi rst step in exploring the use of these cells to model this disease. We performed basic 
characteriza  on of the HCM disease phenotype. We could show that HCM-hiPSC-CM displayed 
dis  nct characteris  cs that are diff erent from the control cardiomyocytes under the same 
condi  ons. However, we were unable to show a diff erence in phenotype between the individual 
pa  ents based on the clinical severity of their symptoms. Other reports of disease models have 
shown cardiomyocytes obtained from hiPSC lines derived from asymptoma  c pa  ents (with 
LQT syndromes and HCM) to be symptoma  c in culture [15,19]. Whether our assays, as well 
as those used in the previous reports, are not sensi  ve enough to see any diff erences between 
individuals or culture condi  ons promote full revela  on of the phenotype independent of its 
clinical severity in pa  ents, is not clear. Furthermore, there are likely extrinsic (lifestyle) factors 
that may precipitate disease onset and severity in pa  ents, which we are unable to capture in 
these rela  vely simple in vitro assays.  It is likely we may have to make the disease cardiomyocytes 
undergo prolonged mechanical work or perhaps some kind of stress before any diff erences are 
revealed. 
The exact mechanism and onset of HCM is s  ll unknown. Correc  ng this muta  on either 
gene  cally or pharmacologically could make it possible to determine whether the muta  on is 
the only cause of the varying severity of the disease phenotype or whether other muta  ons, 
par  cularly in the case of pa  ent 2, have a signifi cant impact. No other muta  ons were found in 
the hotspot region of the sarcomeric gene that are known to be associated with HCM in pa  ent 
2 (data not shown) and it is currently unclear why pa  ent 2 had early onset of what is normally 
a late onset disease. 
Conclusions
hiPSC from HCM pa  ents displayed features of hypertrophy in culture without the experimental 
addi  on of known hypertrophic s  muli independent of the presence or absence of the 
reprogramming transgenes. Cardiomyocytes from the disease lines all exhibited altera  ons in 
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calcium responsiveness. These results illustrate the ability of hiPSC to recapitulate the HCM 
cardiac disease phenotype in much the same way as primary adult human heart cardiomyocytes 
from pa  ents with this disease. hiPSC cardiomyocytes are however, very immature with very 
low forces of contrac  on [43] so that altera  on of contrac  on force to external calcium, using 
the current methods for adult cardiomyocytes, is presently diffi  cult to determine. It is expected 
that various biophysical and engineering approaches may address this in the future [44]. These 
future advance will hopefully make it possible to be  er understand the clinical manifesta  on of 
cardiac diseases, an important component for using hiPSC in disease modeling. 
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It has been known for over 20 years that fetal calf serum can induce hypertrophy in 
cultured cardiomyocytes but this is rarely considered when examining cardiomyocytes 
derived from pluripotent stem cells (PSC). Here, we determined how serum aff ected 
cardiomyocytes from human embryonic- (hESC) and induced pluripotent stem cells 
(hiPSC) and hiPSC from pa  ents with hypertrophic cardiomyopathy linked to a muta  on 
in the MYBPC3 gene. We fi rst confi rmed previously published hypertrophic eff ects of 
serum on cultured neonatal rat cardiomyocytes evidenced as increased cell surface 
area and bea  ng frequency. We then found that serum increased the cell surface area 
of hESC- and hiPSC-derived cardiomyocytes and their spontaneous contrac  on rate. 
Phenylephrine, which normally induces cardiac hypertrophy, had no addi  onal eff ects 
under serum condi  ons. Likewise, hiPSC-derived cardiomyocytes from 3 MYBPC3 
pa  ents which had a greater surface area than controls in the absence of serum as 
predicted by their genotype, did not show this diff erence in the presence of serum. 
Serum can thus alter the phenotype of human PSC derived cardiomyocytes under 
otherwise defi ned condi  ons such that the eff ects of hypertrophic drugs and gene 
muta  ons are underes  mated. It is therefore per  nent to examine cardiac phenotypes 
in culture media without or in low concentra  ons of serum. 
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Introduc  on
Human pluripotent stem cells (hPSC), par  cularly those derived as induced pluripotent stem 
cells (hiPSC) from pa  ents with gene  c diseases, are increasingly regarded as useful for disease 
modeling and drug target discovery. hiPSC are considered par  cularly valuable because they 
capture the genome of the individual from whom they are derived.  They have the ability to 
self-renew over long periods and diff eren  ate into all cell types of the body and thus represent 
a permanent resource for modeling human disease. Although directed diff eren  a  on is s  ll 
challenging for many lineages, cardiomyocytes were among the fi rst func  onal cells to be 
derived and characterized from human embryonic stem cells (hESC) [1-3] and they can now be 
generated effi  ciently from hiPSC using similar protocols. Cardiomyocytes derived from human 
(h)PSC have been successful in mimicking reported drug responses in pa  ents [4-7] including 
the posi  ve chronotropic response to phenylephrine (PE), an α-adrenergic agonist, and 
isoproterenol (ISO), a β-adrenergic agonist [3]. These adrenergic s  muli have also been shown 
to induce pathological hypertrophy in cultured cardiomyocytes [8-10]. Pathological hypertrophy 
is an abnormal increase in cell size accompanied by the re-expression of fetal cardiac genes 
[11]. Aside from drug-induced cardiac hypertrophy, cardiomyocytes from hiPSC of pa  ents 
with muta  ons associated with hypertrophic cardiomyopathy (HCM) also show features of 
hypertrophy and are thus poten  ally useful disease models [12]. Cardiomyocytes from pa  ent 
hiPSC have already increased our knowledge of cardiac diseases [12-14], complemen  ng and 
extending previous work based on clinical data and primary human cardiomyocyte cultures.  
Whilst the uses of hPSC-derived cardiomyocytes are becoming well established, there is s  ll 
no single method to derive these cells in culture. Although diff eren  a  on protocols are 
increasingly based on defi ned media and  med growth factor addi  on [15-17; reviwed in 18], 
fetal calf serum (FCS) is s  ll o  en present, either during diff eren  a  on or during long-term 
maintenance to support survival as the cardiomyocytes a  ain some degree of maturity. Of 119 
ar  cles published using hPSC-CM in 2012 and 2013, 54 used 5% or higher concentra  ons of 
serum in the diff eren  a  on and/or maintenance medium. In others serum was present but at 
concentra  ons ≤2%. Since the exact composi  on of serum is unknown and varies considerably 
from batch to batch [19], its presence can confound interpreta  on of experiments inves  ga  ng 
disease phenotype or drug responses. For example, it has long been known that serum or serum 
depriva  on can profoundly aff ect primary neonatal rat cardiomyocytes (Rat-CM) in culture [20-
24]. Cell size and protein-to-cell ra  o can increase and addi  onal stress-fi ber-like structures may 
be induced in response to serum, which is indica  ve of cardiac hypertrophy [21, 24]. Other 
studies have used serum as a hypertrophic s  mulus for cardiomyocytes[20, 25, 26], in place 
of the more commonly used hypertrophic s  muli PE or ISO [10]. The impact of serum on the 
cardiomyocyte phenotype and, more specifi cally, on the manifesta  on of the disease in the case 
of cardiomyocytes derived from pa  ent hiPSC, remains unreported. 
Here we examined the eff ects of serum and PE in the widely used Rat-CM model and confi rmed 
fi ndings reported previously. We then inves  gated the eff ects of serum on healthy- and HCM 
pa  ent-derived hPSC-CM obtained under serum-free, defi ned condi  ons. Parameters examined 
included cell surface area, sarcomeric structure and bea  ng frequency. These are common 
descriptors of phenotype in the literature. The eff ects of serum were compared with those 
induced by the hypertrophic drugs PE and ISO. We found that serum induced increased cell 
surface area and bea  ng frequency and disrupted sarcomeric structure, indica  ng a hypertrophic 
response in both hESC-CM and hiPSC-CM. This masked the disease-associated hypertrophy 
of HCM-hiPSC-CM that was evident in the absence of serum. These results have important 





The isola  on of neonatal rat cardiomyocytes was approved by the Animal Experiment 
Commi  ee of Leiden University Medical Center and complies with the Guide for the Care and 
Use of Laboratory Animals as stated by the US Na  onal Ins  tutes of Health. Human skin biopsies 
were obtained from pa  ents a  er individual wri  en permission using standard informed 
consent procedures following approval for use in this study by Leiden University Medical 
Center’s medical ethics commi  ee; this conforms to the Declara  on of Helsinki. Control skin 
samples were obtained as waste  ssue from donors in accordance with the Dutch federa  on of 
Biomedical Scien  fi c Socie  es “Use of human  ssue for scien  fi c research” and “Code of good 
use” direc  ves. All samples were collected by the trea  ng physician and then anonymized.
Neonatal rat cardiomyocytes
Neonatal rat cardiomyocytes were isolated as previously described [27]. Briefl y, rats were 
anaesthe  zed with inhaled isofl urane (4-5%) and adequate anesthesia was confi rmed by the 
absence of pain refl exes before excising the hearts. Ventricles from the dissected hearts were 
minced and dissociated using collagenase and DNase and then suspended in Ham’s F10 medium 
(ICN Biomedicals) with 10% horse serum (Invitrogen) and 10% FCS. To allow for preferen  al 
a  achment and nega  ve selec  on of the non-cardiomyocytes, the cell suspension was pre-
plated for 1h in a  ssue culture dish. The non-adherent cardiomyocytes were then collected and 
plated on Matrigel coated coverslips (pla  ng density of 20,000 cells/cm2) in isola  on medium 
or serum-free BEL medium (Iscove’s Modifi ed Dulbecco’s Medium (IMDM) supplemented 
with L-glutamine and 25mM HEPES (Invitrogen,), F12 Nutrient Mixture (HAM) supplemented 
with Glutamax (Invitrogen), 5% protein free hybridoma medium (Invitrogen), 0.25% deionized 
albumin from BSA (Sigma,) in IMDM, 1% Chemically Defi ned Lipid Concentrate (Invitrogen), 
Figure 1) Responses of neonatal Rat-CM to serum. A) Schema  c  meline of treatment procedure. Percentages 
indicate the serum concentra  ons. In parallel controls, PE was omi  ed.  B) Cell surface area of Rat-CM in 20%, or 
0% serum at 12h, 36h and 60h a  er pla  ng and 5% serum 36h and 60h a  er pla  ng. *=p<0.05 20% serum (12h) 
vs. other condi  ons (n≥67). C) Cell surface area of neonatal Rat-CM (60h) maintained in isola  on medium (20% 
serum) throughout or subsequently reduced to 5% or 0% serum, or ini  ally plated in 0% serum ±100 μM PE for 24 
h. *=p<0.05 untreated vs. PE-treated (n≥59 cells). D) Bea  ng frequency of Rat-CM (60h) ± 100 μM PE. *=p <0.05 
untreated vs. PE-treated (n≥7 measurements). 
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0.1% Insulin-Transferrin-Selenium-X supplement (Invitrogen), 450 μM 1-Thioglycerol (Sigma), 
5mg/ml L-ascorbic acid 2-phosphate (Sigma), 1% Glutamax (Invitrogen), 25 U/ml penicillin, 25 
μg/ml streptomycin (both Invitrogen)). 12 h later the medium was replaced and the cells were 
maintained in the original isola  on medium (20% serum), 5% FCS in BEL or serum-free medium 
BEL for 24 h before treatment with 100 μM PE for an addi  onal 24 h. 
hESC culture
The Nkx 2-5eGFP/w hESC line [28] was maintained as a single cell culture in Dulbecco’s 
Modifi ed Eagle Medium (DMEM)/F12 (Invitrogen) containing 20% Knockout Serum replacement 
(Invitrogen), 1x MEM-Non-Essen  al amino acids (Invitrgoen) 0.1 mM 2-Mercaptoethanol 
(Invitrogen), 10 ng/ml Human basic fi broblast growth factor (bFGF) (Peprotech) , 25 U/
ml penicillin and 25 μg/ml streptomycin (both Invitrogen) and passaged every 3-4 days, as 
previously described [29].
Human iPSC Deriva  on
Human dermal fi broblasts were isolated from biopsies from a control subject and pa  ents 
carrying a MYBPC3 gene muta  on and displaying an HCM phenotype. Fibroblasts were 
reprogrammed to hiPSC as previously described [30]. hiPSC were rou  nely cultured on Matrigel 
(BD Biosciences)-coated  ssue culture dishes in mTESR according to the manufacturer’s protocol 
(Stem Cell Technologies). The cells were mechanically passaged weekly using 1 mg/ml Dispase 
(Gibco).  
Transgene removal and confi rma  on
Based on morphology, hESC-like colonies were manually picked 30 days a  er transduc  on.  Cells 
were adapted to enzyma  c culture on mouse embryonic feeder cells [29] and then transfected 
with pLV.hCMV-IE.FLPe.IRES.PurR.hHBVPRE [31] to remove the reprogramming casse  e. Removal 
was confi rmed by PCR of the FRT region (triple primer set): 5’-CGAGTCGGATCTCCCTTTGGGC-3’, 
5’-TGGAAGGGCTACGTAGCTAGC-3’, 5’-GGTTCCCTAGTTAGCCAGAGAGC-3’). Transgene-free clones 
were readapted to mechanical passage on Matrigel with mTESR. Frozen stocks were made at 
passage 5 and cells were used for experimenta  on between passage 10 and 30. LUMC0004iCtrl 
(Healthy), LUMC0033iMyBPC (HCM1), LUMC0034iMyBPC (HCM2), LUMC0035iMyBPC (HCM3) 
hiPSC were used in this study. 
Genera  on of Cardiomyocytes
Cardiomyocytes were generated from the Nkx 2-5eGFP/w hESC line [28] and hiPSC using a 
monolayer method in defi ned medium with  med addi  on of growth factors and small molecules. 
hESC were plated at a density of 10,000 cells/cm2 and hiPSC were dissociated into small clumps 
three days prior to diff eren  a  on and allowed to a  ach on Matrigel coated dishes in mTESR 
(~1.5 clumps/cm2) before star  ng the diff eren  a  on procedure. Diff eren  a  on was induced in 
low-insulin (1mg/L), “BEL medium” [16] plus 20 ng/ml Ac  vin A (R&D systems), 20 ng/ml BMP4 
(R&D systems) and 1.5 μM CHIR99021  (Axon). These factors were removed a  er 3 days and 
replaced with BEL plus 5 μM XAV939 (R& D systems) and Matrigel (BD bioscience) (1:100) to 
prevent cell detachment. The cells were refreshed with BEL three days later and subsequently 
maintained in BEL (changing medium twice a week). On average the diff eren  a  on effi  ciency 
of this method is 28-44% over several hPSC lines as determined by fl ow cytometry for cardiac 
troponin T expression (cTnT) (Fig S1). 
Cell S  mula  on and Cell Surface Area
Cardiomyocytes were dissociated into single cells 20 days a  er the start of diff eren  a  on using 
TrypLE Select (Invitrogen) for 30 minutes at 37°C and plated onto Matrigel-coated coverslips 
(25,000 cell/cm2) in serum-free BEL medium. A  er 10 days, the culture medium was placed 
with BEL containing 100 μM PE (Sigma),100 nM ISO (Sigma), 5% serum, 20% serum (Greiner 
(Serum A) or Gibco (Serum B)), or le   untreated for 72 h. A  er 72 h, all coverslips were fi xed 
in 2% paraformaldehyde for 30 minutes. For long-term experiments, cells on coverslips were 
exposed to serum for 7 days followed by 72 h treatment ±PE prior to fi xa  on. For reversibility 
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Figure 2) Response of hESC-CM to serum. A) Cell surface area of hESC-CM treated with 100 μM PE, 100nM ISO, 5% 
serum or 20% serum for 72 h compared to untreated n≥72 cells. * = p<0.05 untreated vs. treated. B) Cell surface 
area of hESC-CM treated with 5% or 20% serum for 7 days 100μM PE for 72h.*=p<0.05 no PE added vs. PE-treated, 
n≥40. C) Representa  ve immunofl uorescent images of hESC-CM treated with 100 μM PE, 100 nM ISO, 5% serum or 
20% serum for 72 h (short-term exposure) or 5% serum and 20% serum for 7 days (long-term exposure). Stacked bar 
graph of the percentage of cells with sarcomeric stria  on (visible well-organized stria  ons (+), some (disorganized) 
stria  ons (+/-), and poor/non-existent stria  ons (-)); n≥72 cells. Red: α-ac  nin, Blue: DAPI, scale bar: 10 μm. D) 
Rela  ve change in bea  ng frequency of hESC-CM a  er immediate addi  on of 100 μM PE, 100 nM ISO, 5% serum, 
20% serum or vehicle only control. Results normalized to ini  al bea  ng frequency. *=p<0.05 vehicle only vs. treated, 
n≥7 measurements. E) Rela  ve change in bea  ng frequency of long-term serum treated hESC-CM a  er immediate 
addi  on of 100 μM PE, 100 nM ISO or vehicle only control. Results normalized to ini  al bea  ng frequency. *=p<0.05 
vehicle only vs. treated, n≥5 measurements.
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experiments, cells were treated as above and subsequently refreshed with serum-free BEL 
medium for 3, 5, or 10 days.
For determina  on of cardiomyocyte cell surface area, fi xed cells were labeled with an  -α ac  nin 
(1:800; Sigma) followed by Cy3 (ImmunoResearch) secondary as previously described [32]. 
Nuclei were labeled with DAPI. For cell surface area measurements, 9 to 15 areas were randomly 
selected from each 10 mm coverslip and visualized using a Nikon Eclipse Ti-S microscope. Single 
plane of 1200x1600 pixels images at 313nm/pixel resolu  on were recorded using a Plan fl uor 
20x/0.50 lens and analyzed using ImageJ so  ware. Representa  ve sarcomere images were 
visualized using a Leica TCS SP5 confocal microscope; single planes of 1024x1024 pixels images 
at 44nm/pixel resolu  on were recorded using a Plan-Apochromat 40x/1.25 oil and 100x/1.4 oil 
lens. Sarcomeric structures of cardiomyocytes were divided into three categories, visible well-
organized stria  ons (+; category 1), some stria  ons mostly disorganized (+/-; category 2) and 
poor or non-existent stria  ons (-; category 3). 
Calcium imaging
Cell cultures undergoing cardiac diff eren  a  on were dissociated a  er 20 days using TrypLE 
Select and replated on 96-well Matrigel-coated imaging plates (BD Bioscience, 40,000 cells/
cm2). In order to determine calcium transient/contrac  on frequency 13 days a  er pla  ng, cells 
were loaded with 5 μM fl uo-4am (Invitrogen) for 15 minutes in the presence of 0.2% Pluronic in 
Tyrode’s solu  on (140 mM NaCl, 10 mM glucose, 5 mM HEPES, 5.4m M KCl, 1.2 mM MgCl2, 1.8 
mM CaCl2, pH 7.4). The cells were then washed 3  mes with Tyrode’s solu  on and maintained 
in 100μl of Tyrode’s solu  on. With the plate maintained at 37ºC,   me-lapse of Fluo-4am 
fl uorescence was recorded using a Leica AF6000 microscope equipped with a Hamamatsu EM-
CCD camera. Contrac  ng areas were iden  fi ed and imaged consecu  vely for 1.4 minutes (1500 
images at 51ms per cycle). A  er recording a baseline for 20 seconds drug or serum addi  ons 
were made to achieve fi nal concentra  ons of 100 nM ISO, 100 μM PE, 5% serum, 20% serum, 
or vehicle only. Calcium transient frequency before and a  er treatment was determined using 
ImageJ and Z-profi le_ImJ so  ware, tailored for use here to convert raw data to dF/F results [33].
Sta  s  cal Analysis
Results are expressed as mean±SEM. Comparisons were made using one-way ANOVA with 
Bonferroni’s mul  ple comparison post test. Values of p ≤0.05 were considered signifi cant. 
Sta  s  cal analyses were performed using GraphPad Prism. 
Results
A hypertrophic response to serum in neonatal rat cardiomyocytes
We fi rst confi rmed well established hypertrophic eff ects of serum and PE on Rat-CM using cell 
surface area and bea  ng frequency as standard surrogate measures. Rat-CM were plated in the 
original isola  on medium containing 20% serum or in the absence of serum (Fig 1A, 0h). A  er 
12 h, the cells were transferred to 20, 5 or 0% serum and maintained at this serum concentra  on 
un  l the end of the experiment (60h). Although the ini  al pla  ng of these cells with or without 
serum (12 h exposure) did not aff ect cell surface area (Fig 1B), by 36h, cells in serum (5% or 
20%) were signifi cantly larger than those in absence of serum (Fig 1B). By 60h, a concentra  on-
dependent eff ect was evident with cells maintained in 20% serum now signifi cantly the largest 
(Fig 1C) there was no observed diff erence in the sarcomeric structures or organiza  on between 
the groups (Fig S2).  
Exposure of cardiomyocytes to PE has been previously shown to increase their cell surface area 
[34]. We observed a similar hypertrophic eff ect with exposure to PE for cells maintained in 0% or 
5% but not 20% serum (Fig 1C).  It was further noted that Rat-CM beat signifi cantly more slowly 
in the absence than in the presence of serum (Fig 1D, n≥7, p<0.05).  PE exerted an expected 
posi  ve chronotropic ac  on under serum-free condi  ons (Fig 1D, n≥7, p<0.05), eff ects which 
were similar to serum. Cells maintained in serum were refractory to the posi  ve chronotropic 
eff ect of PE.
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Figure 3) The stability of serum-induced altera  ons in hESC-CM. A) Schema  c of treatment protocol. Cell surface 
area of hESC-CM treated with 5% or 20% serum for 3 days (n≥81) (B) or 7 days (n≥42) (C) and then removed for 
3, 5, or 10 days. *=p<0.05 serum vs. -removal. D) Representa  ve immunofl uorescent images of hESC-CM treated 
with 100 0M PE, 5%, and 20% serum for 72 h +3 days (short-term exposure +3 days) or 5 % or 20% serum for 7 
days +3 days (long-term exposure +3days) and then removed for 3 days (short-term exposure-3d and long-term 
exposure-3d, respec  vely). Stacked bar graph of the percentage of cells of diff erent sarcomeric structural class 
(visible well-organized stria  ons (+; category 1), some (disorganized) stria  ons (+/-; category 2), and poor/non-
existent stria  ons (-; category 3)); n≥72. Red: α-ac  nin, Blue: DAPI, scale bar: 10μm.
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A hypertrophic and posi  ve chronotropic response of hESC-CM to serum containing medium
We assessed whether hESC-CM responded similarly to Rat-CM on exposure to serum or known 
adrenergic s  muli. When measured a  er 72h, cells maintained in 5% or 20% serum (2 batches, 
Sigma (Serum A) and Gibco (Serum B)) or PE all showed increased cell surface area (Fig 2A). The 
β-adrenergic agonist ISO failed to induce a signifi cant increase (Fig 2A). Combined exposure of 
cells to both serum (>7days) and PE (72h) did not induce any addi  onal increase in cell surface 
area (Fig 2B).
As results for serum brands A and B were similar, only serum B was used in subsequent 
experiments. Interes  ngly, besides the increased cell surface area, hESC-CM exposed to 5% or 
20% serum developed abnormal sarcomeric structures. These eff ects were quan  fi ed and cells 
were divided into three categories: 1) visible well-organized stria  ons, 2) some (disorganized) 
stria  ons, and 3) poor/non-existent stria  ons. The percentage of cells in category 1 was reduced 
and in category 3 was increased (Fig 2C) as early as 72 h a  er serum addi  on and was further 
exacerbated by long term serum exposure (Fig 2C).
S  mula  on of the α-adrenergic system with PE or the β-adrenergic system with ISO has been 
shown previously to induce a posi  ve chronotropic response in hESC-derived cardiomyocytes 
[3]. We confi rmed these responses in this model. 100 μM PE induced a 2.25 fold rela  ve increase 
in bea  ng frequency (n=11 bea  ng clusters) and 100 nM ISO induced a 1.9 fold rela  ve increase 
(n=11 bea  ng clusters) (Fig 2D). Furthermore, we found that serum addi  on to a serum-free 
culture caused a similar increase in bea  ng frequency. Following chronic exposure to serum (>7 
days) the posi  ve chronotropic eff ect of PE was s  ll evident but the eff ect of ISO was completely 
lost (Fig 2E). Besides the changed in bea  ng frequency all other measurement parameters of the 
calcium transient (e.g. upstroke, slope decay and amplitude) showed no signifi cant diff erence 
between treated and untreated groups (data not shown).
The hypertrophic eff ect of serum on hESC-CM may be irreversible
To assess the stability of the serum- or PE-induced hypertrophy we measured cardiomyocyte 
surface area upon withdrawal of these factors (Fig. 3A). For cells exposed to serum or PE for 72 
h, there was no signifi cant decrease in cell surface area at any  me point and the cells remained 
signifi cantly larger than the untreated cells (Fig 3C). However cells treated with serum for 7 days 
and then deprived of serum showed a signifi cant decrease in cell surface a  er 5 days in serum-
free medium (Fig 3B). By this  me point these cells were no longer signifi cantly larger than the 
untreated cells.
The sarcomeric structures which had already remodeled in the presence of serum appeared 
even more disrupted, with many more cells showing disorganized or missing stria  ons (Fig 3D). 
This loss of sarcomeric structure was increased the longer the cells were deprived of serum (data 
not shown). The removal of PE from the cells had li  le or no eff ect on the sarcomeric structure (Fig 3D).
Serum eff ects on cardiac hypertrophic disease modeling.
Since hiPSC-CM from pa  ents with gene muta  ons aff ec  ng the heart are now being increasingly 
used to model cardiac disease, it is important to determine whether serum, s  ll widely used 
in the culture of cardiomyocytes, would aff ect the measurement of the disease phenotype in 
culture. To address this, we used a series of control and disease hiPSC lines recently derived 
in our laboratory (Chapter 6), diff eren  ated them to cardiomyocytes and assessed the impact 
of exposure to serum or adrenergic agonists on cell surface area and automa  city. hiPSC-CM 
derived from a healthy individual and three pa  ents with a muta  on in the MYBPC3 gene linked 
to HCM (Chapter 6) were kept in serum-free medium and were treated with 5% or 20% serum 
or le   untreated for 3 or 7 days. A  er 3 days, HCM-iPSC-CM kept serum-free were signifi cantly 
larger than the ctrl-hiPSC-CM with a ≥1.5 fold increase in cell surface area (Fig4A). The healthy 
control hiPSC-CM displayed a 3-fold increase in surface area on exposure to either 5% or 20% 
serum (Fig 4B and C). The hiPSC-CM from the HCM disease pa  ents were signifi cantly larger than 
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the control in serum-free condi  ons, sugges  ng that they had become hypertrophic without 
addi  onal s  muli, but these cells failed to show a further increase in surface area in response 
to serum (Fig 4A-C). Similarly to the hESC-CM under serum-free condi  ons, the surface area of 
the control hiPSC-CM increased in response to a 72h exposure to 100μM PE (Fig 4D and 100nM 
of ISO showed no eff ect (Fig S3)), whereas the hiPSC-CM from the three disease pa  ent lines 
showed no response (Fig 4D and Fig S3). 
Longer-term (>7 days) exposure of hiPSC-CM to serum produced similar results as short-term 
exposure (72 h): the healthy control hiPSC-CM showed an increase in cell surface area while 
the HCM-hiPSC-CM showed no change upon serum exposure (Fig 4E).  Refl ec  ng the hESC-CM 
results in Fig 2B, hiPSC-CM also failed to show an addi  onal hypertrophic response to PE when 
maintained in serum (Fig 4E).
Upon examina  on of the sarcomeric structures of the hiPSC-CM the percentage of cells in 
category 3 was increased a  er 72 h treatment with serum only in the healthy control hiPSC-CM 
while the percentage of category 3 cells remained rela  vely the same in the HCM-hiPSC-CM (Fig 4F-H).
Discussion
There are numerous reports documen  ng the adverse eff ects of serum on the effi  ciency of 
cardiac diff eren  a  on of PSCs [35;36]. Nevertheless serum is o  en used as a standard medium 
addi  ve to improve cardiomyocyte viability both during and a  er diff eren  a  on by providing 
growth factors, nutrients and hormones [19]. However, the eff ect of serum on cardiomyocytes 
during their long-term maintenance in culture has not been inves  gated in much depth 
even though several studies have described hypertrophic eff ects of serum on primary rodent 
cardiomyocytes in culture [37;38]. For this reason, serum concentra  ons are usually reduced or 
absent in experiments carried out on these cells. In this study we fi rst confi rmed the published 
eff ects of serum and PE on primary neonatal Rat-CM and then inves  gated the eff ects of 
serum on cardiomyocytes derived from hESC and hiPSC, both from a healthy individual and 
pa  ents with a muta  on in the MYBPC3 gene causing HCM. We found that the hypertrophic 
and physiological eff ects on the Rat-CM were as reported but the eff ects on the hPSC derived 
cardiomyocytes varied depending on how long they were exposed to serum (72h or >7 days) and 
which concentra  on had been present. Hypertrophic and physiological eff ects of serum were 
only seen in healthy hPSC and not in cardiomyocytes from the hiPSC lines derived from pa  ents 
carrying the HCM associated muta  on.    
hESC-CM and hiPSC-CM derived from the healthy individual showed similar responses to 
serum, with an increased cell surface area and altered beat rate. They were also similar in their 
responses to PE and ISO. However the hiPSC-CM derived from pa  ents with a muta  on causing 
HCM showed no response to the addi  on of serum; they were larger than controls at the outset 
in serum free condi  ons and this did not increase further. These cells were also unresponsive 
to PE and ISO. The underlying mechanism for this is not clear but is being inves  gated in an 
independent study.
In the hESC-CM and healthy hiPSC-CM, short-term serum (72 h) exposure resulted in similar 
changes in cell surface area and bea  ng frequency as PE, a known adrenergic agonist and 
inducer of hypertrophy in cardiomyocytes in vitro. This eff ect was not reversed by the removal 
of serum, even a  er 10 days. In addi  on, ISO had no eff ect on the bea  ng frequency of hPSC-
CM exposed to serum while in the absence of serum cells doubled their bea  ng frequency as 
expected (Fig 2D and 2E).  Our results suggest serum may control cardiac hypertrophy through the 
adrenergic pathway while addi  onal unknown components in serum, and not present in the PE 
or ISO condi  ons, could cause the adverse eff ects on the sarcomeric structure. In concordance, 
previous studies demonstrated that isola  ng and maintaining Rat-CM in serum-free medium 
resulted in a decrease in stress-like fi bers which are more commonly seen in cardiac non-muscle 
cells [21]. Moreover, studies in isolated human and chick cardiomyocytes have demonstrated 
the presence of stress-fi bers both in unhealthy [39] and immature [40] cardiomyocytes. On the 
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other hand, it is possible that the breakdown of sarcomere structure may only be remodeling of 
cell structure due to chronotropic or inotropic changes caused by unknown components in the 
serum. However the complexity of the adrenergic pathway and the undefi ned factors in serum 
require addi  onal inves  ga  on. Previous studies on Rat-CM have revealed various parts of the 
hypertrophy pathway with diff ering responses to serum [37;38;41]. In one report, the endothelin 
1 hypertrophic pathway was suppressed by re  noic acid but serum-induced hypertrophy was 
not suppressed [38]. In a later study PE and serum-induced hypertrophy were both found to 
be impaired by the overexpression of CHAMP [41]. Taken together with our results and the lack 
of an eff ect of ISO on the bea  ng frequency of hESC-CM a  er long-term exposure to serum, 
it might be inferred that serum aff ects the same pathway as β-adrenergic s  muli rather than 
α-adrenergic s  muli.
When hESC-CM or healthy hiPSC-CM were treated with serum for longer periods of  me (> 7 
days) they also showed an increase in cell surface area but lost their augmented response to PE. 
While other drugs were not tested, these results implied that serum in cell cultures could mask, 
or otherwise alter, drug induced eff ects. Ren et al (2012) for example showed glucocor  coids 
induced hypertrophy in rat embryonic cardiomyocytes (H9C2 cells) cultured in serum but in the 
absence of serum, glucocor  coids protected the cardiomyocytes from apoptosis. Furthermore, 
this increased cell surface area reverted when the serum was removed for at least 5 days [23. 
However the exact cause of this phenomenon is unclear. It may be that the sudden withdrawal 
 Figure 4) Response of hiPSC-CM to serum. Cell surface area of hiPSC-CM derived from a healthy individual (healthy) 
and three pa  ents with hypertrophic cardiomyopathy (HCM1, HCM2, HCM3) in (A) serum-free medium *p=0.05 
healthy vs. HCM n≥60 cells. (B) treated with 5%  for 72 h. *p=0.05 healthy vs. HCM, n≥66 cells. (C) treated with 20% 
serum for 72 h. *p=0.05 healthy vs. HCM, n≥64 cells. D) Cell surface area of hiPSC-CM ± 100 μM PE for 72 h. *p=0.05 
no PE added vs. PE-treated, n≥50 cells. E) Cell surface area of hiPSC-CM treated with 5% or 20% serum for 7 days ± 
100μM PE for 72h, n≥39 cells. F-H) Stacked bar graph of the percentage of cells of diff erent sarcomeric structural 
class (visible well-organized stria  ons (+; category 1), some (disorganized) stria  ons (+/-; category 2), and poor/
non-existent stria  ons (-; category 3)); F: no serum; G: treated with 5% serum; H: treated with 20% serum; n≥47.
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of growth factors from the serum leads to problems in basic cell metabolism and the synthesis 
and traffi  cking of sarcomeric proteins has become comprised. Thus the cardiomyocytes with 
longer exposure to serum may be on their way to losing viability. Others have previously reported 
similar results in Rat-CM in which serum-depriva  on lead to increased apoptosis [42].
In addi  on to PSC-CM from healthy individuals, we inves  gated the eff ects of serum on cells 
derived from three pa  ents with HCM caused by a muta  on in MYBPC3 gene. Clinically these 
pa  ents had an increase interventricular septum thickness but other heart func  ons, such 
as frac  onal shortening, le   ventricular systolic-end and diastolic-end diameter, remained 
within the normal range [43]. Their deriva  ve hiPSC-CM were resistant to PE and ISO induced 
hypertrophy and chronotropic eff ects and they also lacked the response to serum seen in the 
controls and primary cardiomyocytes. Thus their enlarged cell surface areas and altered beat 
rates rela  ve to controls in the absence of serum were no longer evident in the presence of 
serum. This represents a cau  onary note on the culture condi  ons used to compare diseased 
and control cardiomyocytes derived from pluripotent stem cells. In addi  on, some experiments 
described in the literature use primary rodent cells ±24 h a  er transfer to serum-free medium 
but this may not always be the case. Improved consistency in the results may be achieved by 
carrying out the experiments under serum-free or low serum condi  ons. 
In conclusion, we have demonstrated that the addi  on of serum to PSC-CM derived under 
defi ned and conven  onal serum-free condi  ons can signifi cantly alter the phenotype of 
cardiomyocytes: their surface area, sarcomeric structure and bea  ng frequency are all 
parameters that show relevant altera  ons. These are among the parameters widely used to 
report phenotypes in cardiomyocytes derived from pa  ent hiPSC. Therefore it is highly desirable 
to control experimental condi  ons and to culture hPSC derived cardiomyocytes in fully defi ned 
culture media. 
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Serum masks hypertrophic phenotypes in hPSC-CM
Fig S2) Stacked bar graph of the percentage of RAT-CM with sarcomeric structural class (visible well-
organized stria  ons (+; category 1), some (disorganized) stria  ons (+/-;category 2), and poor/non-












Fig S1) Cardiac diff eren  a  on effi  cien-
cy of the Nkx 2-5eGFP/w hESC line and 
LUMC0004ictrl determined by fl ow 
cytometry of cardiac troponin T (cTnT) 
expression (n=11 for Nkx 2-5eGFP/w, 
two independent experiments for LUM-
C0004ictrl).
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Simple methods for selec  on of cardiomyocytes from mixed popula  ons of diff eren  ated 
human pluripotent stem cells (PSC-CMs) are s  ll limited. Although several surface 
marker combina  ons with some specifi city for cardiomyocytes have been iden  fi ed 
(such as SIRPA and VCAM1), selec  on by fl ow cytometry has been proven to be diffi  cult 
due to poor survival and rea  achment of the sorted cells. Alterna  vely, transgenic 
approaches with selectable marker genes are used but the genera  on of transgenic 
cell lines is labor-intensive. Here, we developed a universal selec  on system for PSC-
CMs with high cell survival and low toxicity based on adeno-associated virus (AAV) 
vectors. These vectors can effi  ciently transduce dividing as well as post-mito  c cells 
without the need to integrate their DNA into the target cell genome. We generated an 
AAV serotype 2 (AAV2) vector with reduced suscep  bility to proteasomal degrada  on 
carrying a striated muscle-specifi c promoter (i.e. MHCK7)-driven puromycin resistance 
gene for selec  ng PSC-CMs. We showed that this vector transduced PSC-CMs be  er 
than fi broblasts. In ini  al experiments, puromycin selec  on resulted in ≥97% pure 
cardiomyocyte popula  ons but in later experiments it proved diffi  cult to reproducibly 
replate the cardiomyocytes following puromycin treatment. Sugges  ons are given for 
further improvement of the vector and selec  on procedure, which could ul  mately 
result in an effi  cient AAV vector-based PSC-CM selec  on method.
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Introduc  on: 
Human pluripotent stem cells (hPSCs) hold great promise as model systems for studying human 
development and gene  c disorders, as source of autologous cells to replace damaged, diseased 
or aged  ssue and to evaluate the eff ec  veness and safety of newly developed drugs. Embryonic 
stem cells were the fi rst pluripotent stem cells to be studied (Thomson et al, 1998) but ethical 
concerns limited research on hPSCs un  l 2006 with the discovery of induced pluripotent stem 
cells (iPSCs) [1-3]. hPSCs have the unique ability to self-renew in culture over long periods and to 
diff eren  ate into deriva  ves of all three germ layers. This has made them a good model system 
for studying normal and abnormal diff eren  a  on in human development. However, a major 
problem facing researchers studying PSC deriva  ves is the heterogeneity of the diff eren  ated cell 
popula  ons they produce [4]. For some cells types such as endothelial cells, there are specifi c cell 
surface markers which allow sor  ng of these cells from the rest of the popula  on but for many 
other cell types, cell surface marker proteins for which there are specifi c an  bodies to select only 
one popula  on by immunological means are limited. Such is the case for cardiomyocytes, which 
un  l recently before reports of par  al enrichment with SIRPA- and VCAM1-specifi c an  bodies 
[5,6] could not be selected out using surface markers.
Recent advances in hPSC technology (e.g. single cell culturing, zing fi nger nuclease-, TALEN- and 
CRISPR/Cas9-based genome edi  ng strategies) have made it easier to gene  cally modify PSC 
lines [7]. This has allowed lineage-specifi c expression of selectable markers (e.g. fl uorescent 
proteins and proteins conferring an  bio  c resistance) in the diff eren  ated progeny of hPSCs. 
One example is the Nkx2.5 GFP/w human embryonic stem cell line published by Elliot and co-
workers [6] of which only the cardiomyogenic progeny display green fl uorescence. Similarly, 
fl uorescence and/or an  bio  c resistance constructs have been combined with the myosin heavy 
chain [8,9] and myosin light chain 2v [10] promoters to iden  fy cardiomyocytes. These cells 
can be separated from other hPSC deriva  ves by fl uorescence-ac  vated cell sor  ng (FACS) or 
an  bio  c addi  on.
A disadvantage of the methods described above is that they depend on the permanent gene  c 
modifi ca  on of hPSCs with genes encoding exogenous proteins. Alterna  ve (physical and 
biochemical) methods to enrich the progeny of hPSCs include the use of Percoll density gradients 
[11], mitochondrial dyes [12], cell surface markers [5,6] and special medium (low glucose, high 
lactate)[13] that supports selec  ve cardiomyocyte survival. However, low puri  es, poor cell 
survival a  er cell sor  ng and disrup  on of cell integrity make these methods far from ideal.    
Another possibility for selec  ng cardiomyocytes is by using viral vector technology. Viral 
vectors can be engineered to contain cell-type specifi c promoters driving the expression 
of selectable marker genes. Adeno-associated virus (AAV) vectors are especially well 
suited for selec  on purposes because (i) they can effi  ciently transduce a wide variety 
of mammalian cell types, (ii) their genomes remain essen  ally episomal minimizing 
the risk of inser  onal mutagenesis, (iii) the absence in their genomes of viral genes 
encoding poten  ally cytotoxic proteins and (iv) their excellent in vivo safety [14].
In this study, we have developed a capsid-modifi ed AAV serotype 2 (AAV2) vector in which a 
hybrid striated (i.e. cardiac and skeletal) muscle-specifi c promoter (MHCK7) (Salva et al., 2007) 
is linked to the coding sequence of Streptomyces alboniger puromycin N-acetyltransferase (PAC) 
in order to purify hPSC-derived cardiomyocytes (hPSC-CMs) from the rest of the diff eren  ated 
hPSC progeny; non-cardiomyocytes should die in the presence of puromycin. Although this 
enrichment strategy was shown to be eff ec  ve in principle, i.e. treatment with puromycin 
resulted in cell cultures with >95% cardiomyocytes, poor survival upon repla  ng of the 
cardiomyocytes nega  vely aff ected reproducibility so that further op  miza  on would clearly be 





The human iPSC (hiPSC) line used in the experiments was derived previously from human dermal 
fi broblasts using the pRRL.PPT.SF.hOKSMidTomato-preFRT polycistronic len  viral vector also 
known as LUMC004ictrl [15,16]. The genera  on of the Nkx2-5GFP/w human embryonic stem cell 
line has been described elsewhere [6]. This cell line has the coding sequence of the Aequorea 
victoria enhanced green fl uorescent protein (GFP) inserted in exon 1 of the NKX2-5 gene, which 
codes for a transcrip  on factor that is almost exclusively expressed in cardiac progenitor cells 
and cardiomyocytes.
PSC culture and diff eren  a  on
PSCs were cultured on growth factor reduced-Matrigel (BD Biosciences)-coated  ssue culture 
dishes in mTeSR1 according to the manufacturer’s protocol (Stem Cell Technologies). To ini  ate 
diff eren  a  on to cardiomyocytes, the PSCs were dissociated into small clusters of cells and 
seeded onto a Matrigel-coated cell culture dish in mTeSR1. Three days later, the medium was 
replaced with low-insulin (1 mg/L) BEL medium  (LI-BEL)[17] supplemented with 20 ng/ml Ac  vin 
A (R&D systems), 20 ng/ml BMP4 (R&D systems) and 1.5 μM CHIR99021  (Axon).  Since the 
cultures were to be maintained for more than 16 days, the cells were overlaid with addi  onal 
Matrigel (1:100) on diff eren  a  on day 3 to prevent their detachment from the bo  om of the 
culture dishes. From diff eren  a  on day 6, the LI-BPEL medium was refreshed twice a week. 
Construc  on of AAV vector shu  le plasmids
As scaff old for the construc  on of plasmids pDD.hEEF1A1.eGFP.WHVPRE.synpA and pDD.MHCK7.
PurR.WHVPRE.synpA, we used the AAV vector shu  le plasmid pDD345 [18]. In pDD.hEEF1A1.eGFP.
WHVPRE.synpA the GFP-coding sequence is preceded by the ubiquitous promoter of the human 
eukaryo  c transla  on elonga  on factor 1α1 gene (hEEF1A1) and followed by the woodchuck 
hepa   s virus post-transcrip  onal regulatory element and a synthe  c polyadenyla  on signal 
derived from the rabbit hemoglobin β gene [19]. pDD.MHCK7.PurR.WHVPRE.synpA has the 
same overall gene  c makeup as pDD.hEEF1A1.eGFP.WHVPRE.synpA except for the replacement 
of the hEEF1A1 gene promoter and GFP open reading frame by the striated muscle-specifi c 
MHCK7 promoter (Salva et al., 2007) and the Streptomyces alboniger PAC-coding sequence, 
respec  vely. The nucleo  de sequences of pDD.hEEF1A1.eGFP.WHVPRE.synpA and pDD.MHCK7.
PurR.WHVPRE.synpA are available upon request.
AAV vector produc  on
The capsid-modifi ed AAV2 vectors AAV2/2mt. hEEF1A1.eGFP.WHVPRE.synpA (Fig 2A) and 
AAV2/2mt.MHCK7.PurR.WHVPRE.synpA (Fig 3A ) were produced by co-transfec  ng 293T cells 
with pAAV2/2Y444500730F(+)[20], pAdΔF6 (Penn Vector Core; h  p://www.med.upenn.edu/
gtp/vectorcore/Catalogue.shtml#AAVplasmids) and either pDD.hEEF1A1.eGFP.WHVPRE.synpA 
or pDD.MHCK7.PurR.WHVPRE.synpA using polyethyleneimine as transfec  on agent. Three days 
a  er transfec  on, the supernatant and cells were harvested and subjected to three freeze-thaw 
cycles to release the AAV vector par  cles from the cells. A  er pelle  ng of the cell debris by 
Figure 1: Schema  c  meline of experimental setup. 
hPSCs: human pluripotent stem cells; AAV: adeno-associated virus. 
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low-speed centrifuga  on, the resul  ng supernatant was mixed with one-fourth of volume of 
2.5 M NaCl, 40% polyethyleneglycol 8000 and incubated overnight at 4°C with gentle s  rring 
and concentrated overnight in a 40% Polyethylene glycol solu  on. The AAV vector par  cles 
were then pelleted by centrifuga  on at 5000×g for 30 minutes. Subsequently, the concentrated 
AAV prepara  on was treated for 30 min with 100 U of OmniCleave Endonuclease (EPICENTRE 
Biotechnologies) per mL of sample at 37 °C before purifying the AAV par  cles using an iodixanol 
block gradient. Following purifi ca  on, the AAV vector par  cles were washed with PBS + 5% 
sucrose and concentrated in three steps to approximately 200 μl per AAV vector in an Amicon 
Ultra-15 fi lter unit with a nominal molecular weight limit of 100 kDa (Millipore) according to the 
manufacture’s proctol.  The physical  ter of the concentrated vector prepara  ons (i.e. genome 
copies [GCs]/ml) was determined using a dot-blot assay. Two μL of AAV stock was treated with 10 
U OmniCleave in 30 μl of 50 mM Tris-HCl (pH 8.0), 1 mM MgCl
2
 for 30 minutes at 37°C to digest 
any unpacked DNA. The AAV vector genomes were then released by a 1 hour treatment at 37°C 
with 1 μg/μl proteinase K. Following denatura  on of the vector DNA, the sample was diluted 1:1 
with 20× saline-sodium citrate buff er  (3M NaCL, 300mM triosodium citrate (pH 7.8)) and blo  ed 
onto a Hybond-N+ nylon membrane (GE Healthcare) using a Bio-Dot microfi ltra  on apparatus 
(Bio-Rad Laboratories). The membrane was incubated for 2 h at 80°C to fi x the vector DNA to 
the membrane. The DNA was quan  fi ed using AlkPhos direct labelling and detec  on system (GE 
healthcare). A 772-bp fragment specifi c for MHCK7 (primers: 5’-accc  caga  aaaaataactga-3’ and 
5’-tcaggagccagccagc-3’) obtained by PCR and isolated from agarose gel was used as probe. The 
membrane was prehybridized for 30 min at 55°C followed by an overnight hybridize at 55°C of 
150ng of the thermostable alkaline phosphatase-labelled probe. Stringency washes and signal 
detec  on was performed according to the manufacturer’s recommended protocol. ImageQuant 
so  ware was used to quan  fy the DNA.
Figure 2: A) Vector map of AAV2/2mt.hEEF1A1.eGFP.WHVPRE.synpA. B) Flow cytometry plots showing the 
percentage of GFP-posi  ve cells detected 5 days a  er transduc  on of hiPSC-CMs and skin fi broblasts with diff erent 
doses of AAV2/2mt. hEEF1A1.eGFP.WHVPRE.synpA.
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Transduc  on of hPSC-CMs with AAV vectors
Twenty days a  er the start of diff eren  a  on the monolayer was treated with TrypLE Select 
(Invitrogen-Life Technologies) for 30 minutes to produce single cells. The single cell suspension 
was exposed to diff erent doses of AAV vector and immediately a  erwards cells were plated on 
Matrigel-coated plates in LI-BEL medium. Forthy-eight hours later the medium was replaced by 
fresh LI-BEL without viral vector par  cles. Five days a  er transduc  on, the cells were treated 
with 2 μg/ml puromyocin for 2 days. Following puromyocin treatment, cells were le   to recover 
for 2 days before either fi xing them by a 30-minute treatment with 2% paraformaldehyde (PFA) 
for immunostaining or dissocia  on of the cells with TrypLE Select to replate them for addi  onal 
experiments (Fig. 1).
Fixed cells were stained for α-ac  nin and fi lamentous ac  n to determine cardiomyocyte number 
and total cell number, respec  vely. Six areas (190,000 μm2 per area) per condi  on were analyzed.
Immunostaining
Immunofl uorescent staining was performed according to standard procedures. Briefl y, PFA-fi xed 
cells were permeabilized with Triton X-100, blocked with 4% normal goat serum (NGS) for 1 
hour before overnight incuba  on at 4°C with α-ac  nin-specifi c mouse monoclonal an  body 
(Sigma-Aldrich) diluted 800-fold in PBS plus 4%NGS. A  er washing, the cells were incubated 
Figure 3: Purifi ca  on of hESC-CMs 
AAV2/2mt.MHCK7.PurR.WHVPRE.synpA. 
A) Vector map of AAV2/2mt.MHCK7.
PurR.WHVPRE.synpA. B) Percentage of 
cardiomyocytes a  er treatment with 
diff erent doses (GCs/cell) of AAV2/2mt.
MHCK7.PurR.WHVPRE.synpA and exposure 
to 2 μg/ml puromyocin for 48 hours for four 
individual experiments. *p<0.05 puromycin 
added vs no puromycin added, n=3. C) The 
average percentage of cardiomyocytes from 
the experiment in B. *p<0.05 puromycin 
added vs no puromycin added, n≥2.
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for 1 hour at room temperature with Cy3-conjugated secondary an  body (1:200, Jackson 
ImmunoResearch).  The cells were washed again and subsequently incubated with Alexa Fluor 
488 Phalloidin (Invitrogen-Life Technologies) for 30 minutes at room temperature. Nuclei were 
stained with DAPI before moun  ng slides with Mowiol (Calbiochem-Merck4Biosciences). 
Results:
AAV2mt transduc  on of cardiomyocytes versus fi broblasts
hiPSC-CMs were dissociated into single cells at diff eren  a  on day 20, transduced with diff erent 
amounts of AAV2/2mt.hEEF1A1.eGFP.WHVPRE.synpA (i.e. 0, 101, 102, 103, 104, 105 GCs/
cell, for vector map, see Fig 2A) and analyzed by fl ow cytometry 5 days later. In parallel, skin 
fi broblasts from the cell batch that serves as source of the hiPSC line were transduced with 
the same AAV vector at various doses. Only at vector doses ≥103 GCs/cell, the hiPSC-CMs and 
dermal fi broblasts showed evidence of successful transduc  on. There appeared to be a direct 
rela  onship between the vector dose and the percentage of cells transduced for both the 
cardiomyocytes and the fi broblasts with the highest vector dose (i.e. 105 GCs/cell) resul  ng in 92 
and 30% GFP-posi  ve cells, respec  vely. Thus, the cardiomyocytes were more easily transduced 
than the fi broblasts (Fig. 2B). It is important to note the some degree of toxicity was observed in 
both the cardiomyocyte and fi broblast cultures at vector doses ≥ 10,000 GCs/cell based on the 
decrease in the number of cells available for fl ow cytometry analysis at day 25 compared to the 
other samples (data not shown). 
Cardiomyocyte selec  on using AAV2/2mt.MHCK7.PurR.WHVPRE.synpA 
Based on the  tra  on experiment described above, hESC-CMs were transduced with 20, 103 or 
104 GCs/cell of AAV2/2mt.MHCK7.PurR.WHVPRE.synpA (for vector map, see Fig. 3A) and treated 
a  er 5 days with 2 μg/ml of puromycin for 48 h.. Following a recovery period of 2 days, the cells 
were stained for α-ac  nin and fi lamentous ac  n. As is shown in Fig. 3B and C, a  er treatment 
with puromycin, 97-100% of hESC-CM popula  on consisted of cardiomyocytes irrespec  ve of 
the vector dose used while the percentage of cardiomyocytes in the untransduced cell cultures 
ranged from 21-100% (Fig. 3B). 
Parallel cultures of cardiomyocytes that were not fi xed were dissociated and replated for 
func  onal assays. However, a  er successful repla  ng of cardiomyocytes in the pilot experiment 
(20 GCs/cell, Fig.4), the AAV vector-transduced and puromycin-treated hESC-CMs did not 
reproducibly a  ach to the dishes or form confl uent monolayers anymore, precluding their use 
in most func  onal assays. 
Discussion
One of the major problems facing PSC-CMs is the purity of the diff eren  ated cell popula  on 
[4]. In this study, we generated a capsid-modifi ed AAV2 vector for the selec  ve expression 
of puromycin N-acetyltransferase in cardiomyocytes. When applied to diff eren  ated hPSCs 
containing a subpopula  on of PSC-CMs, selec  on of cardiomyocytes to greater than 97% purity 
was achieved. However, we were unable to confi rm the cardiomyocyte iden  ty of these cells 
in func  onal assays because of unexplained technical issues associated with low repla  ng 
effi  ciency of the PSC progeny in culture.
Comparison of the transduc  on effi  ciency of PSC-CMs and fi broblasts (as surrogate for the non-
myocytes present in the mixed popula  ons of diff eren  ated cells) with AAV2/2mt. hEEF1A1.eGFP.
WHVPRE.synpA showed that transduc  on of the cardiomyocytes was somewhat more effi  cient. 
This could be due to diff erences in the various steps of the AAV vector transduc  on process (e.g. 
cell a  achment, endocytosis, intracellular traffi  cking, capsid processing, release of the vector 
genome in the cell nucleus and second-strand DNA synthesis [21]), there may be a higher ac  vity 
of the hEEF1A1 gene promoter in cardiomyocytes than in fi broblasts, or diff erences in division 
rate between the two cell types. Fibroblasts divide more rapidly than cardiomyocytes causing 
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more rapid dilu  on/loss of the episomal vector genomes. Of note, in the present study, gene  c 
varia  on could not play a part in the observed diff erences in transduc  on effi  ciency between the 
dermal fi broblasts and the hiPSC-CMCs as both were derived from the same individual.
Although MHCK7 has been shown to be highly ac  ve in both cardiomyocytes and skeletal muscle 
cells [22], this does not pose a problem in selec  ng cardiomyocytes from the mixed deriva  ves 
of hPSCs since it is well-established that the currently used methods to diff eren  ate hPSCs into 
cardiomyocytes yield only a very small percentage of skeletal myocytes [6,17,23]. 
   
While the use of AAV2/2mt.MHCK7.PurR.WHVPRE.synpA allowed selec  on of the cardiomyocytes 
from a mixed popula  on of diff eren  ated hPSC deriva  ves, the applica  on of high vector doses 
resulted in extensive cell death. Moreover, the large varia  on in cardiomyogenic diff eren  a  on 
effi  ciency (ranging from 20% to nearly 100%; Fig. 3B, le  most bars) between individual 
experiments makes it hard to draw defi ni  ve conclusions and  may have contributed to some 
of the discrepancies between the  tra  on results (Fig. 2) and the cardiomyocytes selec  on 
results (Fig. 3).  Addi  onally, a  er treatment with puromycin the cardiomyocytes could not be 
reproducibly replated, making addi  onal experiments on the cells diffi  cult. To be of prac  cal 
use, the AAV vector-based selec  on method described herein clearly required further technical 
op  miza  on. It may, for instance, be possible that cardiomyocytes have a higher tolerance to 
puromycin than the other cells derived during hPSC diff eren  a  on [24-26], possibly due to 
their slower propaga  on rate compared to the non-myocytes in culture. It has been shown that 
diff erent cell types response diff erently to s  muli which could also explain the higher tolerance 
[27]. Either of these points might explain why the selec  on procedure appeared to work at a 
vector dose of only 20 GCs/cell while the  tra  on experiment indicated that at such a low vector 
dose the transduc  on rate was close to zero. This may also explain why the cardiomyocytes 
did not survive the repla  ng procedure. Furthermore  fi gure 3 seems to indicate that while at 
low vector doses puromycin selec  on leads to cardiomyocyte enrichment (accompanied by 
massive cell loss), high vector doses themselves provide a selec  ve advantage to the hPSC-
derived cardiomyocytes even in the absence of puromycin selec  on. This may indicate that viral 
transduc  on and/or puromycin-N-acetyltransferase ac  vity per se provide a selec  ve advantage 
to the hPSC-derived cardiomyocytes or a selec  ve disadvantage to the hPSC-derived non-
cardiomyocytes, similarly to eff ects which have been seen with other aminoglycoside resistance 
selec  on markers [28]. 
The seemingly unexpected eff ec  veness of the AAV2/2mt.MHCK7.PurR.WHVPRE.synpA at 
20GCs/cell may have also been due addi  onal proteins specifi cally expressed by cardiomyocytes 
and not the non-myocytes. Not unlike the results of Wang et al. in which showed that the 
transduc  on of cells with a “gutless” viral vector is not a “neutral” event but may have a large 
impact on the target cell’s biological proper  es [29]. It may thus be possible that the transduc  on 
with AAV2/2mt vector par  cles enhances the cardiomyogenic diff eren  a  on of hPSC-derived cells.
Figure 4: Replated Nkx 2-5eGFP/w-derived 
cardiomyocytes a  er mock-transduc  on 
or transduc  on with 20 GCs/cell of 
AAV2/2mt.MHCK7.PurR.WHVPRE.synpA 
and exposure or no exposure to 2 μg/ml 
puromycin for 2 days.
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In spite of the fact that we were unable to consistently replate the AAV2/2mt.MHCK7.PurR.
WHVPRE.synpA-transduced cardiomyocytes a  er puromycin selec  on, these pilot results 
indicated that AAV vectors do have poten  al for the transient gene  c modifi ca  on of hPSC-
CMs, if the technical problems described above can be resolved. Moreover, since the AAV2/2mt.
MHCK7.PurR.WHVPRE.synpA genome was too large to be packaged in the vector par  cle as 
transcrip  onally competent dimers [30] the cells could not be treated with puromycin un  l 5 
days a  er transduc  on. This addi  onal 5-day incuba  on  me may have contributed to the low 
repla  ng survival/a  achment rate of the hPSC-CMs. The genera  on of a self-complementary 
version of the AAV2/2mt.MHCK7.PurR.WHVPRE.synpA would decrease this 5-day incuba  on 
period and may allow for be  er repla  ng a  achment and survival. Since AAV vectors are non-
integra  ng and will not replicate within the infected cells, any cell division will decrease the 
number of AAV par  cles present in a cell. If the long incuba  on  me and the repla  ng problem 
were resolved, this technology could prove very useful in selec  ng cardiomyocytes from 
diff eren  ated hPSCs.
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Induced Pluripotent Stem Cells
Over the last several years, research on human pluripotent stem cells (both embryonic and 
induced) has begun to fall into two dis  nct areas (i) basic stem cell biology, such as understanding 
the control of diff eren  a  on in development and the process of reprogramming, understanding 
pluripotency and fi nding ways to improve the reprogramming process itself to obtain a more 
“perfect” iPSC closer to hESC [1] and (ii) iPSC and gene  cally modifi ed hESC as a tool to study/
model disease [2]. While some aspects of the approaches and methodologies may be similar, 
their goals are very diff erent so that their requirements of the iPSC and hESC they use may also 
be diff erent. The work described in this thesis is in the second group: using human (h)iPSC as a 
model for human (cardiac) diseases so that the primary feature  and requirement of the hiPSC 
used here is that the cell lines form cardiomyocytes effi  ciently and reproducibly, independent of 
the way in which the hiPSC were derived. 
While it is important to have a fully reprogrammed hiPSC to decrease the varia  on between the 
diff erent pa  ents and the control lines, the need for the hiPSC to remain in a ground state of 
absolute pluripotency is not nearly as important as the ability to diff eren  ate into the desired 
cell type. In this thesis,  cardiomyocyte diff eren  a  on is the principle requirement of the hPSC 
lines. By contrast, those researchers studying the reprogramming process itself [3] or are trying 
to push hiPSC into a more naïve state rather more like mouse (m)iPSC or ESC [4] may require 
more stringent reprogramming and pluripotency tests as well as improved reprogramming 
methods which do not leave any footprint behind in the host DNA [5;6].   
For many purposes, the  ssue source of soma  c cells for reprogramming can be of major 
importance. Dermal fi broblasts for example are easily derived and grow well in culture so that 
they are easy to reprogram to pluripotency but in the case of minors or young children, it may 
not be possible to obtain permission to collect skin biopsies. Some pa  ents may be willing 
to take part in basic research by dona  ng  ssues samples but may be nervous of skin biopsy 
collec  on or injec  ons for local anesthe  c. In these cases, a non- or minimally invasive source 
of soma  c cells would be preferable.  Part of the research described in this thesis concerned 
selec  ng the cell sources that could be collected easily and reliably reprogrammed; this work is 
described in Chapter 3.  We found that skin biopsies could s  ll successfully provide cells able to 
be reprogrammed at about the same effi  ciency as freshly isolated fi broblasts, even a  er 14 days 
of storage in buff ered saline solu  on (a basic salt solu  on). We also inves  gated the use of milk 
teeth and blood as a possible sources of soma  c cells for reprogramming and while cells isolated 
from milk teeth were successfully reprogrammed at similar effi  ciencies to skin fi broblast,  blood 
proved in our hands to be a more challenging cell source for reprogramming and we needed 
large star  ng volumes for success. This was an empirical fi nding and we did not fi nd a reason for 
it. Easily accessible and minimally invasive  ssue sources, such as hair follicle kera  nocytes or 
small quan   es of blood would be allowed for use in both children and adults. Although these 
 ssue sources had been described in the literature as being successfully reprogrammed [7;8], 
we found it diffi  cult to grow cells from these  ssues and to cryopreserve and store them for later 
use in reprogramming.  Banking the isolated soma  c cells is a more feasible op  on when trying 
to collect a large number of samples either from pa  ents or control samples. Fibroblasts could 
be dependably isolated from skin biopsies as small as 4mm, were easily stored and recovered 
well from frozen storage. So while we have successfully generated hiPSC from milk teeth as well 
as blood (Chapter 3) and others have generated hiPSC from other more easily accessible cell 
sources like hair kera  nocytes [7], urine [9] and T-cells [10], fi broblasts were readily available 
and most reliable for the studies described in this thesis.
Aside from the  ssue cell source, the method used for reprogramming and the technique used 
to induce diff eren  a  on could impact the use of iPSC technology for genera  ng disease models. 
There has been much development since the fi rst published ar  cles claiming soma  c cells 
could be reprogrammed to embryonic-like stem cells (ESC-like)[11-13]. There has been a variety 
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of protocols and methods of reprogramming factor delivery reported, including viral vectors 
(retro-, len  -,adeno-, Sendai) mRNA, and episomes, with a range of reported effi  ciencies [14], 
which could be related their ability to recruit the Mbd3/NuRD repressor complex [15]. However 
most studies compare experiments with those  described in the literature previously, and are 
not direct comparisons of methods in single reprogramming experiments [16]. This paucity 
of data that can be directly compared as well as a lack of a consistent method for calcula  ng 
and presen  ng effi  ciencies make statements on effi  ciencies open to misinterpreta  on. For 
example, the total number of cells at the start of the reprogramming is some  mes compared 
to the number of morphologically iden  fi ed ESC-like colonies and this is some  mes reported 
as “effi  ciency” but the number of cells iden  fi ed as taking up the reprogramming factors vs 
number of morphologically iden  fi ed ESC-like colonies has also been reported as a measure of 
effi  ciency.  This makes comparing methods diffi  cult and decisions on which methods are ‘best’ 
depends highly on the experience of the laboratory performing the experiments and whether 
it even ma  ers, depends on the purpose for which the reprogrammed cells will be used. At the 
 me at which the work in this thesis was ini  ated the best method for reprogramming which le   
only a minimal scar in the genome was using an excisable len  viral vector. Later it became clear 
that non-integra  ng methods such as episomal [17] and Sendai virus-based protocols [6] which 
leave no trace in the genome at all could be used at a high effi  ciency and are now being rou  nely 
used to produce hiPSC in our lab as well.   
With the development of transgene free methods which have been found to be robust and 
reproducible (e.g. Sendai virus, [6], the ques  on arises if there is a need to develop techniques 
to iden  fy insert number and loca  ons such as in Chapter 4. In chapter 4 we found that by using 
a combina  on of splinkere  e-PCR and ion torrent sequencing we could rapidly and accurately 
iden  fy not only the number of len  viral inserts in our hiPSC but also the loca  on. While most 
groups are now implemen  ng transgene free methods, there is a large number of lines which 
have already been generated and that for various reasons cannot be reprogrammed again (e.g. 
the loss or lack of source material). To the end of 2013, >90% of the published iPSC lines were 
generated using viral vectors. 
There are several studies that have compared hiPSC lines to hESC to address the ques  on on 
the extent to which they are similar or diff er. There is at present no consensus but it seems the 
more lines that are compared, the smaller the diff erences between them become [16]. Some 
discrepancies have also been a  ributed to incomplete reprogramming, the insert number or 
the site in the genome that the reprogramming genes were inserted.  Most of these studies 
have compared undiff eren  ated hESC and hiPSC lines but reports of characteriza  on of their 
diff eren  ated deriva  ves, such as cardiomyocytes, are now becoming more prevalent in 
literature, allowing comparisons of diff erent lines at a diff erent level. If diff erences are found, 
knowing and understanding the insert number and loca  on could help explain some of these 
controversies. 
Cardiac Disease Modeling
Most informa  on on cardiac diseases is from clinical data and transgenic mouse models. While 
both can provide useful informa  on they both have their disadvantages. Clinical assessment of 
disease is limited to symptoms (which may be explained by a number of diseases) and gene  c 
tes  ng; informa  on regarding mechanism or cellular func  onality is limited or unavailable. 
Gene  cally modifi ed mouse models provide a wealth of knowledge by providing a con  nuous 
supply of cells as well as providing a full body model in which to study disease development and 
progression;  however the diff erences between animals and humans, especially with respect to 
the heart is great [18;19].   
There are a number of physiological, metabolic and protein marker expression diff erences 
between the human and rodent heart. The most obvious diff erence between the mouse (or any 
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small rodents) and human heart is heart rate. The mouse heart beats at 5-600 beats per minute 
(b/m) while the human heart beats at 60-70 b/m. The high heart rate of the mouse makes 
studying human arrhythmias caused by specifi c gene muta  ons diffi  cult even when the mutated 
gene is successfully introduced. Furthermore, the diff erences in ion channels composi  on and 
their contribu  on to the ac  on poten  al puts channelopathy studies solely carried out in the 
mouse in ques  on. Another diff erence is the expression of myosin heavy chain (MHC) isoforms. 
βMHC is the isoform predominantly expressed in fetal mouse hearts whilst αMHC is predominant 
in the adult; the reverse is seen in humans [20].
In the past two decades our knowledge of cardiac development and disease has been greatly 
aided by pluripotent stem cell derived cardiomyocytes (PSC-CM). However there are s  ll many 
issues which must be addressed before PSC-CM can contribute fully to cardiac research. In 
this thesis we have a  empted to address a few of these points (Chapter 4-8). One of the fi rst 
factors to consider is which diff eren  a  on method to use [21]. In Chapter 4 and 5, we described 
two diff erent diff eren  a  on methods, both using defi ned medium and specifi c growth factors, 
however with striking diff erences. In chapter 4 we describe a new rapid method for cardiac 
diff eren  a  on of hPSC directly from mechanically passaged colonies on mTESR without the 
need for adap  on to enzyma  c passage. We showed this method to produce cardiomyocytes 
with at least 30% effi  ciency from 5 established hPSC lines as well as from a newly reprogrammed 
(less than  passage 2) hiPSC line. The cardiomyocytes produced were posi  ve for specifi c cardiac 
markers (e.g. α-ac  nin, troponin T and Nkx2.5) and basic electrophysiological proper  es (e.g. 
ac  on poten  al and calcium transients) could be measured.
The method described in Chapter 5 used an embryoid body (EB) based system. It required 
op  mizing the concentra  ons and  ming of the growth factors, a necessity for many 
diff eren  a  on protocols due to the varia  on in endogenously produced factors as well as 
varying kine  cs of the diff eren  a  on process itself [22]. This method yielded a large number 
of uniform, bea  ng EBs. It is very suitable when a large number of cardiomyocytes is required 
from one PSC line, such as for drug discovery or toxicity tes  ng and in combina  on with 
bioreactors,to be scaled to produce millions of cells. It is proving especially useful in this context 
when a cardiomyocyte-expressed promoter driving an an  bio  c resistance gene is included that 
allows selec  ve survival of cardiomyocytes, as described in chapter 8. This allows the large-scale 
deriva  on of pure popula  ons of cardiomyocytes. The other diff eren  a  on method described 
in Chapter 4, does not require op  miza  on or adapta  on and can result in very rapid produc  on 
of cardiomyocytes. This method is well suited to/for cases when a large number of diff erent cell 
lines or clones (for screening a  er gene  c modifi ca  on) are being studied, for example in disease 
modeling when it is considered that minimally three clones from three diff erent individuals are 
required for proper sta  s  cal comparison [23;24].  
Another important point in phenotypic comparison and func  onal characteriza  on of 
cardiomyocytes is the use of proper maintenance media (Chapter 7). Much eff ort has gone into 
op  mizing the diff eren  a  on protocols for hPSC into cardiomyocytes [25-27]; however we are 
only beginning to analyze in detail the resul  ng cardiomyocytes that are being generated. In 
Chapter 7, we examined the eff ects of fetal calf serum (FCS), commonly used for cardiomyocyte 
maintenance to support survival and/or a  ain some degree of maturity, on PSC-CM. We found 
that treatment of PSC-CM derived using defi ned medium with FCS not only had hypertrophic 
eff ects similar to the addi  on of the known hypertrophic s  mulus phenylephrine which was 
irreversible but also produced a posi  ve chronotropic response. FCS is a common medium 
supplement with incompletely known and batch-to-batch variable composi  on [28]. It has been 
shown to cause hypertrophy in cultured cardiomyocytes [29;30] and yet is s  ll o  en used to 
maintain PSC-CM for extended periods of  me [31-33]. By comparing the eff ects of FCS on PSC-
CM derived and maintained in defi ned medium, we highlighted the importance of the need to 
understand the eff ects of FCS components, which we o  en overlook, can have on results. In 
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chapter 7, we clearly showed that the disease phenotype that was described in chapter 6 was 
masked when FCS was present in the culture medium. This brings into ques  on the results and 
conclusions of other groups (e.g. K. Laugwitz, SE Harding, and C. Denning) that have rou  nely 
used FCS or other sera in the cardiomyocyte culture. Lastly,we a  empted to develop a generic 
method for purifying the popula  on of cardiomyocytes among diff eren  ated cells by selec  on 
using transiently expressed adeno-associated viruses (Chapter 8). Preliminary data using this 
construct was promising but the technology needs to be developed further and addi  onal 
tes  ng is needed before wider use of this virus for selec  ng cardiomyocytes. Researchers have 
o  en used other ways to get around having impure popula  ons by using single cell assays 
or normalizing popula  on data (for example in Western blots or RT-PCR) for the number of 
cardiomyocytes using cardiomyocyte-specifi c gene or protein expression; however this does not 
negate the need for a ubiquitous selec  on method which has low toxicity and can be easily 
applied to mul  ple PSC lines.
PSC-CM use in drug discovery is increasingly well documented [34;35] and their use in disease 
modelling has been further developed with the increased use of hiPSC from pa  ents [2;24]. In 
this thesis we have also shown how hiPSC can be used in modeling hypertrophic cardiomyopathy 
(HCM). In chapter 6 we describe the reprogramming and basic disease characteriza  on of hiPSC 
derived from pa  ents with HCM.  Fibroblasts from three pa  ents (2 related and one unrelated 
male) carrying the Dutch founder muta  on 2373inG in myosin binding protein C3 (MYBPC3) 
were collected and reprogrammed into hiPSC. Subsequently cardiomyocytes were derived. We 
found the cardiomyocytes from the HCM pa  ents contained less MYBPC3 protein and were 
larger in cell surface area compared to cardiomyocytes from a healthy hiPSC line, comparable 
to the clinical situa  on. Also, the HCM-derived cardiomyocytes had an altered response to 
changes in external calcium as well as a larger caff eine-induced calcium release. Our results 
were comparable to those found in cardiac samples retrieved from pa  ents [36;37]. However 
the mechanism of disease is s  ll unknown and is currently being inves  gated along with more in 
depth disease characteriza  on by other researchers in the lab.  
The research described in this thesis is just the fi rst step in modeling the HCM disease. We 
showed basic phenotypic characteris  cs but the exact disease mechanism and the reason for 
diff erences in clinical manifesta  on of the disease in pa  ents are s  ll unknown. However, these 
hiPSC-CM contain/provide the poten  al to answer these ques  ons which have eluded research 
and clinician thus far. 
Future Perspec  ve
With the fi rst successful cardiac diff eren  a  on of PSC [38], their use for regenera  ve medicine, 
drug tes  ng and disease modeling became just a ma  er of  me. The use of PSC-derived 
cardiomyocytes in cell therapy has unfortunately been fraught with diffi  cul  es and has had 
limited success so far [39]. However, their use in drug tes  ng and disease modeling is a real 
possibility. Nevertheless there are s  ll many ques  ons that need to be answered to improve 
their use in drug tes  ng and disease modeling. 
In this thesis we have addressed some of these issues but there are s  ll many which need to 
be inves  gated. One of the major obstacles to full use of PSC-CM is their immaturity [40;41]. 
While there have been many developments in improving diff eren  a  on procedures, most 
cardiomyocytes produced, like those generated in this thesis (Chapters 4-8), are s  ll in an 
immature or fetal-like state based on electrophysiological - [42],  physical  and gene expression 
characteris  cs.  While the immature cells have been able to mimic the phenotype of some 
late onset diseases (Chapter 6 of this thesis and [24] it is s  ll unclear if the current state of 
maturity is enough to assay all phenotypes. If the fi eld of PSC-CM research is to move forward, 
understanding of the immature state of PSC-CM and how to mature them in culture is key. 
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Addi  onally several reports to date have demonstrated a cardiac disease phenotype in culture 
[23;24;43] while disease phenotypes have not always been evident in pa  ents[24;33]. This can 
be intrinsic to the technology or could indicate that pa  ents will develop symptoms only in later 
life, or that there are lifestyle factors which trigger symptoms (extreme exercise for example). 
Future development in engineering technology that could modify stress/stretch, pacing or  ssue 
environment combined with increased sensi  vity of current assays, may resolve these issues. 
On the other hand it could be the lack of cellular maturity, men  oned earlier in this sec  on, 
which has not allowed disease phenotypes to be fully revealed. Lastly it could be the absence 
of environmental factors, which cannot be replicated in culture that will remain a shortcoming 
of PSC technology. However which of these possibili  es is correct will remain unanswered un  l 
the fi eld progresses further and we have the tools that truly mimic all aspects of cardiomyocyte 
biology in culture.
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Since the fi rst reports of human induced pluripotent stem cells (hiPSC), the fi eld of pluripotent 
stem cell (PSC) research has grown in leap and bounds, par  cularly in the area of (cardiac) 
disease modeling. This is in part because it is fairly easy to produce cardiomyocytes from hPSC 
and also there are now more assays available which can determine phenotypic behavior. This 
thesis describes and discusses improvements to reprogramming technology as well as its use 
in cardiac development and disease modeling. Chapter 1 and 2 give a general background 
on PSCs, covering embryonic stem cells (ESC) and the discovery and development of induced 
pluripotent stem cells, with a par  cular focus on their use in studying cardiac development and 
disease modeling. 
In chapter 3 we examined some prac  cal aspects relevant to the collec  on of  ssues from 
pa  ents in the clinic.  We compared (i) skin biopsies stored in standard physiological salt solu  on 
for up to 2 weeks (ii) blood outgrowth endothelial cells (BOECs) isolated from fresh peripheral 
blood and (iii) children’s milk teeth lost during normal replacement, for their ability to form 
soma  c cell cultures suitable for reprogramming to hiPSCs. All hiPSC lines were derived using 
the same reprogramming method (a condi  onal (FLPe) polycistronic len  virus) and under 
similar condi  ons (same batch of virus, fetal calf serum and feeder cells).  Skin fi broblasts could 
be reprogrammed robustly even a  er long-term biopsy storage. Genera  on of hiPSCs from 
juvenile dental pulp cells gave similar high effi  ciencies but that of BOECs was lower. In terms of 
invasiveness of biopsy sampling, biopsy storage and reprogramming effi  ciencies, skin fi broblasts 
appeared best for the genera  on of hiPSCs but where non-invasive procedures are required (e.g. 
for children) dental pulp cells from milk teeth represent a valuable alterna  ve.  
In chapter 4 we described a useful combina  on of procedures that enables the simultaneous 
screening of mul  ple iPSC clones to determine their genomic integrity as well as their cardiac 
diff eren  a  on poten  al within two weeks of the puta  ve reprogrammed colonies ini  ally 
appearing in culture. By coupling a splinkere  e-PCR method with Ion Torrent sequencing, we 
could ascertain the number of and map the proviral integra  on sites in len  viral-reprogrammed 
hiPSCs, enabling iden  fi ca  on of clones containing single copy integra  ons in genomic regions 
devoid of known genes or transcrip  onal control elements. In parallel, we developed an 
eff ec  ve cardiac diff eren  a  on protocol that generated func  onal cardiomyocytes within 10 
days without requiring line-specifi c op  miza  on for any of 6 independent human pluripotent 
stem cell lines tested. Finally, to demonstrate the scalability of these procedures, we picked 
20 nascent iPSC clones and performed these independent assays concurrently. Before the 
clones required passaging, we were able to iden  fy clones with a single integrated copy of the 
reprogramming vector and robust cardiac diff eren  a  on poten  al for further analysis.
Chapter 5 describes another cardiac diff eren  a  on method. Star  ng from mechanically 
passaging PSC grown on mouse embryonic fi broblasts, this chapter describes adap  ng PSC to 
enzyma  c passaged bulk cultures in order to genera  on spin EBs for directed defi ned cardiac 
diff eren  a  on. This method is useful for the genera  on of large numbers of uniformly produced 
cardiomyocytes from a single cell line, as each line would most likely require op  miza  on of the 
growth factors used (also described in this chapter).
In chapter 6 we derived hiPSC from three hypertrophic cardiomyopathy (HCM) pa  ents by 
reprogramming fi broblasts from skin biopsies; two related pa  ents and an unrelated individual 
who also had the same Dutch founder muta  on (2373insG) in the myosin binding protein C type 
3 (MYBPC type 3) gene.  MYBPC type 3 protein levels were signifi cantly reduced by Western 
blo   ng in HCM-iPSC cardiomyocytes compared to the control, consistent with reduced MYBPC3 
levels previously found in heart biopsies from pa  ents. Dissociated and replated single HCM-
iPSC derived cardiomyocytes had a cell surface area more than 2-fold greater than control 
cardiomyocytes. In addi  on, calcium signaling was altered in the disease cardiomyocytes 
compared with controls, consistent with previously published data. Cardiomyocytes from HCM-
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iPSC thus show essen  al features of the disease and provide a basis for further studies on the 
nature of HCM caused by muta  ons in MYBPC3.
In chapter 7 we examined the direct eff ects of serum on cardiomyocytes from hESC, hiPSC and 
hiPSC from pa  ents with HCM linked to a muta  on in the MYBPC type 3 gene to understand 
how they might aff ect interpreta  on of phenotypes in culture.  We fi rst confi rmed previously 
published hypertrophic eff ects of serum on cultured neonatal rat cardiomyocytes evidenced by 
increased cell surface area and bea  ng frequency. We then found that serum induced similar and 
poorly reversible increases in the cell surface area of hESC- and hiPSC-derived cardiomyocytes 
and signifi cantly increased their rate of contrac  on. Phenylephrine, which normally induces 
hypertrophy in cultured cardiomyocytes, had no addi  onal eff ects under these serum condi  ons. 
We further showed that hiPSC-derived cardiomyocytes from 3 MYBPC3 pa  ents had a greater 
surface area than control cardiomyocytes in the absence of serum, indica  ng hypertrophy as 
predicted by their genotype, but this diff erence was not evident in the presence of serum. Serum 
can signifi cantly alter the phenotype of human PSC derived cardiomyocytes under otherwise 
defi ned condi  ons such that the eff ects of drugs and gene muta  ons aff ec  ng hypertrophy may 
be underes  mated. It is per  nent therefore to examine cardiac phenotypes, whenever possible, 
in fully defi ned culture media without or in low concentra  ons of serum. 
In chapter 8 we developed a universal selec  on system for PSC-CMs with high cell survival 
and low toxicity based on adeno-associated virus (AAV) vectors. The generated AAV serotype 
2 (AAV2) vector had a reduced suscep  bility to proteasomal degrada  on and carried a striated 
muscle-specifi c promoter (i.e. MHCK7)-driven puromycin resistance gene for selec  ng PSC-CMs. 
We showed that this vector transduced PSC-CMs be  er than fi broblasts. In ini  al experiments, 
puromycin selec  on resulted in ≥97%, pure cardiomyocyte popula  ons but in later experiments 
it proved diffi  cult to reproducibly replate the cardiomyocytes following puromycin treatment. 
Sugges  ons are given for further improvement of the vector and selec  on procedure, which 
could ul  mately result in an effi  cient AAV vector-based PSC-CM selec  on method.
Finally chapter 9 is a general discussion linking fi ndings in the diff erent chapters in this thesis as 
well as discussing future perspec  ves and obstacles which s  ll limit some uses of PSC technology 
principally in regards to obtaining informa  on on diseases from disease bearing hPSC lines e.g. 
immaturity of PSC-CM and disease phenotype in clinically asymptoma  c pa  ents.








































































































Sinds de eerste studies naar humane geïnduceerde pluripotente stamcellen (hiPSC) is het 
onderzoeksgebied van pluripotente stamcellen (PSC) met grote stappen vooruitgegaan, met 
name op het gebied van (hart)ziektemodellering. Dit komt deels doordat het vrij eenvoudig is om 
hartspiercellen te produceren uit humane (h)PSC en deels doordat er een aantal testen beschikbaar 
zijn die fenotypisch gedrag kunnen analyseren. In dit proefschri   worden verbeteringen in 
herprogrammeringstechnologie beschreven en besproken, evenals het gebruik van deze 
technologieën in hartontwikkeling en ziektemodellering. In hoofdstuk 1 en 2 wordt de algemene 
achtergrond van PSC besproken. Hierbij wordt aandacht besteed aan embryonale stamcellen 
(ESC) en de ontdekking en ontwikkeling van geïnduceerde pluripotente stamcellen (iPSC) 
voornamelijk gericht op hun gebruik in het bestuderen van hartontwikkeling en ziektemodellering.
In hoofdstuk 3 wordt verder ingegaan op enkele prak  sche aspecten met betrekking tot het 
verzamelen van weefsels van pa  ënten in de kliniek. Er wordt een vergelijking gemaakt tussen (i) 
huidbiopten die maximaal twee weken zijn opgeslagen in reguliere fysiologische zoutoplossing 
(ii) endotheelcellen geïsoleerd uit vers perifeer bloed (BOEC) en (iii) melktanden verkregen uit 
normaal verlopende tandwisseling om het vermogen te bepalen soma  sche celculturen te 
vormen die geschikt zijn voor het herprogrammeren naar hiPSC. Alle hiPSC-lijnen zijn verkregen 
volgens dezelfde herprogrammeringsmethode (een condi  oneel (FLPe) polycistronisch 
len  virus) en onder soortgelijke omstandigheden (dezelfde batch virus, foetaal kalfsserum 
en feeder-cellen). Huidfi broblasten konden, zelfs na langdurige opslag van het biopt, krach  g 
worden geherprogrammeerd. Het ontwikkelen van hiPSC uit kindertandmerg cellen leverde een 
vergelijkbaar hoog rendement op, maar dat van BOEC lag lager. Ten aanzien van de invasiviteit van de 
biopsies, de opslag van biopten en de effi  ciën  e van herprogrammering, blijken huidfi broblasten 
het meest geschikt voor het ontwikkelen van hiPSC. Waar niet-invasieve procedures vereist zijn, 
bijvoorbeeld bij kinderen, vormen tandmergcellen van melktanden een waardevol alterna  ef.
In hoofdstuk 4 wordt een nu   ge combina  e van procedures beschreven die de gelijk  jdige 
screening van meerdere iPSC-klonen mogelijk maakt om hun genomische integriteit en hun 
cardiaal diff eren  a  epoten  eel binnen twee weken na het verschijnen van de vermoedelijk 
geherprogrammeerde kolonies in de kweek te bepalen. Door het combineren van een splinkere  e-
PCR-methode met Ion Torrent sequencing, konden we het aantal vaststellen van en de provirale 
integra  egebieden van len  virale geherprogrammeerde hiPSC in kaart brengen. Hierdoor werd 
de iden  fi ca  e van klonen mogelijk gemaakt die single copy-integra  es beva  en in genomische 
regio’s zonder bekende genen of transcrip  onele controle-elementen. Tegelijker  jd ontwikkelden 
we een eff ec  ef hartcel diff eren  a  eprotocol dat binnen 10 dagen func  onele hartspiercellen 
genereert waarbij geen lijnspecifi eke op  malisa  e nodig was voor de 6 geteste, ona  ankelijke 
humane pluripotente stamcellijnen. Om de mogelijkheden voor het opschalen van deze 
procedures aan te tonen, hebben we tot slot 20 beginnende iPSC-klonen geselecteerd en daarop 
deze ona  ankelijke testen gelijk  jdig uitgevoerd. Voordat het doorze  en van de klonen nodig was, 
waren we in staat om klonen met een single intergrated copy van de herprogrammeringsvector 
en een breed cardiaal diff eren  a  epoten  eel te iden  fi ceren voor verdere analyse.
In hoofdstuk 5 wordt een andere diff eren  a  emethode voor hartcellen beschreven. Als 
eerste wordt ingegaan op de mechanische passage van PSC gekweekt op embryonale muis-
fi broblasten. Vervolgens wordt beschreven hoe PSC worden omgezet in enzyma  sche 
bulk-kweken om EBs te genereren voor gerichte gedefi nieerde hartcel diff eren  a  e. 
Deze methode is nu   g voor het genereren van grote aantallen uniform geproduceerde 
hartspiercellen uit dezelfde cellijn, aangezien voor elke lijn hoogstwaarschijnlijk 
op  malisa  e van de gebruikte groeifactoren nodig is (tevens beschreven in dit hoofdstuk).
In hoofdstuk 6 wordt gekeken naar het verkrijgen van hiPSC van drie pa  ënten met 
hypertrofi sche cardiomyopathie (HCM) door het herprogrammeren van fi broblasten uit de 
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huidbiopten. Twee van de pa  ënten behoorden tot dezelfde familie, de derde pa  ënt niet, 
maar deze had wel dezelfde Nederlandse foundermuta  e (2373insG) in het myosinebindend 
eiwit C Type 3-gen (MYBPC3). Met behulp van western blo   ng konden we detecteren dat in 
vergelijking met de controlegroep de MYBPC3-eiwitniveaus signifi cant verlaagd waren in HCM-
iPSC hartspiercellen (HCM-iPSC-CM). Dit komt overeen met eerder gevonden verminderde 
MYBPC3-niveaus in hartbiopten van pa  ënten. De gedissocieerde en uitgeplate enkele 
hartspiercellen van HCM-iPSC hadden een celoppervlak dat tweemaal groter was dan dat 
van de controlehartspiercellen. Bovendien was in zieke hartspiercellen de calciumsignalering 
veranderd ten opzichte van de controlecellen, wat aansluit bij eerder gepubliceerde gegevens. 
Hartspiercellen van HCM-iPSC vertonen dus essen  ële kenmerken van de ziekte en bieden een 
basis voor verder onderzoek naar de aard van HCM veroorzaakt door muta  es in MYBPC3.
In hoofdstuk 7 worden de directe gevolgen van serum op hartspiercellen van menselijk ESC, 
gezonde hiPSC en hiPSC van pa  ënten met HCM door een muta  e in het gen MYBPC3 besproken 
om te begrijpen hoe ze van invloed kunnen zijn op de interpreta  e van het fenotype gedurende 
de kweek. Als eerste hebben we de eerder gepubliceerde hypertrofi sche eff ecten van serum, 
die blijken uit een vergroot celoppervlak en hogere slagfrequen  e, beves  gd bij gekweekte 
hartspiercellen van neonatale ra  en. Vervolgens hebben we aangetoond dat serum soortgelijke 
en slecht omkeerbare vergro  ngen van het celoppervlak van hartspiercellen uit hESC- en 
hiPSC veroorzaakte, evenals een signifi cante verhoging van het tempo van samentrekking. 
Fenylefrine, dat normaliter hypertrofi e veroorzaakt in gekweekte hartspiercellen, had geen 
addi  oneel eff ect onder deze serumomstandigheden. Daarnaast hebben we aangetoond dat 
hartspiercellen van iPSC van drie MYBPC3-pa  ënten een groter celoppervlak hadden dan de 
controlehartspiercellen bij afwezigheid van serum. Dit wijst op hypertrofi e zoals voorspeld door 
hun genotype, maar dit verschil was niet aanwezig bij gebruik van serum. Serum kan het fenotype 
van hartspiercellen van hPSC zodanig signifi cant veranderen onder anderszins omstandigheden 
dat de eff ecten van geneesmiddelen- en genmuta  es die van invloed zijn op hypertrofi e 
mogelijk onderschat worden. Het is daarom belangrijk om cardiale fenotypes, waar mogelijk, 
te onderzoeken in volledig gedefi nieerde cultuurmedia zonder of met lage concentra  es serum.
Hoofdstuk 8 richt zich op de ontwikkeling van een universeel selec  esysteem voor hartcellen 
van PSC (PSC-CM) met hoge celoverleving en lage toxiciteit gebaseerd op adeno-associated 
virusvectoren (AAV). De gegenereerde AAV serotype 2 vector (AAV2 ) was minder gevoelig 
voor proteasomale degrada  e en had een dwarsgestreept spierweefsel promotorgedreven 
(d.w.z. MHCK7) puromycineresisten  egen voor het selecteren van PSC-CM. We hebben 
aangetoond dat deze vector beter PSC-CM transduceerde dan fi broblasten. Tijdens de eerste 
experimenten resulteerde puromycineselec  e in een ≥ 97%-zuivere hartspiercelpopula  e, 
maar in vervolgexperimenten bleek het moeilijk om de hartspiercellen reproduceerbaar 
uit te platen na de puromycinebehandeling. In dit hoofdstuk worden eveneens sugges  es 
gedaan voor verdere verbetering van de vector en selec  eprocedure, wat uiteindelijk 
kan leiden tot een eff ec  eve op AAV-vector gebaseerde PSC-CM selec  emethode.
Ten slo  e worden in hoofdstuk 9 in een algemene discussie de bevindingen van de verschillende 
hoofdstukken van dit proefschri   samengebracht en worden eveneens de toekomstperspec  even 
en belemmeringen besproken. Het gebruik van PSC-technologie maakt het bestuderen van 
ziekte van de ziektedragende hPSC-lijnen las  g, vooral door moeilijkheden met immaturiteit van 
PSC-CM en met ziektefenotype in klinisch asymptoma  sche pa  ënten.
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